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Introduction and aims of the thesis
CHAPTER 110
Therapeutic monoclonal antibody alemtuzumab
Immune therapy has been successfully introduced as treatment modality in the fields of hematology, 
oncology and autoimmune diseases. Monoclonal antibody therapy is a prime member of this class of 
treatments. Alemtuzumab (ALM) was one of the first monoclonal antibodies commercially available for 
therapeutic use. ALM is the final product of the Campath project that was started in 1979 by Herman 
Waldmann and colleagues at the pathology department of Cambridge University. The goal of this project 
was to create a monoclonal antibody for the purpose of depleting lymphocytes from bone marrow 
allografts, thereby preventing graft-versus-host disease (GvHD).1 Immunization of rats with human 
lymphocytes generated various antibody clones directed against the membrane-associated protein 
CD52.2 CD52 is expressed on the cell membrane of all mature lymphocytes, but not (or only marginally) 
on hematopoietic stem cells, red blood cells, or non-hematopoietic tissue.2-5 The exact biological function 
of CD52 is not known. Clinical tests with various variants of CD52-targeting antibodies demonstrated 
that CD52 was a suitable target to achieve the goals that had been set with limited accompanying 
toxicity.2,6,7 To prevent immunogenicity and to realize optimal recruitment of effector mechanisms 
(see below), a humanized IgG1 variant of anti-CD52 was created resulting in the final format of the 
therapeutic antibody ALM.8,9 
Clinical applications of ALM
In 2001, ALM was approved by the European Medicine Agency (EMA) and the US Food and Drug 
Administration (FDA) as a second-line monotherapy for B-cell chronic lymphocytic leukemia (CLL). 
Based on its mechanism of action (depletion of CD52-expressing lymphocytes), additional off-label 
uses have been developed. These include T-cell depletion before allogeneic hematopoietic stem cell 
transplantation (alloSCT), treatment of B-cell (e.g. B-lymphoblastic leukemia, follicular lymphoma, 
Waldenström’s macroglobulinemia)10 and T-cell malignancies (e.g. cutaneous T-cell lymphoma, T-cell 
prolymphocytic leukemia, T-cell acute lymphoblastic leukemia, Sézary syndrome)11, B-cell or T-cell 
depletion in the setting of auto-immune diseases (e.g. rheumatoid arthritis12 and multiple sclerosis13) 
and as immunoprophylaxis in solid organ transplant.14 In 2012, the original Campath formulation of ALM 
was withdrawn from the market. Rebranded as Lemtrada, ALM was shortly after approved by the FDA 
and EMA for the purpose of T-cell depletion in patients suffering from multiple sclerosis. Despite this 




ALM-based T-cell depletion in alloSCT
AlloSCT is a potentially curative treatment for patients who suffer from hematological malignancies or 
from non-malignant hematological diseases. The goal of the treatment is to replace the patient’s diseased 
hematopoiesis with normal hematopoiesis by infusion of hematopoietic stem cells from a healthy donor. 
The therapeutic effect and toxicity of alloSCT are determined by closely related mechanisms which 
are based on the genetic disparities between the donor and patient and are especially mediated via 
mature T cells that are infused with the donor stem cell graft.15,16 Recognition and elimination of residual 
malignant cells by these donor T cells conveys the therapeutic effect, termed graft-versus-tumor effect 
(GvT).17 On the other hand, recognition and destruction of non-hematopoietic healthy patient tissue (e.g. 
skin, liver, or gut) by donor T cells results in toxicity, known as GvHD.18,19 The clinical relevance of GvHD is 
reflected in the numbers with up to 35 - 50% of patients developing ≥grade 2 GvHD 20,21 and accounting 
for approximately 10% of deaths following alloSCT according to worldwide census data.22 To mitigate 
GvHD, strategies have been developed to remove donor T cells during the initial phase of alloSCT. One 
of the strategies relies on depletion of T cells by addition of ALM to the patient’s conditioning regimen 
(in-vivo depletion).23 Administration of ALM as part of the patient’s conditioning regimen serves two 
purposes; depletion of patient T cells to prevent graft rejection and depletion of donor T cells upon their 
infusion with the graft to prevent GvHD.24 Following in-vivo depletion of T cells by addition of 100 mg 
ALM to the conditioning regimen, incidence of ≥grade 2 GvHD in large cohort studies typically decreased 
to less than 10% in non-myeloablative conditioned patients transplanted with a sibling donor graft and 
to less than 20% of patients transplanted with an unrelated (matched or mismatched) donor graft.25-28 
As an alternative, donor T cells can be removed from the donor graft before infusion (In-vitro depletion, 
various techniques reviewed in Daniele et al.29). In-vitro depletion of T cells by administration of 20 
mg ALM to the bag containing the stem cell graft resulted in reduction of ≥grade 2 GvHD to 22% of 
myeloablative conditioned patients receiving an HLA-identical sibling graft.30 A combination of in-vivo 
and in-vitro T-cell depletion in non-myeloablative conditioned patients receiving a graft from an HLA-
matched unrelated donor resulted in almost complete absence of severe GvHD (6.7% of patients).31 
Together these clinical data illustrate the effectiveness of reducing GvHD through ALM-based T-cell 
depletion before alloSCT.
Treatment of B-lymphoblastic leukemia with ALM
A second clinical application of ALM is treatment of hematological malignancies. The shared characteristic 
of the malignancies treated with ALM is expression of the ALM target antigen CD52. One of these 
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malignancies is B-lymphoblastic leukemia (B-ALL). B-ALL is characterized by rapid and uncontrolled 
proliferation of B-lymphocyte progenitor cells within the bone marrow.32 Within The Netherlands, around 
165 new cases are diagnosed yearly and approximately 1160 patients suffer from B-ALL.33 Treatment of 
B-ALL has been shown to be challenging due to accumulation of additional genetic abnormalities upon 
progression of the malignancy, resulting in a complex subclonal architecture of the malignancy.34-37 
Nearly all subtypes of B-ALL display high levels of CD52 membrane expression, with the only exception 
being the B-ALL subtype carrying the mixed lineage leukemia (MLL)-translocation t(4;11).38 As such, ALM 
was considered a promising new treatment modality for patients with B-ALL resulting in their inclusion 
in the earliest clinical trials that were conducted with ALM.39 Unfortunately, despite initial good clinical 
responses, most patients who received ALM as a monotherapy relapsed early after treatment.40-42
Mechanisms of target-cell depletion by ALM
To understand the factors that determine the effectiveness of ALM as a therapeutic agent, it is 
necessary to understand how ALM exerts its function. ALM is an unconjugated cytotoxic antibody. Other 
well-known therapeutic agents in this category are the CD20-targeting antibodies rituximab (RTX) and 
ofatumumab (OFA). Upon binding to target antigens expressed on the surface of a cell, unconjugated 
cytotoxic antibodies recruit and activate the patient’s own immune effector mechanisms to induce 
death of the targeted cell. Immune mechanisms that have been recognized to be able to induce 
antibody-mediated target-cell death are antibody-dependent cellular cytotoxicity (ADCC), antibody-
dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC).43-47 In ADCC, 
clustered antibodies on the surface of a target cell recruit via their Fc-tails effector cells that express Fc-
receptors (e.g. natural killer cells). Crosslinking of Fc-receptors activates the effector cell, which is further 
enhanced in the presence of additional stimulatory signals, resulting in directional release of perforins 
and granzymes. Perforins are able to form pores in the target-cell membrane which allows granzymes 
to enter the cell and initiate apoptosis by cleavage of the apoptosis pathway proteins caspases and bid. 
In ADCP, antibody-opsonized target cells are recognized by macrophages which are able to engulf, take 
up, and enzymatically digest the cells. In CDC, clustering of antigen-bound antibodies (for IgG at least 2, 
but ideally 6)48 on the cell surface of target cells recruits C1q, the first component of the complement 
pathway. Upon recruitment of C1q, the complement pathway is activated resulting in a proteolytic 
cleavage cascade which ends with the formation of the membrane attack complex (MAC). This MAC 
consists of multiple membrane spanning C9 proteins that together form a pore in the membrane of the 
target cell resulting in an ion flux and ultimately osmotic lysis. 
1
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Factors that contribute to differential target-cell depletion by ALM
Many factors have been documented to influence the potential of cytotoxic antibodies to induce target-
cell depletion mediated via the immune effector mechanisms. These factors may thereby influence 
the overall efficacy of the treatment. Depending on the degree that they can be manipulated, better 
understanding of these factors may allow treatment optimization. In addition, factors that are patient 
or target-cell specific may allow us to understand why some patients are or become non-responsive to 
the treatment or experience side effects. Factors that are within the scope of this thesis were selected 
and described below.
Antibody concentration
One of the primary factors that influences effectiveness of treatment with therapeutic antibodies 
is antibody concentration. Higher concentrations allow more therapeutic antibodies to be bound to 
the target cell, leading to more efficient recruitment and activation of the individual immune effector 
mechanisms.5,49 The relevant antibody concentration range for effective induction of cell death is likely 
to be different for the various immune effector mechanisms. Based on in-vitro studies, the cell-mediated 
effector mechanisms ADCC and ADCP are anticipated to efficiently induce target-cell death at 10 to 
100 fold lower antibody concentrations than CDC (1-10 µg/mL).8 Whether similar concentrations also 
effectively trigger these mechanisms in-vivo remains under debate.
It is generally accepted that antibody concentration is an important variable affecting the efficacy of 
treatment with monoclonal antibodies. However, implementing strategies to optimize in-vivo antibody 
concentration by adjusting the treatment dose for individual patients has proven to be difficult. As a 
result most therapeutic antibody therapies, including ALM, are dosed according to a fixed schedule and 
with fixed amounts for all adult patients. Since most monoclonal antibody therapies are accompanied 
by no or only limited direct toxicity, most schedules use a relatively high antibody dose. To optimize 
antibody concentration it would be advantageous to be able to correctly estimate the antibody level 
at the site of the target cells as it would allow for an easier establishment of the correlation between 
antibody concentration and clinical effect. Since in the hematological setting target cells are directly in 
circulation or in well perfused tissue, blood plasma concentration is an accurate proxy for the antibody 
concentration near the target cells. As such, various clinical applications in which ALM is used would be 
appropriate candidates for patient-specific dose optimization. Implementing such approaches would 
require two yet to be established factors, (1) the optimal concentration range for clinical efficacy and (2) 
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patient-specific factors that could be used as predictors for plasma concentration.
CD52 antigen expression
Expression of target antigen on the membrane of the target-cell population is essential for treatment 
with cytotoxic therapeutic antibodies. Variation in antigen density has been shown to affect the 
effectiveness of antibody-mediated target-cell lysis, with higher antigen levels resulting in higher levels 
of ADCC, ADCP, and CDC.3,4,50,51 In terms of antigens per cell, CD52 is one of the highest expressed 
membrane-associated antigens on lymphocytes. Expression levels are typically 5 to 20 fold higher than 
for other membrane-associated antigens targeted by therapeutic antibodies, such as CD3, CD19, and 
CD20.52,53 CD52 is expressed on all mature lymphocytes subsets, but at different levels. In general, B and 
T cells express high CD52 levels whereas only low levels are present on NK cells and monocytes. Within 
these hematopoietic cell lineages, CD52 expression levels further differ between the various subsets. 
Within the T cell lineage, CD52 expression is highest on naive and memory CD4 cells and naive CD8 T 
cells followed by CD4 effector T cells and is lowest on memory and effector CD8 cells.4 For B cells, CD52 
expression is high on memory and naive B cells, but is almost completely absent on plasma cells.4,54 
Upon malignant transformation, antigen expression levels for CD52 were shown to remain relatively 
stable in relation to the healthy cell population from which they originate.50,54,55 
Inhibition of CDC by complement inhibitors
Complement inhibitors may affect the level of target-cell death induced via the mechanism of CDC. 
Complement activation is a complex multi-step pathway and various regulatory processes are known to 
be able to interfere with this pathway, ultimately blocking formation of the MAC. Most of the regulators 
of complement reside in the plasma and therefore convey protection to all host cells. Decay accelerating 
factor (DAF, CD55) and membrane inhibitor of reactive lysis (MIRL, CD59) are membrane-bound 
complement regulatory proteins (mCRP) and their expression level may vary considerably on cells. These 
mCRP may function as target-cell specific down-regulators of CDC.56-58 These proteins normally protect 
healthy human cells from the effect of spontaneous and bystander complement pathway activation. 
The level of protection conveyed by these mCRP to target cells from antibody-induced cell death via 




Resistance to ALM treatment
Following treatment with therapeutic antibodies, loss of antigen expression has frequently been 
observed. In many cases this is the result of biological variation in the level of target antigen expression 
on different cells within the original target population and subsequent treatment evasion of cells with 
low expression. Upon termination of the treatment, target antigen expression on the population may 
revert to original levels. However, in some cases loss of target antigen expression is permanent and 
outgrowth of these cells results in disease relapse resistant to this specific treatment. Following ALM 
treatment, loss of CD52 antigen expression has been observed intriguingly frequent. 
Loss of CD52 membrane expression
The exact incidence of development of these CD52 loss variants following the various ALM treatment 
regimens is largely unknown due to the absence of cohort studies. One exception is a study in which 
ALM was used for T-cell depletion before alloSCT, reporting presence of CD52-negative T cells early 
after transplantation in 23 of 26 patients.59 Other studies have also reported loss of CD52 expression 
following ALM-based T-cell depleted alloSCT,60,61 but not quantitatively. In the setting of treatment 
of T-cell malignancies, loss of CD52 expression following ALM treatment has been described in two 
case reports concerning Sézary syndrome and T-cell prolymphocytic leukemia.62,63 Remarkably, in 
several studies where ALM was used for the purpose of B-cell depletion, e.g. treatment of patients with 
rheumatoid arthritis,64 B-cell non-Hodgkin lymphoma,65 and chronic lymphocytic leukemia,66,67 loss of 
CD52 antigen expression from the membrane of T cells and not the B cells was described, despite 
these cells not being the target of treatment. Only two studies reported on CD52-negative cells other 
than T cells. These studies showed the presence of small populations of CD52-negative B cells present 
at diagnosis in patients with B-ALL.68,69 Interestingly, most reports describe permanent loss of CD52 
membrane expression, suggesting an underlying genetic involvement.
GPI-anchor expression is essential for CD52 membrane expression
CD52 is encoded by a single copy gene located on chromosome 1 (1p36) and is initially expressed as 
a 61 amino acid (aa) transmembrane protein. Subsequently, in the lumen of the endoplasmic reticulum, 
recognition of a glycophosphatidylinositol (GPI)-attachment signal at the carboxyl-terminus of CD52 by 
the GPI-transamidase complex results in removal of the transmembrane domain and transfer of the 
residual 12aa core peptide sequence (GQNDTSQTSSPS) onto the GPI anchor.70,71 As a consequence of 
this posttranslational modification, CD52 is marked for translocation to the plasma membrane where 
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it is mainly confined to membrane lipid rafts.72,73 Since the epitope of ALM includes part of the CD52 
peptide as well as part of the GPI anchor, GPI-anchor expression is essential for ALM binding.70
Besides CD52, at least 150 different proteins are attached to the plasma membrane via the GPI anchor. 
Correct synthesis of the GPI anchor is essential for membrane expression of these proteins. This is 
most evident for the rare acquired blood disorder paroxysmal nocturnal hemoglobinuria (PNH) wherein 
a single crippling mutation in the PIGA gene in a hematopoietic stem cell results in loss of GPI-anchor 
expression and consequently complement-mediated hemolysis of erythrocytes that lack membrane 
expression of GPI-anchored complement inhibitors CD55 and CD59.74,75 In total, 26 different genes are 
involved in the GPI-anchor biosynthesis pathway, of which almost all are essential for expression of the 
mature GPI anchor.76 Except for the PIGA gene which is located on the X-chromosome, all GPI genes 
are encoded on autosomal chromosomes. These GPI genes are expressed in all major tissues of the 
human body and are essential for normal tissue development as suggested by knock-out experiments 
performed in mice.77 An intriguing exception to this rule are cells from hematopoietic origin which were 
able to mature normally in the absence of GPI-anchor expression.77 Loss of GPI-anchor expression from 
the membrane of lymphocytes did not result in intrinsic survival or growth benefits compared to GPI-
anchor-positive lymphocytes,78 indicating that loss of GPI-anchor expression is relatively neutral in its 
effect on differentiation and proliferation of hematopoietic cells in the absence of artificially introduced 
selective pressure.
Loss of GPI-anchor expression following ALM treatment
The mechanisms that result in loss of CD52 target antigen expression following ALM treatment have 
been the topic of several studies. Interestingly, these studies showed that the common cause of loss 
of CD52 membrane expression was loss of expression of the GPI anchor. This was concluded based on 
simultaneous loss of membrane expression of multiple GPI-anchored proteins such as CD55, CD59, or 
CD48,59,64-66,68,69 and by absence of direct staining with the fluorescently labeled GPI-anchor specific 
inactivated toxin pro-aerolysin (FLAER).62 In three case studies, concerning patients with Sézary 
syndrome, non-Hodgkin lymphoma, or CLL, additional analyses were performed to elucidate how GPI-
anchor expression was lost. Genetic aberrations in the PIGA gene were found in all cases.62,65,66 Since 
PIGA is X-linked, only one mutation (in women due to genomic imprinting) can be sufficient to result in a 
non-functional protein, thereby explaining its frequent association with a GPI-anchor-negative phenotype. 
Remarkably, in GPI-anchor-negative malignant B cells found in patients with B-ALL no aberrations in the 
1
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PIGA gene were found.69 This indicates that a yet to be established mechanism other than a genetic 
aberrations in the PIGA gene resulted in loss of GPI-anchor expression in these B-ALL cells.
Challenges that hamper the clinical use of ALM
Adoption of ALM-based T-cell depleted alloSCT by the transplantation community has been limited, 
which is in part due to the difficulty of performing large randomized clinical trials to demonstrate the 
feasibility and efficacy of the approach. Solid scientific support for ALM-based T-cell depleted alloSCT 
from studies on the mechanistics of this approach may aid its acceptance. 
Application of ALM in treatment regimens for adults with B-ALL have been unsatisfactory. Little 
improvement was observed following the implementation of ALM monotherapy. The extent to which 
various factors contribute to effective activation of the immune effector mechanisms by ALM remain 
unknown. In addition, lack of molecular understanding of the mechanism that leads to relapse following 
ALM monotherapy prevents the use of this treatment as an effective therapy. Solving these issues could 
allow revival of this treatment modality, potentially by co-administration of synergistic drugs.
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Aims of the thesis
To optimally exploit the therapeutic potential of ALM it is essential to understand which factors contribute 
to the effectiveness of ALM-induced target-cell depletion. Despite being one of the first monoclonal 
antibodies to be used for clinical purposes, many basic questions on this topic remained unanswered. 
In this thesis we examined the relative contribution of several key factors that result in differential 
sensitivity of target cells for ALM-induced lysis in the clinical setting of T-cell depletion before alloSCT and 
treatment of B-ALL. 
ALM is successfully being used for in-vitro T-cell depletion before alloSCT to decrease the incidence of 
severe GvHD. However, in a small subset of patients acute GvHD is still observed. Also, it was anticipated 
that residual ALM after alloSCT delays T-cell reconstitution which may negatively affect protection 
against viral infections. To investigate the extent to which these processes are impacted by ALM levels, in 
chapter 2 we set out to measure ALM serum levels and the numbers of circulating T cells in a cohort 
of patients who had received an allogeneic in-vitro T-cell depleted graft with or without prior ALM as part 
of the conditioning regimen. Patient specific variables were tested for their effect on ALM serum level 
during and after transplantation. Pharmacokinetic modeling was used to predict ALM clearance within 
individual patients over time and to relate this to reconstitution of CD52-negative and CD52-positive T 
cells. Finally, the impact of post-transplant ALM peak levels and total ALM exposure was related to the 
incidence of GvHD and occurrence of viral infections.
CDC is a potent mechanism by which therapeutic monoclonal antibodies are able to kill target cells, but 
the effect and interplay of factors such as antibody concentration, antigen expression, and expression 
of the membrane-bound complement inhibitors, such as CD55 and CD59, on the efficiency of antibody-
induced target-cell lysis remained debated. In chapter 3 we aimed to investigate the interplay of these 
factors using B-ALL as a model. To broaden the relevance of the potential findings, therapeutic antibodies 
RTX and OFA that are frequently used in the treatment of B-cell malignancies were assessed alongside 
ALM. The effect of natural variation in the expression levels of the complement inhibiting factors was also 
assessed using primary malignant cells to examine their potential to serve as a predictor for effective 
CDC.
Following ALM-based T-cell depleted alloSCT, relatively rapid recovery of circulating T cells with a 
CD52-negative phenotype was observed in graft recipients (chapter 2). To establish the extent to 
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which CD52-negative cells contribute to reconstitution following ALM-based T-cell depleted alloSCT, 
a comprehensive phenotypic analysis of lymphocytes was done using samples taken from a cohort 
of patients who had received alloSCT for the treatment of various malignant and non-malignant 
hematological diseases. Results from this analysis are described in chapter 4. To establish the origin 
of the CD52-negative cells and to elucidate the mechanism resulting in their loss of CD52 membrane 
expression, chimerism analysis and an extensive genetic analysis was performed. Since CD52-negative 
T cells may be important in the early protection of alloSCT recipients against viral infections, we lastly 
studied the functional potential of CD52-deficient virus-specific T cells.
In patients with B-ALL, outgrowth of pre-existing malignant cells that are deficient for CD52 membrane 
expression may explain the short-lived treatment success of ALM-monotherapy. However, the extent 
to which these cells are present in patients was not known. In chapter 5 we aimed to determine 
the prevalence and frequency of these cells in a cohort of patients with B-ALL. Further, we set out to 
elucidate the mechanism by which these cells had become CD52 target antigen negative. Based on the 
newly gained insights we tested whether we could revert the phenotype by stimulation of the malignant 
B-ALL cells with a compound already established for clinical use.
In chapter 6, the results that are presented in chapters 2-5 are summarized and discussed based 
on current knowledge. We discuss the potential implication of these findings in relation to the various 
therapies in which ALM is applied and we discuss potential implications for future settings in which ALM, 
or medication targeting other GPI-anchored antigens, may be used. 
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Administration of alemtuzumab (targeting the CD52 antigen) to the patient (in-
vivo) or to the graft (in-vitro) before allogeneic stem cell transplantation (alloSCT) 
decreases the incidence of graft-versus-host disease (GvHD). Effectiveness of 
this treatment relies on depletion of donor T cells. Currently, no data are available 
on alemtuzumab pharmacokinetics and pharmacodynamics in patients who 
received combined in-vivo and in-vitro alemtuzumab-based T-cell depletion. In this 
prospective study, we analyzed alemtuzumab pharmacokinetics and its effect on 
the circulating T cells in 36 patients who received an allogeneic T-cell-depleted graft 
by addition of 20 mg alemtuzumab “to the bag” with or without prior alemtuzumab 
(30 mg cumulative dose intravenously) as part of the conditioning regimen. 
Effective T-cell depletion was shown for all patients, even though alemtuzumab 
plasma levels varied considerably. Peak alemtuzumab levels were observed directly 
after graft infusion and were not associated with the number of circulating T 
cells pre-infusion, but with plasma volumes of the patients. All patients engrafted, 
confirming feasibility of this transplantation protocol. Only three patients with low 
alemtuzumab levels developed acute GvHD (grade II in 2 patients and grade III in 
1 patient). Persistence of circulating alemtuzumab at 3 weeks after transplantation 
had prevented reconstitution of CD52-positive T cells when alemtuzumab plasma 
levels were above 0.7 µg/mL. However, overall T-cell reconstitution did not 
correlate with the levels of alemtuzumab exposure, due to early reconstitution of 
CD52-negative alemtuzumab-resistant T cells. The protective effect of these cells 
likely explains the low incidence of Epstein-Barr-virus- and cytomegalovirus-related 
disease despite circulating alemtuzumab.
ABSTRACT
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Allogeneic stem cell transplantation (alloSCT) is a potentially curative treatment for a variety of malignant 
and non-malignant hematological diseases. However, treatment related morbidity and mortality as a 
result of graft-versus-host disease (GvHD) remains a challenge. GvHD is caused by an immune reaction 
against non-hematopoietic healthy tissue mediated by donor T cells infused with the graft. Depletion of 
donor T cells can prevent the development of GvHD. The therapeutic graft-versus-tumor effect, which 
results from recognition of residual malignant cells by the donor T cells, is also diminished by donor T-cell 
depletion,1 but can be restored by postponed application of donor lymphocyte infusions.2-5
Alemtuzumab (Campath-1H) is a humanized IgG1 antibody which targets the glycophosphatidylinositol 
(GPI)-anchored protein CD52 that is expressed on lymphocytes, but not (or only marginally) on 
hematopoietic stem cells.6,7 Alemtuzumab efficiently depletes CD52-expressing cells through antibody-
dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and potentially by 
direct activation of pro-apoptotic pathways. Addition of alemtuzumab to the pre-transplant conditioning 
regimen to deplete donor T cells upon their infusion with the graft (in-vivo depletion), decreases the 
incidence of severe acute GvHD from 35-50% to 10-20%.8-11 Even more efficient prevention of GvHD is 
achieved when alemtuzumab is added directly to the stem cell graft (in-vitro depletion , or alemtuzumab 
“in the bag”).5,12-15 The efficacy of alemtuzumab-induced depletion of potentially alloreactive T cells 
depends on their CD52 expression in relation to the amount of alemtuzumab. After graft infusion, 
persistence of lytic plasma levels of alemtuzumab will prevent T-cell reconstitution and thereby increase 
the risk for patients to develop infections.16,17 Previously, we have shown that T cells that lost expression 
of CD52 due to loss of GPI-anchor expression have antiviral activity and expand early after alemtuzumab-
based in-vitro T-cell-depleted alloSCT.18 These CD52-negative T cells can contribute to the antiviral 
protection early after alemtuzumab-based T-cell-depleted alloSCT irrespectively of alemtuzumab levels. 
Over the years, alemtuzumab pharmacokinetics have been evaluated in various conditioning regimens 
using in-vivo alemtuzumab-based T-cell depletion in combination with post-transplantation cyclosporine 
as GvHD prophylaxis.8,9,19-21 However, the effect of combined in-vivo and in-vitro T-cell depletion on 
alemtuzumab pharmacokinetics has not been established. During in-vitro alemtuzumab incubation 
donor T cells are exposed to a high alemtuzumab concentration and upon graft infusion residual 
unbound alemtuzumab is co-infused into the circulation. In this study, we performed a comprehensive 
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analysis of alemtuzumab pharmacokinetics in relation to T-cell depletion, T-cell reconstitution, and the 
occurrence of GvHD and viral infections in 36 patients who had received an allogeneic graft depleted 
of T cells by addition of alemtuzumab “to the bag” with or without prior in-vivo patient T-cell depletion.
MATERIAL AND METHODS
Patients and samples
A cohort of 36 adult patients who received alemtuzumab-based T-cell-depleted alloSCT following 
one of four transplantation protocols (Table 1) at Leiden University Medical Center (LUMC, Leiden, 
the Netherlands) between November 2015 and February 2017 were included. Informed consent was 
obtained for treatment and scientific evaluation (LUMC protocol numbers P03.114, P04.003, P03.173). 
Sixteen patients received myeloablative (MA) conditioning, consisting of cyclophosphamide and either 
total body irradiation (TBI, n = 13) or busulfan (n = 3). In the case of an unrelated donor (UD, n = 8) 15 
mg alemtuzumab (MabCampath, Sanofi Genzyme, Naarden, the Netherlands) intravenously (IV) at days 
-6 and -5 (relative to the day of graft infusion) was added to the conditioning regimen. Twenty patients 
received non-myeloablative (NMA) conditioning consisting of 15 mg alemtuzumab IV at days -4 and -3, 
fludarabine, and busulfan. In case of an UD (n = 11) 1 mg/kg anti-thymocyte globulin (ATG; thymoglobulin, 
Sanofi Genzyme) was added at day -2. All patients received an allogeneic, G-CSF-mobilized peripheral 
blood stem cell (PBSC, n = 35) or bone marrow (BM, n = 1) graft subjected to T-cell depletion by addition 
of 20 mg alemtuzumab “to the bag”.22 Cyclosporin as prophylactic immune suppression was only 
given to patients with an UD after MA conditioning, starting day -1 and tapered from day 30. GvHD was 
graded according to modified Glucksberg and Shulman criteria.23 Peripheral blood (PB) samples were 
scheduled for collection immediately before, 30 min and 1 day after each alemtuzumab cycle and the 
graft infusion, and at weeks 1, 2, 3, 6, 9 after graft infusion. PB was collected in cell preparation tubes 
(CPT, BD, Becton Dickinson B.V., Breda, the Netherlands) to isolate mononuclear cells (MNC) and in EDTA 
tubes (BD) for direct flow cytometric analysis and for plasma isolation. MNC and plasma samples were 
cryopreserved at -180°C and -80°C, respectively.
Analysis of circulating alemtuzumab plasma levels
Alemtuzumab plasma levels were measured using a flow cytometry-based indirect immunofluorescence 
assay modified from the methodology described by Rebello and Hale.24 The CD52-positive 
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Table 1. Protocols, and patient and graft characteristics
Protocol   Patient-donor relation Number of patients
Myeloablative, n  Sibling donor  8
   Unrelated donor  8
Non-myeloablative, n  Sibling donor  9
   Unrelated donor  11
Patients
Age at alloSCT, y     54 (26 – 74)a
Gender, n   Male   27
   Female   9
BSA, m2      2.06 (1.57 – 2.42)a
Weight, kg      85 (58 – 115)a
Initial diagnosis, n  AML   15
   MM   5
   T-NHL   4
   ALL   3
   MDS   3    
   Myelofibrosis  2
   B-NHL   1
   MCL   1
   CMML   1
   WM   1
Grafts
Stem cell source, n  G-CSF stimulated PB  35
   BM   1 
HLA-match, n  10 out 10   32
   9 out 10   4
CD34 cells, 106 cells     496.2 (178.6 – 1414.4)a,b
TNC, 109 cells     63.8 (7.7 – 139.2)a
a Median and range are given.
b One patient received a BM graft for whom the number of CD34 cells was not quantified. 
Abbreviations: AML, acute myeloid leukemia; MM, multiple myeloma; T-NHL, T-cell non-Hodgkin lymphoma; ALL; acute lymphoblastic 
leukemia; MDS, myelodysplastic syndrome; B-NHL, B-cell non-Hodgkin lymphoma; MCL, mantle cell lymphoma; CMML, chronic 
myelomonocytic leukemia; WM, Waldenström macroglobinemia; TNC, total nucleated cells.
B-lymphoblastic leukemia cell line Leiden-ALL-HP 25 was seeded in a 96 wells plate (20.000 cells/well) 
and incubated with 10 µL of patient plasma at 0, 5, 10, 20, and 40 fold dilutions (in PBS) or as a reference 
(in duplicate) with 10 µL healthy donor plasma containing serially diluted alemtuzumab ranging from 
5.0-0.03 µg/mL. After incubation for 30 min at 4°C, cells were washed 4 times with PBS and incubated 
with phycoerythrin (PE)-conjugated F(ab’)2-goat anti-Human IgG Fc (Thermo Fisher Scientific, Bleiswijk, 
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the Netherlands) for 30 min at 4°C to detect bound alemtuzumab. Cells were washed twice with PBS 
and kept on ice until analysis. Fluorescence was measured on an LSRII analyzer (BD) and analyzed using 
FlowJo software (Treestar, Ashland, OR, USA). The alemtuzumab concentrations within the dilutions 
of the patient plasma sample were interpolated using the reference samples and multiplied by the 
respective dilution factor. Alemtuzumab plasma levels in patient samples were calculated from the 
average concentration from at least two sample dilutions. The lower detection limit of this assay was 
0.03 µg/mL alemtuzumab. In 6 patients, non-specific (e.g. anti-HLA antibodies, as determined by testing 
the samples against a GPI-anchor-deficient subculture of Leiden-ALL-HP that lacks CD52 membrane 
expression)26 low background levels (<0.176 µg/mL) were detected in the pre-treatment samples which 
were subtracted from subsequent measurements from the same patient. One patient who had received 
treatment with rituximab up to two months before alloSCT was excluded from this analysis as rituximab 
is also detected in this assay.
Flow cytometry
Absolute numbers of circulating CD4 T, CD8 T, B, and NK cells were determined by the clinical Laboratory 
for Specialized Hematology (LUMC) as part of routine immune monitoring after transplantation on 
anticoagulated fresh venous blood using Trucount tubes (BD, Becton Dickinson, Breda, the Netherlands) 
following the manufacturer’s instructions. Samples were stained with allophycocyanin (APC)-conjugated 
anti-CD3, PacificBlue-conjugated anti-CD4, fluorescein isothiocyanate (FITC)-conjugated anti-CD8, APC-
H7-conjugated anti-CD14, R-phycoerythrin (PE)-conjugated anti-CD16, PE-Cy7-conjugated anti-CD19, 
V500-conjugated CD45, and PE-conjugated CD56 (all from BD). Fluorescence was analyzed using a 
FACSCanto (BD). The lower detection limit for this analysis was 0.5x106 cells/L.
Absolute numbers of T cells in the graft were determined in samples taken before and after 30 min 
incubation with alemtuzumab. Cells were kept at 4˚C throughout the following steps to prevent 
additional cell loss due to processing. For each sample, the absolute number of nucleated cells was 
determined using a Sysmex KX-21 N (Sysmex, Etten-Leur, the Netherlands). Samples were pelleted and 
resuspended in red blood cell lysis buffer (8.4 g/L NH4CL and 1 g/L KHCO3, pH 7.4) (LUMC pharmacy). 
After 10 min incubation, cells were pelleted and resuspended in 10% v/v inactivated human serum 
at a concentration of 1x106–2x106 cells/mL. For logistic reasons samples were stored overnight at 
4°C. Afterwards, the percentages of viable cells were determined using a Bürker cell counter chamber 
and eosin staining. Cells were pelleted and resuspended in 600 µL PBS with pasteurized plasma 
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proteins 2% w/v (GPO, Sanquin, Amsterdam, the Netherlands) of which 150 µL was used to determine 
the percentages of T cells within the samples by flow cytometry after with APC-H7-conjugated anti-
CD3 (BD). The total numbers of viable T cells in the grafts were calculated by multiplying the Sysmex 
measurement with the graft volume subtracting the percentage of non-viable cells and multiplying by 
the percentage of T cells.
GPI-anchor and CD52 membrane expression on CD4 and CD8 T cells was analyzed by flow cytometry 
on thawed MNC by staining with the GPI-anchor-specific inactivated toxin pro-aerolysin coupled to Alexa 
Fluor 488 (FLAER-AF488, Sanbio, Uden, the Netherlands), APC-conjugated anti-CD52 (ITK diagnostics, 
Uithoorn, the Netherlands), APC-H7-conjugated anti-CD3, v500-conjugated anti-CD4 (BD), PacificBlue-
conjugated anti-CD8 (BD), and AlexaFluor700-conjugated anti-CD45 (ITK diagnostics). Fluorescence 
was analyzed using an LSRII (BD).
Population pharmacokinetics model building
Pharmacokinetic parameters were estimated using a developed population pharmacokinetic model 
based on the alemtuzumab plasma concentration-time data by non-linear mixed-effects modeling using 
NONMEM (V7.3, Icon Development Solutions, Ellicot City, MD, USA). The Perl-speaks-NONMEM toolkit 
version 4.7.0 (ref Lindbom et al.)27 and Pirana version 2.8.0 (ref Keizer et al.)28 were used as modeling 
environment. Results were plotted using R (V2.25.2, Boston, MA, USA) and RStudio (V0.97.248). First-
order conditional estimation method with interaction was used throughout the analysis. One and two 
compartmental pharmacokinetic models with first order elimination or non-linear elimination were 
compared with the observed alemtuzumab plasma concentration-time data to find the optimal fit. 
Model selection was based on statistical significance, goodness of fit and stability. Throughout the 
model building process, an altered model was chosen over a pre-cursor model if the difference in the 
objective functions (−2 log likelihood) was >6.63 (P < 0.01, with 1 degree of freedom, assuming χ2 
distribution). To identify possible covariates influencing alemtuzumab pharmacokinetics, diagnostic 
plots were constructed of the random effects of clearance (Cl), distribution volume (V1) versus the 
demographic (gender, age, body weight, height, body surface area, body mass index) and clinical 
covariates (initial diagnosis, absolute number of circulating patient T cells per liter of blood before IV 
alemtuzumab infusions, absolute number of donor leukocytes in the graft, hematocrit, and plasma 
volume). Plasma volume was calculated from blood volume using the Nadler method 29 and corrected 
for the patients hematocrit (ht) (formulas in Table S1). The final population pharmacokinetic model was 
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validated by means of a prediction corrected visual predictive check (pcVPC, 500 runs) and bootstrap 
(1000 runs).30 
EBV and CMV detection and management
Epstein-Barr virus (EBV)-reactivation was defined as a detectable EBV DNA load in the serum by qPCR. 
Rituximab treatment (375 mg/m2) for EBV-reactivation was initiated if EBV DNA load was above 103 
copies/mL. Cytomegalovirus (CMV)-reactivation was defined as a DNA CMV load higher than 103 copies/
mL in serum by qPCR.31 Treatment for CMV-reactivation was initiated if the load was higher than 103 
copies/mL at two consecutive measurements and consisted of oral valganciclovir (900 mg twice daily) 
or IV ganciclovir (5 mg twice daily) for 2 weeks. CMV-disease was defined as CMV-reactivation with 
proven organ involvement.
Statistical analysis
Statistical analyses were performed using Prism 6 (GraphPad, La Jolla, CA, USA) using tests as indicated.
RESULTS
In-vivo depletion of patient T cells by alemtuzumab before graft infusion
All 20 NMA-conditioned patients and all 8 MA-conditioned patients with an unrelated donor received 
two intravenous (IV) infusions of 15 mg alemtuzumab as part of the conditioning regimen. To examine 
the effectiveness of alemtuzumab-induced in-vivo patient T-cell depletion, we determined the absolute 
numbers of circulating T cells directly before the first alemtuzumab infusion and 30 min after the second 
alemtuzumab infusion using flow cytometry. 6 patients were excluded from this analysis as either the 
pre- or post-alemtuzumab infusion sample was absent. The median T-cell count before the alemtuzumab 
infusions was 50x106 cells/L (range 4x106–829x106 cells/L). After the alemtuzumab infusions, complete 
depletion of circulating T cells was observed in 18 out of 22 patients (Figure 1A), whereas in the 
remaining 4 patients minimal numbers of residual T cells were found (range 0.6x106–1.0x106 cells/L).
To establish the alemtuzumab levels after the IV alemtuzumab infusions, we measured alemtuzumab 
plasma concentrations in available samples taken from patients before and 30 min after each infusion. 
After infusion 1, the median alemtuzumab plasma level was 2.5 µg/mL (range 1.1–6.5 µg/mL, n = 25, 
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Figure 1. Efficient in-vivo patient T-cell depletion following IV alemtuzumab
(A) Absolute numbers of circulating T cells before IV alemtuzumab infusion 1 and after IV alemtuzumab infusion 
2. Red symbols depict patients that displayed low numbers of residual T cells following infusion 2. The dotted line 
represents the detection limit for this analysis. (B) Alemtuzumab plasma levels 30 min after IV alemtuzumab infusion 
1 and 2. Dotted lines connect measurements from the same patient. (C) Relation between the number of circulating 
T cells before IV alemtuzumab infusion 1 and the alemtuzumab plasma level directly after IV alemtuzumab infusion 1. 
(D) Correlation between the alemtuzumab plasma levels 30 min after IV alemtuzumab infusion 1 and the increase in 
alemtuzumab plasma levels by IV alemtuzumab infusion 2. The increase in alemtuzumab plasma levels following infusion 
2 was calculated by subtracting the alemtuzumab plasma levels before (max 8h) infusion 2 and 30 min after infusion 
2. (E) Correlation between the alemtuzumab plasma levels directly after IV alemtuzumab infusion 2 and the calculated 
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Figure 1B). No correlation was found between the alemtuzumab plasma levels and the numbers of 
circulating T cells (r = 0.11, p = 0.63, Figure 1C) or the total numbers of circulating lymphocytes (r = 
0.13, p = 0.58, data not shown) before infusion. Alemtuzumab plasma levels were comparable between 
patients diagnosed with different malignancies (data not shown). The median alemtuzumab plasma 
level before the second infusion was 1.7 µg/mL (range 0.8–3.4 µg/mL, n = 23, data not shown) and 
increased to 3.9 µg/mL (range 2.4–9.7 µg/mL, n = 26, Figure 1B) after the second infusion. In patients 
with detectable T cells after the two alemtuzumab infusions (Figure 1A red symbols), alemtuzumab 
plasma levels were within the normal range (Figure 1B red symbols). The increase in the alemtuzumab 
plasma levels by infusion 2 correlated with the alemtuzumab plasma levels that had been reached 
in individual patients after infusion 1 (p < 0.0001, both samples available for 22 patients, Figure 1D). 
Because therapeutic antibodies are initially distributed in the blood plasma volume,32 we analyzed 
whether the alemtuzumab plasma levels in individual patients correlated with their calculated plasma 
volumes. A strong negative correlation was found between the calculated plasma volumes and the 
alemtuzumab plasma levels measured after infusion 1 (r = 0.58, p = 0.002, data not shown) and infusion 
2 (r = 0.63, p = 0.0005, Figure 1E). Weaker or no significant correlation was found between body surface 
area and weight and alemtuzumab plasma levels after infusion 2 (r = 0.48, p = 0.01 and r = 0.31, p = 
0.13, respectively; Figure S1). In conclusion, the plasma volumes and not the numbers of circulating 
lymphocytes correlated with the alemtuzumab plasma levels in patients after IV alemtuzumab infusions.
Alemtuzumab-induced lysis of donor T cells 
To prevent acute GvHD, 20 mg alemtuzumab was added to the stem cell grafts. Due to the limited graft 
volumes (median 360 mL, range 115–730 mL), high alemtuzumab concentrations were reached in the 
bags (estimated median 55 µg/mL, range 27–177 µg/mL), thereby promoting efficient coating of target 
cells. Since grafts are only incubated with alemtuzumab for 30 minutes before infusion, we expected 
partial lysis of donor T cells “in the bag” followed by ongoing in-vivo lysis after infusion of the stem cell 
grafts into the patients. To estimate the magnitude of in-vitro T-cell depletion, absolute numbers of T 
cells before and after 30 minutes alemtuzumab incubation were determined in five grafts. The median 
T-cell count before alemtuzumab infusion was 14.6x109 T cells (range 8.3x109–17.3x109 T cells) and 
after incubation 0.5x109 T cells (range 0.2x109–1.3x109 T cells), indicating a 30 fold reduction (range 
11–44 fold). After alemtuzumab incubation, the stem cell grafts including residual alemtuzumab-coated 
donor T cells and unbound alemtuzumab were infused into the patients. We determined the absolute 
numbers of circulating T cells in patient PB samples taken 30 min after graft infusion (available for 30 
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patients). In 22 patients, no circulating T cells were found. In the remaining 8 patients, low numbers of 
T cells (range 0.2x106–7x106 cells/L) were detected at that time, but these were no longer found in 
subsequent samples (taken between days 1 and 7 after graft infusion) in 7 out of 8 patients (data not 
shown). The remaining patient continued to have low numbers of circulating T cells with the lowest 
number (1.04x106 cells/L) at day 14 after graft infusion. Insufficient cells were available to determine 
whether these cells were of patient or donor origin. These data show that in the majority of patients no 
circulating T cells are found after the infusion of a stem cell graft to which 20 mg alemtuzumab is added. 
To evaluate the effect of alemtuzumab infused with the graft on the alemtuzumab plasma levels in 
the patients, we analyzed the alemtuzumab plasma levels in samples taken before (maximum 8h) 
and 30 min after graft infusion. In MA-conditioned patients with a sibling donor who had only received 
 Figure 2. Increase in patients alemtuzumab plasma levels following graft infusion
(A) Relation between the alemtuzumab plasma levels directly after graft infusion and the patients’ plasma volumes 
in patients who had not received alemtuzumab as part of the patient conditioning regimen. (B) Alemtuzumab plasma 
levels directly before and after graft infusion in patients who had already received alemtuzumab as part of the 
patients conditioning regimen. Dotted lines connect measurement from the same patient. (C) Correlation between 
the alemtuzumab plasma levels directly after graft infusion and the patients’ plasma volumes in patients who had 
already received alemtuzumab as part of the patients conditioning regimen. The solid line depicts a non-linear 



















































































































































































































































alemtuzumab “in the bag”, alemtuzumab plasma levels reached a median of 3.0 µg/mL (range 0.4–4.5 
µg/mL, samples were available for 7 out of 8 patients). Since in these patients alemtuzumab was not 
part of the patient conditioning regimen, residual circulating patient T cells were present before graft 
infusion (range 1x106–64x106 cells/L), but these did not correlate with alemtuzumab plasma levels after 
graft infusion (r = 0.30, p = 0.51, data not shown). A trend was observed between higher calculated 
plasma volumes and lower alemtuzumab plasma levels (r = 0.40, p = 0.43, Figure 2A). In one patient, 
alemtuzumab levels were particularly low (0.4 µg/mL, Figure 2C open circle). This patient had a history 
of hairy cell leukemia and splenomegaly at the time of transplantation, which may have contributed to 
absorption of alemtuzumab. For patients who had already received alemtuzumab as part of the patient 
conditioning regimen, pre and post graft infusion samples were available for 23 out of 28 patients. 
Before graft infusion, a median alemtuzumab concentration of 2.0 µg/mL (range 1.0–5.3 µg/mL, Figure 
2B) was present. After graft infusion, alemtuzumab plasma levels increased to a median of 4.8 µg/
mL (range 2.6–10.4 µg/mL, Figure 2B). Similar alemtuzumab plasma levels were found between NMA-
conditioned patient who had (median 4.8 µg/mL, range 3.4-10.4 µg/mL) or had not (median 4.6 µg/mL, 
range 2.6-9.8 µg/mL) received additional ATG during in-vivo conditioning. A strong negative correlation 
was found between the calculated patients’ plasma volumes and the alemtuzumab plasma levels before 
(r = 0.67, p = 0.0001, data not shown) and after graft infusion (r = 0.59, p = 0.003, Figure 2C). Together 
these data show that the increase in alemtuzumab levels by graft infusion was independent of pre-
treatment with alemtuzumab during patient conditioning. The increase in alemtuzumab levels were in 
line with an increase expected from direct IV injection, indicating presence of an excess amount of 
alemtuzumab “in the bag” whereby the bulk of alemtuzumab remained unbound.
Influence of circulating alemtuzumab on reconstitution of T cells
After transplantation, neutrophil repopulation indicated engraftment in all patients. To study the influence 
of alemtuzumab on T-cell reconstitution, we determined the absolute numbers of circulating CD4 and 
CD8 T cells starting at three weeks after the transplantation. At week three after graft infusion (data 
were available for 33 out of 36 patients), 23 patients had already reconstituted with CD4 T cells (range 
0.9x106–106x106 cells/L) and 21 patients with CD8 T cells (range 0.7x106–848x106 cells/L). At week 
nine after graft infusion (data were available for 31 patients), 30 patients had circulating CD4 T cells 
(range 1.1x106–864x106 cells/L) and 29 patients had circulating CD8 T cells (range 4x106–3367x106 
cells/L). Persistence of circulating alemtuzumab after graft infusion was modelled by population 
pharmacokinetics analysis with non-linear mixed effects modeling using alemtuzumab plasma 
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concentration-time data. Alemtuzumab pharmacokinetics was best described by a two-compartment 
intravenous model with first-order elimination. Random effect parameters for inter-individual variability 
in clearance, distribution volume of the central compartment and the peripheral compartment were 
identified (model parameters in Table 2; pcVPC and goodness of fit plots in Figure S2 and S3, respectively). 
The mean half-life of alemtuzumab in the elimination phase was 8.7 days (range 2.4-19.1). No direct 
correlations were found between the number of CD4 or CD8 T cells and modelled alemtuzumab plasma 
levels at 3 weeks (r = 0.23 and r = 0.14, respectively) or 9 weeks (r = 0.06 and r = 0.16, respectively) 
post-transplantation. These data show no direct correlation between T-cell reconstitution and residual 
circulating alemtuzumab.
We and others have previously shown that after alemtuzumab-based T-cell-depleted alloSCT, 
reconstituting T cells have frequently lost CD52 membrane expression18,33 making them resistant to 
alemtuzumab. We therefore evaluated the effect of residual alemtuzumab on reconstitution of CD52-
positive and CD52-negative T cells. CD52 membrane expression was analyzed by flow cytometry and 
combined with the absolute numbers of circulating CD4 and CD8 T cells determined in samples taken at 
the same time point. Complete absence of CD52-positive CD4 and CD8 T cells was observed at week 3 
when alemtuzumab plasma levels were above 0.7 µg/mL (Figure 3A and 3B, respectively). In contrast, 
no association was found between alemtuzumab plasma levels and the numbers of CD52-negative CD4 
and CD8 T cells (Figure 3C and 3D, respectively). At week nine, all patients had alemtuzumab plasma 
levels <0.34 µg/mL and no effect of alemtuzumab plasma levels was observed on either CD52-negative 
of CD52-positive T-cell reconstitution (data not shown).
Table 2. Model parameter estimates
 Clearance (L/day)     0.9 (0.2 – 14.0)
 Half-life distribution phase (hours)    10 (4 – 23) 
 Half-life elimination phase (days)    8.7 (2.4 – 19.1) 
 Volume central compartment (L)    2.8 (1.1 – 29.2)
 Inter-compartmental clearance (L/day)    2.9
 Volume peripheral compartment (L)    6.3 (3.1 – 12.2) 
 Peak alemtuzumab concentration (µg/mL)   8.4 (0.7 – 22.2)
 Total alemtuzumab exposure* (µg.day/mL)   25.2 (1.4 – 54.1)
* After graft infusion 
Median values (range) are given unless stated otherwise.
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Figure 3.  Reconstitution of CD52-positive T cells is blocked by persistence of lytic alemtuzumab plasma levels 
Absolute number of circulating CD52-positive (A) CD4 and (B) CD8 and CD52-negative (C) CD4 and (D) CD8 T 
cells at week 3 after graft infusion. Each dot represents the analysis for one patient. The dotted lines indicate the 
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These data show that in-vivo alemtuzumab levels above 0.7 µg/mL prevented reconstitution of CD52-
positive T cells.
Absence of GvHD in the presence of high alemtuzumab levels
Because acute GvHD is mediated by naïve donor T cells infused with the graft,34 we investigated 
whether modelled alemtuzumab peak concentrations directly after graft infusion correlated with the 
incidence of GvHD. Two patients who had developed an early relapse (weeks 6 and 7 post graft infusion) 
and received additional chemotherapy were not included in the analysis. Three patients (one MA- and 
one NMA-conditioned patient with sibling donors and one MA-conditioned patient with an UD) had 
developed GvHD grade II or III within the first 10 weeks following graft infusion. All three patients had 
low peak alemtuzumab plasma concentrations (Figure 4). No GvHD was observed in patients with peak 
alemtuzumab levels above 6.5 µg/mL.
Effect of alemtuzumab exposure on viral complications
Because persistence of alemtuzumab was shown to affect CD52-positive T-cell reconstitution, we 
analyzed whether differences in alemtuzumab exposure after graft infusion had affected the incidence 
of viral complications. Alemtuzumab exposure was estimated for each patient using population 
pharmacokinetics and related to reactivations of EBV and CMV occurring within the first 10 weeks 
after graft infusion. 5 out of 36 patients were excluded from this analysis as they had developed an 
early relapse (n = 2) or GvHD (n = 3) and received additional chemotherapy or steroid treatment. 
No EBV-reactivation was observed in patients that were EBV-seronegative before transplantation (n 
= 3). From the 28 pre-transplant EBV-seropositive patients, 7 had an EBV-reactivation (of whom 2 
had an EBV-seronegative donor). None of these patients required treatment for the EBV-reactivation 
and alemtuzumab exposure was comparable to patients without EBV-reactivation (mean area under 
the curve 28.4 ± 11.9 µg.day/mL compared to mean 31.2 ± 10.4 µg.day/mL, p = 0.63). For CMV, no 
reactivation was observed in the patients who were CMV-seronegative before transplantation (n = 14). 
From the 17 pre-transplant CMV-seropositive patients, all had detectable CMV-reactivations within the 
first 10 weeks after graft infusion and 14 patients were consequently treated with antiviral drugs. None 
of the patients developed CMV-disease. There was a weak correlation between alemtuzumab exposure 
and the duration of CMV viremia (Figure 5). Although circulating alemtuzumab levels in this cohort were 
sufficient to prevent the development of acute GvHD in the majority of patients, no patient developed 
viral disease in this period. 
CHAPTER 242
Figure 4. Absence of GvHD in the presence of high 
alemtuzumab levels 
Peak alemtuzumab plasma levels and the occurrence of GvHD 
within the first 10 weeks after graft infusion. Alemtuzumab peak 
levels were estimated for each patient using pharmacokinetics 
modelling. Each dot represents the analysis for one patient.
Figure 5. Effect of alemtuzumab exposure on CMV-clearance
Relation between alemtuzumab exposure and time to clear a 
CMV-reactivation. Alemtuzumab exposure was estimated for 
each patient using population pharmacokinetics modelling. 
Each dot represents the analysis for one patient. The solid line 
depicts a non-linear regression analysis and P values were 
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This study confirms that the combination of in-vivo and in-vitro alemtuzumab effectively prevents acute 
GvHD after alloSCT without compromising engraftment.35,36 Our data demonstrate that plasma volume 
rather than the number of circulating lymphocytes determines inter-individual variation in alemtuzumab 
plasma peak. Patients with a plasma peak level after transplantation above 6.5 µg/mL did not develop 
acute GvHD. Although the post-transplantation T-cell suppression in this cohort was sufficient to prevent 
acute GvHD in the majority of patients, no cases of EBV-PTLD or CMV-disease were seen. Antiviral 
immune protection results from an early outgrowth of CD52-negative T cells. Whereas circulating CD52-
positive T cells were absent when residual alemtuzumab level were above 0.7 µg/mL, the reconstitution 
of CD52-negative T cells was not affected by alemtuzumab.
One of the aims of adding of alemtuzumab to the conditioning regimen of a patient before alloSCT is 
the eradication of patient T cells to avoid graft rejection. We showed that virtually all circulating T cells 
were efficiently depleted in patients who had received infusion of 30 mg alemtuzumab IV. In contrast, in 
MA-conditioned patients with a sibling donor who had not received alemtuzumab IV, circulating T cells 
were found up to the moment of graft infusion. Alemtuzumab plasma levels in our cohort correlated 
with the patients’ plasma volumes. In patients with CLL treated with alemtuzumab, alemtuzumab plasma 
levels were found to be highly affected by the tumor burden due to target-cell-mediated alemtuzumab 
absorbtion37-39. In our cohort, alemtuzumab plasma levels did not correlate with the numbers of circulating 
T cells present at time of alemtuzumab infusion, likely because patients in our cohort were in remission 
for the primary disease when receiving the alloSCT and had received TBI and/or chemotherapy before 
alemtuzumab, together resulting in low numbers of circulating lymphocytes. One patient had particularly 
low alemtuzumab plasma levels. This patient had a history of hairy cell leukemia and had splenomegaly 
at the start of the alloSCT, which was given to treat a therapy related acute myeloid leukemia. We 
hypothesize that the spleen effectively absorbed alemtuzumab and therefore we suggest that patients 
with residual bulky disease require higher alemtuzumab dosing to overcome alemtuzumab absorption, 
as previously suggested by Chakraverty et al.40
Alemtuzumab is added to the graft to eradicate donor-derived T cells thereby preventing GvHD. We 
showed that pre-incubation of the graft with 20 mg alemtuzumab reduced donor T-cell numbers on 
average by a factor of 30. After infusion of the graft with remaining donor T cells with bound and 
DISCUSSION
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unbound alemtuzumab, circulating alemtuzumab led to ongoing lysis of circulating T lymphocytes. In 
order to correlate alemtuzumab pharmacokinetics with clinical outcomes like the occurrence of acute 
GvHD, viral reactivation, and T cell reconstitution after alloSCT, alemtuzumab peak concentrations and 
alemtuzumab exposure were estimated for each patient using population pharmacokinetics analysis 
with non-linear mixed effects modeling. Three patients in our cohort developed limited GvHD after 
alloSCT, suggesting that some donor T cells had escaped alemtuzumab treatment. Because GvHD is 
predominantly mediated by naïve donor T cells infused with the graft,34 which express high levels of 
CD52 and as a consequence are highly sensitive to alemtuzumab-mediated cell lysis,41 acute GvHD 
would be expected to occur because of inadequate peak alemtuzumab levels. Indeed, low alemtuzumab 
peak concentrations were found in all three patients who developed GvHD. Furthermore, no GvHD 
was observed in patients with alemtuzumab peak levels above 6.5 µg/mL, illustrating that adequate 
alemtuzumab peak levels indeed effectively prevent GvHD. These plasma peak levels were the product 
of alemtuzumab added to the graft and alemtuzumab applied IV as part of the conditioning. Since 
the plasma peak levels correlated with the patients’ plasma volume, modifying the alemtuzumab dose 
based on this parameter could be considered as a way to dictate the plasma peak level post-transplant. 
Indeed, the three patients in our cohort who developed GvHD coinciding with low alemtuzumab peak 
levels had relatively high plasma volumes. However, we are somewhat reluctant to suggest patient-
specific adjustment of the alemtuzumab dose based on plasma volume only, due to the low patient 
numbers and the likelihood that proper prediction of the peak levels post-transplant most likely requires 
inclusion of additional parameters such as pre-transplant alemtuzumab serum measurements, and 
factors like splenomegaly. The incidence of GvHD in our cohort was comparable to previous studies in 
which patients received in-vivo alemtuzumab in combination with post-transplant immune suppression 
with cyclosporin.40,42
Persistence of high levels of residual alemtuzumab can also delay reconstitution of protective virus-
specific T cells. Here we established an in-vivo lytic alemtuzumab plasma level of 0.7 µg/mL as the 
lower threshold for reconstitution with CD52-positive CD4 and CD8 T cells. This level is substantially 
higher than the previously suggested lytic alemtuzumab level of 0.1 µg/mL, which was based on the 
anticipated combined effect of ADCC and CDC as effector mechanisms.42,43 Low numbers of effectors 
cells early after alloSCT may decrease the contribution of ADCC to in-vivo cell lysis. CDC, which is known 
from in-vitro tests to be efficient only at higher alemtuzumab concentrations starting at levels identical 
to the minimal lytic alemtuzumab level we found,44 may be the main mechanism causing T-cell depletion 
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after transplantation. Although a correlation between alemtuzumab levels and outgrowth of CD52-
positive T cells was found, there was no correlation between total numbers of T cells and alemtuzumab 
exposure. This discrepancy resulted from rapid outgrowth of large populations of CD52-negative 
alemtuzumab-resistant T cells early after transplantation. Previously we have reported that these CD52-
negative T-cell populations are mainly of a memory phenotype and contain functional virus-specific 
CD8 T cells, including CMV-specific T cells. These CD52-negaive memory T cells appeared to be mainly 
of donor origin, but also profound outgrowth of CD52-negative memory T cells of recipient origin was 
observed in some patients, especially associated with viral clearance shortly after the transplantation.18 
The protective effect of these cells likely explains why no correlation was found between the level of 
alemtuzumab exposure and the incidence of EBV- or CMV-reactivation, or on EBV-clearance, and only a 
minimal effect on CMV-clearance. Of note, unlike naïve T cells, these CD52-negative memory T cells are 
not expected to contribute to GvHD. 
We conclude that after alloSCT using in-vitro with or without prior in-vivo T-cell depletion with 
alemtuzumab, plasma alemtuzumab peak levels above 6.5 µg/mL prevent the development of acute 
GvHD. After alloSCT, circulating CD52-positive T cells are absent as long as the circulating alemtuzumab 
level is above 0.7 µg/mL. The reconstitution of CD52-negative cells is not influenced by alemtuzumab 
level and contributes to the prevention of viral disease after alloSCT.
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Table S1. Demographic formulas
Body surface area   BSA (m2) =         Height (cm) x Weight (kg)
      √ 3600
Body mass index   BMI          =           Weight (kg)
                    [Height (m)]2
Blood volume (male)   BV (L) = [Length (m)]3  x 0.367 + Weight (kg)x 0.032+0.604
Blood volume (female)   BV (L) = [Length (m)]3  x 0.356 + Weight (kg)x 0.033+0.183
Plasma volume corrected for hematocrit PV (L) = BV (L) x  1-ht      
(     )kgm2
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Figure S1. (A) Correlation between the alemtuzumab plasma levels directly after IV alemtuzumab infusion 2 and 
the calculated patients’ body surface area. (B) Correlation between the alemtuzumab plasma levels directly after IV 
alemtuzumab infusion 2 and the patients’ body weight. The solid lines depicts linear regression analyses and P values 
were generated by F test.
Figure S2. Prediction corrected visual predictive check with median, 10th and 90th observation percentile. The 
observed alemtuzumab plasma concentrations are shown as open circles. The red and blue lines represent the 
observed median and 10th and 90th percentile. The shaded areas represent the 95% confidence interval around 
each of the prediction percentiles.
Figure S3. Representative examples of goodness of fit plots of individuals receiving MA-conditioning and a sibling 
donor graft (A) or an UD graft (B), or receiving NMA-conditioning and a sibling donor graft (C) or an UD graft (D). 
Blue circles indicate the measured concentration, the red line is the individual prediction of the model. The moment 
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CHAPTER 3
Complement-dependent cytotoxicity induced 
by therapeutic antibodies in B-cell acute 
lymphoblastic leukemia is dictated by target 
antigen expression levels and augmented by 
loss of membrane-bound complement inhibitors
1 Department of Hematology  - Leiden University Medical Center - Leiden - the Netherlands
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CHAPTER 354
To optimally utilize therapeutic monoclonal antibodies in the treatment of 
B-cell acute lymphoblastic leukemia (B-ALL) understanding their mechanisms 
of action and the factors influencing these mechanisms is required. We show 
strong correlations between target antigen expression levels and sensitivity to 
complement-dependent cytotoxicity (CDC) induced by rituximab, ofatumumab, or 
alemtuzumab in a panel of cell lines derived from primary B-ALL cells and in primary 
B-ALL samples. Simultaneous loss of expression of membrane-bound complement 
regulatory proteins (mCRP) CD55 and CD59 due to glycophosphatidylinositol-anchor 
deficiency, significantly increased sensitivity to CDC. Accordingly, induced increase 
in CD55 or CD59 expression protected cells against CDC. The extent of protection 
co-depended on antigen expression and antibody concentration. In contrast, 
natural variation in mCRP expression could not be used as a single factor to predict 
sensitivity to CDC. In conclusion, sensitivity of B-ALL cells to CDC was predominantly 




Incorporation of chimeric and humanized monoclonal antibodies in the management of B-cell derived 
hematologic malignancies improved treatment outcome in recent years. Successes in treatment of 
chronic lymphocytic leukemia (CLL) and B-cell lymphoma by targeting surface antigens CD20 using 
rituximab (RTX) or ofatumumab (OFA) and CD52 using alemtuzumab (ALM),1 has initiated the interest of 
using these antibodies in the treatment of B-cell acute lymphoblastic leukemia (B-ALL). Although results 
from initial single-agent approaches were disappointing,2 single-arm and comparative studies using 
CD20 targeting antibodies in combination with chemotherapeutics have shown safety and efficacy.3,4 
These results were underlined by results from the randomized Group for Research on Adult Acute 
Lymphoblastic Leukemia 2005 trial, in which addition of RTX to standard therapy improved event free 
survival.5
To optimally exploit the potential of therapeutic antibodies it is essential to understand their mechanisms 
of action and the factors that influence these mechanisms. The primary mechanisms of action include 
antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), 
and complement-dependent cytotoxicity (CDC).6-9 Although their relative contribution in-vivo is not fully 
clarified, experiments in C1q knock-out mice and in mice pretreated with cobra venom factor indicate a 
dominant role for CDC.10,11 This is supported by the observation of complement consumption in patients 
treated with RTX, OFA, or ALM,12-14 longer time to progression in RTX-treated follicular lymphoma (FL) 
patients carrying a specific C1q phenotype,15 and superior correlation between clinical outcome and 
in-vitro CDC compared with ADCC experiments in patients with B-cell malignancies.16 
Several factors contribute to successful eradication of tumor cells by CDC. For instance, higher antigen 
expression levels are associated with higher levels of complement activation by the therapeutic 
antibodies, increased CDC in-vitro,17,18 and improved clinical outcome.19 In contrast, expression of 
membrane-bound complement regulatory proteins (mCRP) decay accelerating factor (DAF, CD55) 
and membrane inhibitor of reactive lysis (MIRL, CD59), which normally protect cells from the effect of 
spontaneous and bystander complement pathway activation, have been suggested as down-regulators 
of CDC.20-23 However, whether these mechanisms are relevant in B-ALL which is characterized by a 
particular heterogeneous level of antigen expression is not known.
INTRODUCTION
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In this study, we analyzed the relation between effectiveness of CDC induction by therapeutic antibodies 
and antibody concentration, the level of target antigen expression, and expression of mCRPs CD55 
and CD59 in B-ALL. We hypothesized that the down-modulating effect of mCRPs CD55 and CD59 on 
the level of CDC is co-dependent on the level of target antigen expression, with the most prominent 
effect in samples that display intermediate target antigen expression levels. Our results showed that 
full, simultaneous loss of CD55 and CD59 expression, due to glycophosphatidylinositol (GPI)-anchor 
deficiency, greatly enhanced the sensitivity to antibody-induced CDC of B-ALL cells with intermediate 
levels of target antigen expression. By retrovirally inducing increased CD55 or CD59 expression we 
showed that both mCRPs were individually able to convey protection against antibody-induced CDC 
and that this protection co-depended on antibody concentration and target antigen expression level. In 
contrast, we showed that natural variation in expression of these mCRPs could not be used as a single 
factor to predict sensitivity of B-ALL cells to CDC. In conclusion, sensitivity of B-ALL cells to antibody-
induced CDC is dictated by antibody concentration and target antigen expression and is increased in 
cells displaying complete loss of mCRP expression.
MATERIAL AND METHODS
Patient samples and cell culture
After informed consent, mononuclear cells (MNC) isolated by Ficoll-Isopaque separation from bone 
marrow (BM) or peripheral blood (PB) taken for the purpose of diagnosis from patients with B-ALL 
were stored anonymously for future research by cryopreservation in Iscove’s modified Dulbecco’s 
media (IMDM, Lonza, Verviers, Belgium) supplemented with 25% fetal calf serum (FCS, Lonza) and 10% 
dimethyl sulfoxide (DMSO, Sigma-Aldrich, Zwijdrecht, the Netherlands). Before each experiment cells 
were thawed, washed twice with IMDM to remove DMSO, and maintained on ice in IMDM with 10% 
FCS. B-ALL cell lines used in this study were generated in our laboratory from primary B-ALL cells and 
maintained as described before24 in an IMDM-based serum-free medium.
Immunofluorescence
Target antigen and mCRP expression was measured by staining samples with RTX (MabThera, 
Roche Diagnostics, Woerden, the Netherlands) or ALM (MabCampath, Sanofi Genzyme, Naarden, 
the Netherlands) conjugated to fluorescein isothiocyanate (FITC, Sigma-Aldrich) as described,25 
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or phycoerythrin (PE)-conjugated anti-CD55 (IA10, BD, Becton Dickinson, San Jose, CA, USA), or 
allophycocyanin (APC)-conjugated anti-CD59 (OV9A2, eBioscience, Vienna, Austria). Primary samples 
were additionally stained with PE or APC-conjugated anti-CD19 (HIB19, BD). GPI-anchor expression was 
analyzed by staining cells with Alexa Fluor 488 labeled inactivated toxin pro-aerolysin (FLAER, Sanbio, 
Uden, the Netherlands) and anti-CD52-APC (HI186, ITK diagnostics BV, Uithoorn, the Netherlands). 
Fluorescence was analyzed by flow cytometric analysis. 
CDC-assay
2.5x104 B-ALL cells suspended in 40 µL medium were seeded per well in 96-well round bottom 
plates and incubated with serial dilutions of clinical grade monoclonal antibodies RTX, OFA (Arzerra, 
GlaxoSmithKline, Zeist, the Netherlands), or ALM in 10 µL PBS for 30 min at 4°C. Incubation with PBS 
only served as reference condition. Next, blood serum from healthy volunteers (normal human serum, 
NHS) was added at 50% (v/v) as a source of complement. Heat inactivated serum or medium were 
used as controls. After 4 h (primary B-ALL samples) or 18 h (B-ALL cell lines) incubation at 37°C and 5% 
CO2, samples were stained with anti-CD19-APC for 30 min at 4°C followed by incubation with propidium 
iodide (PI, Millipore, Amsterdam-Zuidoost, the Netherlands) to exclude dead cells. Cells were kept on ice 
until analysis. Target cell death was determined using quantitative flow cytometry as described before.26 
Briefly, a fixed number (10,000) of CytoCount™ (DAKO, Glostrup, Denmark) or Accucount (Spherotech, 
Lake Forest, IL, USA) fluorescent beads was supplemented to each sample as an internal reference 
directly before sample acquisition. Per sample, 2000 beads were acquired. The number of viable cells 
(PI-negative, CD19-positive) per sample was calculated using the following formula:
% CDC = * 100%
# Cells  reference  condition - # Cells  experimental  condition
# Cells  reference  condition
Total # viable  cells  per  sample = * 10,000
# PI-negative, CD19-positive  cells
# Beads
The magnitude of cell loss (% CDC) was calculated using the formula:
Retroviral transduction of B-ALL cells with CD55 and CD59
B-ALL cell lines were stably transduced using retroviral particles encoding CD55 or CD59 as described 
before.27,28 Briefly, CD55 and CD59(ref. 29) were individually subcloned into the bicistronic LZRS vector 
containing a truncated form of the nerve growth factor receptor (tNGFR), which served as marker gene. 
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Retroviral particles were generated using the ϕ-NX-A packaging cell line and supplemented to wells of a 
flat bottom non-tissue treated 96-well plate pre-coated with human fibronectin fragments (Retronectin, 
TaKaRa Biotec). 1.5x105 B-ALL cells were incubated per well for 24 h at 37°C, then transferred to tissue 
culture-treated plates and allowed to expand. Transduced cells were purified by magnetic activated 
cell sorting (MACS) based on marker gene expression using anti-tNGFR-APC (ME20.4, Sanbio, Uden, 
the Netherlands) and anti-APC MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany), following 
manufacturer’s instructions. Cells were kept in culture until used in CDC-assays.
RESULTS
Sensitivity to antibody-induced CDC is strongly influenced 
by target antigen expression levels
To test the effect of antigen expression on the sensitivity to CDC induced by the therapeutic antibodies 
RTX and OFA (targeting CD20), and ALM (targeting CD52), we used a panel of B-ALL cell lines (n = 11) 
that resemble the primary malignancy both in terms of phenotype and karyotype.24 A wide distribution 
of antigen expression levels (median fluorescence intensity; MFI) was observed on these B-ALL cells by 
flow cytometry (range 44-5898 for CD20 and 100-2033 for CD52) (Table 1). Sensitivity to antibody-
induced CDC was analyzed by incubating the B-ALL cells with concentrations of RTX, OFA, or ALM ranging 
from 3.3 µg/mL to 100 µg/mL, using NHS as a source of complement. Strong positive correlations were 
Table 1. Cell lines characteristics, antigen and complement inhibitor expression
Membrane expression of target antigens CD20 and CD52, and complement inhibitors CD55 and CD59 is displayed as average 
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Figure 1. Effects of antibody concentration and the level of target antigen expression on sensitivity to antibody-
induced CDC in B-ALL cells
Association between target antigen expression and CDC was analyzed by incubation of individual B-ALL cell lines 
(n = 11) with RTX, OFA, or ALM at indicated concentrations for 30 min at 4°C followed by addition of 50% NHS as a 
source of complement. After 18 h incubation at 37°C, the absolute number of surviving cells was measured using a 
quantitative flow cytometry-based cytotoxicity assay. Percentage CDC was determined by calculating the percentage 
cell loss compared to the reference condition without antibody. Each dot represents the average percentage of CDC 
induced in one cell line in three separate experiments and whiskers represent the standard deviation. Correlations 
between target antigen expression and the induced CDC percentage were calculated using a four parameter logistic 
regression analysis and are depicted by solid lines and the R-values are presented in the upper left corner of each 
graph. Cell lines Leiden-ALL-BV and Leiden-ALL-HP contained small populations of GPI-anchor negative cells (9.9% 
and 0.3%, respectively) and are highlighted in gray. Cell lines that were not prone to CDC induction despite the 
addition of saturating antibody concentrations (100 µg/mL) are indicated with triangels in the right panels.
found between the level of CDC induced by RTX (R = 0.93 or higher), OFA (R = 0.96 or higher), and ALM 
(R = 0.78 or higher) and target antigen expression in a non-linear regression analysis (Figure 1). No 
lysis was observed when antibody-coated cells were incubated with heat inactivated NHS (Figure S1), 
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Complete absence of mCRP expression increases 
the sensitivity to antibody-induced CDC
Since B-ALL cells with intermediate antigen density (MFI 250-1500) reached a maximum level of CDC 
below 100% despite saturating antibody concentrations (Figure 1, 100 µg/mL), we tested whether 
expression of mCRPs CD55 and CD59 affected the maximum level of lysis. Two B-ALL cell lines that 
displayed intermediate levels of antigen expression contained small populations of GPI-anchor negative 
cells as determined by FLAER staining (Leiden-ALL-BV 9.9%, Leiden-ALL-HP 0.3%; Figure 1, highlighted 
in gray). As a result, these cell populations lacked membrane expression of the GPI-anchored proteins 
CD55 and CD59. Purified GPI-anchor negative and GPI-anchor positive B-ALL subcultures were 
generated from Leiden-ALL-BV and Leiden-ALL-HP using flow cytometric cell sorting. Loss of CD55 and 
CD59 expression in the GPI-anchor negative cells was confirmed using flow cytometric analysis (Figure 
2A). CD20 expression levels were identical between the GPI-anchor negative and GPI-anchor positive 
subcultures (Figure 2B). Sensitivity of these subcultures to antibody-induced CDC was evaluated by 
incubation with concentrations of RTX or OFA ranging between 3.3 µg/mL and 100 µg/mL. Considering 
that the CD52 antigen is also GPI-anchored and therefore not expressed on the GPI-anchor negative 
cells, ALM-induced CDC was not examined. Higher levels of antibody-induced CDC were observed in GPI-
anchor negative B-ALL cells compared with their GPI-anchor positive counterparts, with up to 2.3 fold 
(Leiden-ALL-BV) and 6.3 fold (Leiden-ALL-HP) increase when induced by RTX and up to 1.7 fold (Leiden-
ALL-BV) and 4.1 fold (Leiden-ALL-HP) increase when induced by OFA (Figure 2C). This resulted in almost 
complete eradication of GPI-anchor negative B-ALL cells.
Level of expression of either CD55 or CD59 can individually influence 
sensitivity to antibody-induced CDC
Since loss of GPI-anchor expression resulted in complete loss of both CD55 and CD59 expression, we 
next examined to which extent CD55 and CD59 individually contribute to a protective effect against 
CDC. Since it is impossible to induce re-expression of CD55 or CD59 in GPI-anchor negative cell lines, 
we selected several B-ALL cell lines with various target antigen expression levels from our B-ALL panel 
and transduced them with a construct encoding CD55 (Leiden-ALL-CM, Leiden-ALL-VG, Leiden-ALL-VB, 
Leiden-ALL-RL, Leiden-ALL-BL) or CD59 (Leiden-ALL-CM, Leiden-ALL-PH, Leiden-ALL-VG, Leiden-ALL-VB, 
Leiden-ALL-BL), or with empty vector (mock) as a control. Transduced cells were purified and expanded 
resulting in B-ALL subcultures with homogeneous expression of at least 3.3 fold increase for CD55 and at 
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Figure 2. Complete absence of expression of mCRPs CD55 and CD59 due to GPI-anchor deficiency results in 
increased sensitivity to antibody-induced CDC
Representative example of CD55, CD59 (A), and CD20 (B) expression patterns of GPI-anchor negative (black-filled 
curves) and GPI-anchor positive (gray-filed curve) subcultures of cell lines Leiden-ALL-BV and Leiden-ALL-HP as 
measured by flow cytometric analysis. Unstained cells were used as reference (open curves). (C) Sensitivity to 
antibody-induced CDC of GPI-anchor positive versus GPI-anchor negative subcultures of cell lines Leiden-ALL-BV and 
Leiden-ALL-HP. CDC was induced by RTX or OFA at 100 µg/mL, 33 µg/mL, 10 µg/mL, or 3.3 µg/mL and analyzed as 
described before. Bars represent average percentage of CDC induced in three separate experiments and whiskers 
represent the standard deviation.
To measure the effect of the induced CD55 and CD59 expression, CDC experiments were performed 
with RTX, OFA, or ALM at concentrations of 100 µg/mL, 10 µg/mL, and 1.0 µg/mL. In Leiden-ALL-CM, 
which displayed a high CD20 expression level, the protective effect of CD55 and CD59 transduction was 
only minimal when CDC was induced at high RTX or OFA concentrations (100 µg/mL), while at lower RTX 
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transduction (Figure 3B) and 20% and 22% upon CD59 transduction (Figure 4B), respectively, compared 
with the mock transduced counterpart. In B-ALL cells with intermediate levels of CD20 expression (CD55 
transduced: Leiden-ALL-VG, Leiden-ALL-RL, and Leiden-ALL-BL; CD59 transduced: Leiden-ALL-PH and 
Leiden-ALL-VG), levels of CDC were already substantially decreased when induced at high RTX or OFA 
antibody concentrations (100 µg/mL) with up to 48% and 34% decrease upon CD55 (Figure 3B) and 
20% and 47% upon CD59 (Figure 4B) transduction, respectively. At lower RTX and OFA concentrations 
(10 µg/mL, 1.0 µg/mL), CDC was decreased up to 31% and 35% in CD55 (Figure 3B) and up to 13% and 
49% in CD59 (Figure 4B) transduced B-ALL cells, respectively. When CDC was induced by ALM, again 
minimal effect of CD55 and CD59 transduction was observed in Leiden-ALL-CM, which displayed a high 
CD52 expression level, when CDC was induced at high antibody concentrations (100 µg/mL), while at 
lower ALM concentrations (10 µg/mL and 1.0 µg/mL) CDC decreased up to 30% upon CD55 (Figure 
3B) and 27% upon CD59 transduction (Figure 4B). In Leiden-ALL-PH, which also displayed a high CD52 
expression level, CDC was decreased by 34% when induced at high ALM concentrations (100 µg/mL) 
Figure 3. Induction of increased CD55 expression increases the sensitivity to antibody-induced CDC of B-ALL cells
(A) Bar graph depicts the fold increase in CD55 expression of 5 B-ALL cell lines retrovirally transduced with a construct 
encoding CD55 (CD55) relative to their empty vector (Mock) transduced controls. Fold increase was calculated using 
the mean CD55 MFI as determined from three separate flow cytometric analyses. (B) Sensitivity to antibody-CDC 
induced of Mock (gray) versus CD55 (black) transduced cell lines. CDC was induced as described before by RTX, 
OFA, or ALM at indicated concentrations. Bars represent the average percentage of CDC induced in three separate 
experiments and whiskers represent the standard deviation. The statistical significance is shown by asterisks, * P < 
0.05; ** P < 0.01; *** P < 0.001 (one-sided paired T-test).









































































































Figure 4. Induction of increased CD59 expression increases the sensitivity to antibody-induced CDC of B-ALL cells
(A) Bar graph depicts the fold increase in CD59 expression of 5 B-ALL cell lines retrovirally transduced with a construct 
encoding CD59 (CD59) relative to their empty vector (Mock) transduced controls. Fold increase was calculated using 
the mean CD59 MFI as determined from three separate flow cytometric analyses. (B) Sensitivity to antibody-CDC 
induced of Mock (gray) versus CD59 (black) transduced cell lines. CDC was induced as described before by RTX, 
OFA, or ALM at indicated concentrations. Bars represent the average percentage of CDC induced in three separate 
experiments and whiskers represent the standard deviation. The statistical significance is shown by asterisks, * P < 
0.05; ** P < 0.01; *** P < 0.001 (one-sided paired T-test). 
and by up to 52% at lower ALM concentrations (10 µg/mL and 1.0 µg/mL) upon CD59 transduction. 
In B-ALL cells with intermediate CD52 antigen expression levels (Leiden-ALL-VB and Leiden-ALL-BL), CDC 
induced at high ALM concentrations (100 µg/mL) decreased with up to 40% in CD55 (Figure 3B) and 23% 
in CD59 (Figure 4B) transduced B-ALL cells and when induced at lower ALM concentrations (10 µg/mL, 
1.0 µg/mL) with up to 53% upon CD55 (Figure 3B) and up to 36% in CD59 (Figure 4B) upon transduction.
Together these data illustrate that induced CD55 and CD59 expression can individually supply 
a level of protection against antibody-induced CDC, especially in cells displaying intermediate 
target antigen expression levels. However, this protective effect was overpowered when CDC 
was induced at high antibody concentrations in B-ALL cells that display high target antigen 
expression levels. Furthermore, despite substantial increase of CD55 and CD59 expression 
upon transduction, complete abrogation of CDC induction was not accomplished. These results 
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Natural variation of CD55 and CD59 expression cannot be used as a single marker 
to predict sensitivity of B-ALL cells to antibody-induced CDC
To assess whether natural variation in CD55 or CD59 expression can be used as a marker to 
predict the sensitivity of B-ALL cells to antibody-induced CDC, we analyzed their expression levels 
in our panel of B-ALL cell lines (Table 1). The level of expression within individual cell lines was 
homogeneous, but varied largely between cell lines (range MFI 191-587 for CD55 and 1459-
4996 for CD59) and was always clearly positive. No correlation was found between the levels 
of CD55 (Figure 5, left panels) or CD59 (Figure 5, right panels) expression on B-ALL cell lines 
and their sensitivity to CDC induced by RTX, OFA, or ALM at 10 µg/mL. Identical results were 
obtained at higher (100 µg/mL) and lower (3.3 µg/mL) antibody concentrations (data not shown).
Next, we evaluated whether similar results would be obtained using primary B-ALL cells. For this, CD20, 
CD52, CD55 and CD59 expression levels were measured on CD19+ B-cells within MNC samples (n = 7) 
derived from B-ALL patients (Table 2). The CD20 antigen expression was too low to analyze RTX and 
OFA induced CDC. CD52 antigen expression was substantial and ranged from MFI 120 to 1662. Clear 
correlations were present between CD52 expression and ALM-induced CDC in a non-linear regression 
analysis (maximum R = 0.98, Figure 6A). In contrast, in accordance with the observations in the B-ALL 
cell lines, no correlations were found between levels of CD55 or CD59 expression and the level of ALM-
induced CDC at 10 µg/mL (Figure 6B), or at 0.1 µg/mL, 1.0 µg/mL, or 100 µg/mL (data not shown). 
Together these data show that the natural level of CD55 or CD59 expression on the B-ALL cells had no 























Table 2. Primary sample characteristics, antigen and complement inhibitor expression
Membrane expression of target antigens CD20 and CD52, and complement inhibitors CD55 and CD59 was measured on CD19+ cells 
within primary B-ALL patient samples by flow cytometric analysis; MFI: median fluorescence intensity; PB: peripheral blood; BM: bone 

































Figure 5. Relation between natural variation in the level of complement inhibitors CD55 and CD59 expression and 
sensitivity of B-ALL cells for antibody-induced CDC
CD55 (left panels) and CD59 (right panels) expression (MFI) as determined by flow cytometry is plotted against the 
level of CDC induced by RTX, OFA, or ALM at 10 µg/mL. Dots represent average percentage of CDC induced in three 







































Figure 6. Relation between natural variation in the level of antigen expression or complement inhibitors CD55 or 
CD59 and sensitivity of primary malignant B-cells for antibody-induced CDC
(A) Association between CD52 target antigen expression and CDC was analyzed by incubation of primary B-ALL 
samples with ALM at indicated concentrations and 50% NHS. Each dot represents the average percentage of CDC per 
sample in a duplicate measurement and whiskers represent the range. The correlations between CD52 target antigen 
expression and the level of ALM-induced CDC were calculated using a three parameter logistic regression analysis 
and are depicted by solid lines and the R-values of these correlations are presented in the upper left corner of each 
graph. (B) Relation between complement inhibitor expression and sensitivity of primary B-ALL patient samples for 
ALM-induced CDC. CD55 (left panel) and CD59 (right panel) expression as determined by flow cytometry on primary 




















































Recent advances in use of monoclonal therapeutic antibodies against B-ALL required a comprehensive 
analysis of the factors that determine the sensitivity of B-ALL cells to antibody-induced CDC. We 
investigated the role of antibody concentration, target antigen expression, and expression of mCRPs 
CD55 and CD59 on the sensitivity of B-ALL cells to CDC induced by RTX, OFA, and ALM in a panel of 11 
cell lines generated from primary B-ALL cells and in primary B-ALL samples. Strong positive correlations 
were found between target antigen expression levels and the sensitivity to antibody-induced CDC. 
Manipulation of individual B-ALL cell lines allowed us to study to what extent mCRP expression affected 
the sensitivity of B-ALL cells to antibody-induced CDC at distinct target antigen expression levels. In 
B-ALL cells expressing intermediate levels of target antigen, the sensitivity to antibody-induced CDC was 
significantly increased upon simultaneous loss of CD55 and CD59 membrane expression which resulted 
from GPI-anchor deficiency. In accordance, induction of increased membrane expression of CD55 and 
CD59 individually by retroviral transduction decreased the sensitivity to antibody-induced CDC of the 
B-ALL cell lines, illustrating that both molecules were able to convey relative protection against antibody-
induced CDC. The extent of the protective effect by mCRPs was co-dependent on target antigen 
expression and the concentration of the therapeutic antibody. Nonetheless, natural variation in CD55 and 
CD59 expression within our panel of B-ALL cell lines and within primary B-ALL samples could not be used 
as a single factor to predict the sensitivity of these cells to antibody-induced CDC, indicating that these 
mCRPs do not dominantly affect the sensitivity of B-ALL cells to CDC induced by therapeutic antibodies. 
Since expression levels of CD20 and CD52 on malignant cells of different patients with B-ALL are highly 
variable,6,19,30 we analyzed the relation between target antigen expression and sensitivity of B-ALL 
cells to CDC induced by CD20 or CD52 targeting therapeutic antibodies. We found strong correlations 
between higher levels of CD20 and CD52 antigen expression and higher levels of CDC induced by RTX 
and OFA, or ALM. This confirms results from several studies that suggested the presence of these 
correlations based on experiments using samples from patients with various B-cell malignancies.19,31,32 
However, in contrast with these studies, and analogous to what has been shown by van Meerten et al. 
in a study of RTX-induced CDC in T-cell clones with induced CD20 expression,18 correlations in our model 
were defined by sigmoidal instead of linear functions. This type of correlation suggests a threshold of 
minimal target antigen expression required to initiate antibody-induced CDC. Indeed, we found that even 
at saturating antibody concentrations no substantial CDC was induced in the B-ALL cells displaying the 
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lowest levels of target antigen expression. Although we cannot exclude that in-vivo these cells might still 
be sensitive to other mechanisms such as ADCC or ADCP, which are reported to induce lysis even if target 
cells display low target antigen expression levels,16,18 it may explain the disappointing outcome using 
these antibodies as single-agent treatment in patients with B-ALL, which is particularly characterized 
by low and heterogeneous target antigen expression within and between patients. Addition of antibody 
treatment to standard therapy may overcome this problem as malignant cells with low target antigen 
expression may still be sensitive to chemotherapeutics, resulting in additive or even synergistic effects.33 
An alternative approach that may improve the effectiveness of antibody therapy is removing the brake 
for CDC induction by elimination of the protective effect of mCRPs. We showed that simultaneous loss 
of CD55 and CD59, which resulted from GPI-anchor deficiency, significantly increased the sensitivity of 
B-ALL cells to antibody-induced CDC. Several strategies have been developed aimed at eliminating the 
protective effect of mCRPs in-vitro, including pretreatment of target cells with specific mCRP blocking 
antibodies or with small interfering RNA (siRNA) aimed to decrease mCRP expression. Thus far, these 
strategies have shown only modest effects on the sensitivity of cells to antibody-induced CDC.19,32,34 We 
hypothesized that this may in part result from the fact that these studies did not account for the effect of 
differential target antigen levels expressed by target cells. The relevance of this additional level of detail 
was demonstrated in experiments where we showed by artificially increasing expression of CD55 and 
CD59 on target cells that their protective effect against antibody-induced CDC was co-dependent on 
the level of target antigen expression. The most prominent protective effect was observed in B-ALL cells 
with intermediate target antigen expression levels, whereas only minimal effect was seen in B-ALL cells 
with high target antigen expression levels. Consequently, these results suggest that only malignant cells 
displaying intermediate levels of target antigen expression will be prone to the effect of mCRP targeting 
antibodies or siRNAs. In the clinical setting, this may imply that only a subpopulation of patients will 
benefit from implementing methods to eliminate the protective effect of mCRPs. This hypothesis may be 
tested by studying the clinical results from patients that received a combination of RTX and fludarabine, 
which showed a strong synergistic cytotoxic effect in FL and CLL cells likely resulting from fludarabine-
induced down-regulation of CD55 expression,35 and relate this to target antigen and mCRP expression.
Lack of effectiveness of strategies to eliminate the protective effect of complement inhibitors may also 
in part result from the inability of blocking antibodies and siRNAs to completely abrogate expression of 
CD55 and CD59.34,36 We showed that relative variation in the naturally occurring levels expression of 
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CD55 and CD59 in B-ALL cells did not dominantly affect the sensitivity to antibody-induced CDC, unless 
they were completely absent as seen in the GPI-anchor deficient B-ALL cells. 
In conclusion, our data showed that the concentration of the therapeutic antibody and the level of target 
antigen expression are the dominant factors determining the sensitivity to antibody-induced CDC in 
B-ALL cells. Expression of the mCRPs CD55 and CD59 was shown to affect antibody-induced CDC, but 
their level of expression could not be used as a single factor to predict the sensitivity of B-ALL cells to 
antibody-induced CDC.
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SUPPLEMENTAL DATA
Figure S1. No antibody induced lysis in B-ALL cell lines when incubated with heat inactivated NHS
Relation between antibody concentration and lysis induced by heat inactivated NHS. Lysis was induced by incubation 
of cell lines Leiden-ALL-CM, Leiden-ALL-BV, and Leiden-ALL-SK with serial dilutions of RTX, OFA, or ALM for 30 min at 
4°C followed by addition of 50% heat inactivated NHS. After 18 h incubation at 37°C, the absolute number of surviving 
cells was measured using a quantitative flow cytometry-based cytotoxicity assay. Percentage lysis was determined 
by calculating the percentage cell loss compared to reference conditions without antibody. Each dot represents the 
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Alemtuzumab (ALM) is used for T-cell depletion in the context of allogeneic 
hematopoietic stem cell transplantation (alloSCT) to prevent acute graft versus host 
disease and graft rejection. Following ALM-based T-cell depleted alloSCT, relatively 
rapid recovery of circulating T cells has been described, including T cells that lack 
membrane expression of the glycophosphatidylinositol (GPI)-anchored ALM target 
antigen CD52. We show in a cohort of 89 human recipients of an ALM-based T-cell 
depleted alloSCT graft that early lymphocyte reconstitution always coincided with 
the presence of large populations of T cells lacking CD52 membrane expression. 
In contrast, loss of CD52 expression was not overt within B cells or NK cells. We 
show that loss of CD52 expression from the T-cell membrane resulted from loss of 
GPI-anchor expression caused by a highly polyclonal mutational landscape in the 
PIGA gene. This polyclonal mutational landscape in the PIGA gene was also found 
in CD52-negative T cells present at a low frequency in peripheral blood of healthy 
donors. Finally, we demonstrate that the GPI/CD52-negative T-cell populations that 
arise after ALM-based T-cell depleted alloSCT contain functional T cells directed 
against multiple viral targets that can play an important role in immune protection 
early after ALM-based T-cell depleted transplantation.
ABSTRACT
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Allogeneic hematopoietic stem cell transplantation (alloSCT) is being used in the treatment of patients 
with a variety of malignant and non-malignant hematological diseases. The goal of alloSCT is to 
replace a patient’s hematopoiesis (including the malignancy) with cells derived from a healthy donor 
by administration of a hematopoietic stem cell graft. T cells derived from patient and donor play a 
major role in the effectiveness and toxicity of this treatment. Although recognition of residual malignant 
cells by donor T cells can induce a therapeutic graft-versus-tumor effect (GvT),1 recognition of non-
hematopoietic healthy tissue by these donor T cells can result in detrimental graft-versus-host disease 
(GvHD).2,3 In contrast, recognition of donor hematopoiesis by residual patient T cells may induce graft 
rejection. Depletion strategies for patient and donor T cells before transplantation, have been developed 
to reduce the risk for graft rejection and GvHD. Postponed application of donor lymphocyte infusions is 
used to induce therapeutic GvT and conversion to full donor chimerism.4,5
 
Alemtuzumab (ALM, Campath-1H), a humanized therapeutic IgG1 antibody, has been successfully used 
for in vivo and in-vitro T-cell depletion in the alloSCT setting for several decades.6,7 ALM targets the 
glycophosphatidylinositol (GPI)-anchored protein CD52 that is expressed on all mature lymphocytes, 
but not (or only marginally) on hematopoietic stem cells.8 Although ALM induces profound depletion 
of lymphocytes, relatively rapid recovery of circulating T cells can be observed after ALM-based in-
vitro T-cell depleted alloSCT. Moreover, reconstitution of populations of T cells completely lacking CD52 
membrane expression has been described.9,10 The mechanism underlying this lack of CD52 expression 
and the effect on the functionality of these T cells are not known.
The aims of this study were to comprehensively analyze to what extent CD52-negative lymphocytes 
contribute to early lymphocyte reconstitution in recipients of an ALM-based T-cell depleted alloSCT and 
to unravel the mechanism underlying the loss of CD52 membrane expression. We show in a cohort 
of 89 patients with hematological diseases treated with an ALM-based T-cell depleted alloSCT that 
reconstitution of CD52-negative cells is common within the CD4 and the CD8 T-cell compartments, 
but not within the B-cell and NK-cell compartments. We demonstrate that loss of CD52 expression 
from the membrane of these cells did not result from loss of CD52 gene expression, but, instead, from 
loss of GPI-anchor expression. In turn, loss of GPI-anchor expression resulted from a highly polyclonal 
mutational landscape in the PIGA gene, one of the genes essential for GPI-anchor biosynthesis. We show 
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that GPI/CD52-negative PIGA mutant T cells are also present at low frequencies in peripheral blood 
(PB) of healthy donors. Finally, we show that GPI/CD52-negative T-cell populations contain functional T 
cells specific against multiple viral targets that can contribute to early immune protection after alloSCT.
MATERIAL AND METHODS
Patient and samples
A consecutive cohort of 89 adult patients who underwent alloSCT with ALM-based T-cell depleted 
grafts at Leiden University Medical Center was included in this retrospective study. Study protocols 
were approved by the Leiden University Medical Center Research Ethics Committee, and patients 
had given informed consent for treatment and scientific evaluation. Patients received a myeloablative 
(MA) or a non-myeloablative (NMA) conditioning regimen (Table S1). MA conditioning consisted of 
cyclophosphamide combined with total body irradiation or i.v. busulfan. In the case of an unrelated 
donor (UD), patients received 15 mg of ALM (MabCampath, Sanofi Genzyme, Naarden, the Netherlands) 
i.v. at days -6 and -5. NMA conditioning consisted of 15 mg of ALM i.v. at days -4 and -3, fludarabine, 
and i.v. busulfan. Nine NMA-conditioned patients with a UD also received antithymocyte globulin 
(thymoglobulin, 1 or 2 mg/kg at day -2, Table S1). Patients received an allogeneic G-CSF-mobilized 
peripheral stem cell graft (n = 86) or a bone marrow graft (n = 3). All grafts were subjected to T-cell 
depletion by the addition of 20 mg of ALM “to the bag”.11 Cyclosporin, as posttransplantation immune 
suppression, was only given to MA-conditioned patients with a UD, starting at day -1 and tapered off 
from day 30 onward. PB was collected for direct routine clinical evaluation, and PB mononuclear cells 
(PBMC) were isolated by Ficoll-isopaque separation and cryopreserved for later scientific evaluation.
CD52 and GPI-anchor expression analysis
PBMC were thawed, and CD52 membrane expression was analyzed on CD4 and CD8 T cells (gating on 
CD3+CD4+ or CD3+CD8+ cells, respectively), NK cells (gating on CD3-CD56+ cells), and B cells (gating 
on CD3-CD19+ cells) by counterstaining with ALM conjugated to fluorescein isothiocyanate (FITC, Sigma-
Aldrich, Zwijndrecht, the Netherlands), as described previously,12 combined with allophycocyanin (APC)-
conjugated anti-CD3, phycoerythrin (PE)-conjugated anti-CD4, and peridinin chlorophyll (PerCP)- or 
pacific blue (PacBlue)-conjugated anti-CD8 or anti-CD3-APC, anti-CD8-PerCP, and anti-CD56-PE or anti-
CD3-PerCP and anti-CD19-APC antibodies (BD, Becton Dickinson, Breda, the Netherlands).
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GPI-anchor expression was analyzed on CD4 and CD8 T cells (gating on CD3+CD4+ or CD3+CD4+ cells, 
respectively) by staining with the GPI-anchor specific inactivated toxin proaerolysin coupled to Alexa 
Fluor 488 (FLAER-AF488; Sanbio, Uden, the Netherlands), anti-CD3-PE-Texas Red (PETxR; Invitrogen, 
Thermo Fisher Scientific, Bleiswijk, the Netherlands), anti-CD4-PerCP (BD), anti-CD8-PacBlue (BD), and 
anti-CD52-APC (HI186; ITK diagnostics BV, Uithoorn, the Netherlands). Fluorescence was measured by 
flow cytometry on a FACSCalibur or LSRII analyzer (both from BD).
Analysis of absolute numbers of circulating cells
Absolute numbers of circulating CD4 T cells (gating on CD45+CD3+CD4+ cells), CD8 T cells (gating on 
CD45+CD3+CD8+ cells), B cells (gating on CD45+CD3-CD19+ cells), and NK cells (gating on CD45+CD3-
CD16/CD56+ cells) were determined as part of routine clinical evaluations on fresh venous blood using 
BD Trucount tubes, following the manufacturer’s instructions. Samples were stained with anti-CD3-APC, 
anti-CD4-FITC, anti-CD8-PE, and anti-CD45-PerCP, or with anti-CD3-FITC, anti-CD16-PE, anti-CD19-APC, 
anti-CD45-PerCP, and anti-CD56-PE (BD). Fluorescence was measured on a FACSCalibur.
Chimerism analysis
Donor-patient chimerism analysis was performed on FACS-purified CD4 and CD8 T cells using a short 
tandem repeat PCR-based protocol, as described previously.13
CD52 and GPI-anchor synthesis pathway gene expression analysis
GPI/CD52-negative and GPI/CD52-positive CD4 and CD8 T-cell populations were purified from thawed 
PBMC using FACS after staining with FLAER-AF488, anti-CD3-PETxR, anti-CD8-PacBlue, anti-CD4-PerCP, 
and anti-CD52-APC. mRNA was isolated from 2.5x104 cells using an RNAqueous-Micro Total RNA Isolation 
Kit (Thermo Fisher Scientific) and completely converted to cDNA using Moloney murine leukemia 
virus reverse transcriptase (Invitrogen) and oligo-dT primers. CD52 mRNA was amplified by PCR using 
specific primers (Table S2) and Phusion Flash High-Fidelity PCR Master Mix (Thermo Fisher Scientific). 
As a control GAPDH was amplified. mRNA coding for the 28 GPI-anchor synthesis pathway genes was 
amplified by individual PCRs using specific primers (Table S2) and Pwo SuperYield DNA Polymerase 
(Roche, Woerden, the Netherlands). Resulting products were analyzed by gel electrophoresis.
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Isolation and culture of T-cell clones
GPI/CD52-negative and GPI/CD52-positive CD4 and CD8 T-cell clones were generated by single-cell 
FACS from thawed PBMC collected at 3 months after transplantation. PBMC were stained with FLAER-
AF488, anti-CD4-PacBlue, anti-CD8-PacBlue, anti-CD45-PerCP, and anti-CD52-APC. Isolated T cells 
were stimulated with irradiated PBMC as feeder cells, phytohaemagglutinin, and IL-2, as described.14 
Proliferating T-cell clones were restimulated every 14 days. The phenotype of individual clones was 
analyzed by staining with FLAER-AF488, anti-CD4-PE, anti-CD8-PerCP, and anti-CD52-APC.
GPI/CD52-negative T cells from a healthy donor were pre-enriched by MACS before single-cell FACS. T 
cells were isolated from 100x106 PBMC using a MACS Pan T Cell Isolation Kit (Miltenyi Biotec, Bergisch 
Gladbach, Germany). Subsequently, CD52-positive cells were depleted by MACS using anti-CD52-APC 
and anti-APC Microbeads (Miltenyi), following the manufacturer’s instructions.
PIGA mutational analysis 
mRNA was isolated from 5x105 cells from each T-cell clone and converted to cDNA as described. PIGA 
mRNA was amplified using primer set 1 (Table S2) and Phusion Flash High-Fidelity PCR Master Mix. The 
resulting product was directly cleaned using the Wizard SV Gel and PCR Clean-Up System (Promega, 
Leiden, the Netherlands). Nested PCRs were performed using primer sets 2a and 2b (Table S2) for which 
the forward or reverse primer nested in the terminal region of exon 2, thereby amplifying only PIGA 
transcription variant 1 (NM_002641.3). The resulting products were directly cleaned and analyzed by 
Sanger sequencing using the four primers from sets 2a and 2b.
Retroviral transduction
A construct encoding wild-type (wt)PIGA coupled via a GSG linker and a self-cleaving T2A peptide 
sequence to a truncated form of the nerve growth factor receptor (tNGFR), which served as a marker 
gene, was cloned into the LZRS plasmid. As control (mock), wtPIGA was removed from the plasmid by 
restriction enzyme digestion, followed by religation. Retroviral transduction was performed as described 
previously.15 In brief, for each T-cell clone 2.5x104 cells were restimulated. After 3 or 4 days, T-cell clones 
were transferred to wells containing retroviral particles, generated using the ϕ-NX-A packaging cell line, 
and incubated for 24 h at 37°C. T-cell clones were subsequently transferred to new plates and expanded 
for 7 days before analysis by flow cytometry, counterstaining with FLAER-AF488, anti-CD52-APC, anti-
CD3-PETxR, and anti-NGFR-PE (BD).
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Functional analysis
Virus antigen-specific T-cell populations were identified, using flow cytometry, by staining with 
PE-conjugated peptide/MHC complexes 16 (tetramers) (Table S3), for 15 min at 37°C, followed by 
counterstaining with anti-CD8-PerCP for 15 min at 4°C. Tetramer-positive CD8 T cells were isolated 
by FACS and expanded as described for the T-cell clones. After 2 weeks, reactivity of isolated T cells 
was assessed. A total of 4x103 (HLA-B*08:01/CMV-IE1-QIKVRVDMV) or 5x103 (HLA-B*35:01/CMV-pp65-
IPSINVHHY, HLA-A*02:01/CMV-IE1-VLEETSVML, and HLA-B*08:01/EBV-BZLF1-RAKFKQLL) virus antigen-
specific T cells was cocultured for 24 h at 37°C with Epstein-Barr virus-transformed lymphoblastoid 
cells (EBV-LCLs) (E:T ratio of 1:5) exogenously loaded with a serial dilution (10 pM to 1 µM) of the 
relevant peptide. IFN-γ secretion was analyzed in the supernatant by ELISA (PeliKine compact human 
IFN-γ; Sanquin, Amsterdam, the Netherlands), following the manufacturer’s instructions.
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Reconstitution of CD52-negative T cells after ALM-based T-cell depleted 
alloSCT is a common phenomenon
To evaluate whether reconstitution of CD52-negative lymphocytes is a common phenomenon 
after ALM-based T-cell depleted alloSCT, we retrospectively analyzed PBMC samples taken from 89 
alloSCT recipients at a median of 42 days after transplantation (range 35 - 98 days). CD52 expression 
on CD4 and CD8 T cells, B cells, and NK cells was determined by multicolor flow cytometry (results 
are summarized in Table S1). CD52-negative T cells were found in all recipients that displayed T-cell 
reconstitution and accounted for a median of 81% of circulating CD4 T cells (range 0.0 - 98.2%) and for 
a median of 32% of circulating CD8 T cells (range 0.0 - 97.5%). In contrast, CD52-negative B cells were 
not common, with populations observed in only three recipients (5.7, 7.7, and 88.2% of the circulating 
B cells). Within NK cells, no CD52-negative cell populations were detected in 59 recipients, whereas 
in the remaining 30 recipients, potential CD52-negative NK cells could not be discriminated from the 
bulk of cells that displayed low CD52 expression. Combining these results with the absolute number 
of circulating lymphocytes, which was determined for individual lymphocyte subsets as part of routine 
clinical evaluation at the same time point (Table S1), showed that sizeable populations of CD52-negative 
CD4 T cells (median 65.5x106 cells/L, range 0.0x106 – 608.8x106 cells/L, Figure 1A) and CD52-negative 
CD8 T cells (median 6.1x106 cells/L, range 0.0x106 – 1718.9x106 cells/L, Figure 1B) were present 
within recipients early after ALM-based T-cell depleted alloSCT. These CD52-negative T cells remained 
detectable in some patients years after transplantation (data not shown).
These data show that CD52-negative T cells form a mayor contribution to T-cell reconstitution after 
ALM-based T-cell depleted alloSCT.
Reconstituted CD52-negative T cells are primarily of donor origin
Because donor cells (20 mg of ALM “to the bag” containing the stem cell graft) and patient cells (by 
ALM in the conditioning and/or residual ALM infused with the graft) are exposed to ALM, we investigated 
whether CD52-negative T cells found in recipients after alloSCT were of donor or patient hematopoietic 
origin. Donor-patient chimerism analysis was performed on purified CD4 (n = 52) and CD8 (n = 46) 
T-cell subsets derived from 53 of the 89 patients (for whom sufficient sample was available) and plotted 
against the percentages of CD52-negative T cells present in these respective subsets (Figure 2). In 
RESULTS
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Figure 1. Presence of CD52-negative T-cell populations in alloSCT recipients early after transplantation
Absolute numbers of circulating CD52-negative (filled bars) and CD52-positive (open bars) within the CD4 (A) and 
CD8 (B) T-cell compartment were calculated for 89 alloSCT recipients by multiplying the absolute T cell counts, 
which were obtained for routine transplantation monitoring, with the portion of CD52-negative cells determined by 
flow cytometry on cryopreserved PBMC samples obtained from recipients at the same day. Results from individual 
recipients are arranged horizontally. Recipients were ordered based on the percentage of GPI-anchor negative cells 



























































   









   



































































































   









   





































































   









   













































































   









   





































































   









   












Figure 2. Reconstituted CD52-negative T cells are mainly from donor origin 
Relation between the percentages of CD52-negative CD4 (A) and CD8 (B) T cells and the levels of donor-patient 
chimerism in these respective subsets. Each dot represents the analysis for a single recipient. Analysis of recipient 6, 
19, 38, and 57 are indicated with their respective recipient number. A 45 degree dotted line is depicted as reference. 
Donor-patient chimerism analysis was performed on samples that had been taken from the recipients at the same 
day as the samples used for CD52 membrane expression analysis.
general, for each recipient equal or higher percentages of donor chimerism were found compared with 
the percentages of CD52-negative T cells within the CD4 and CD8 T cell subsets, indicating a marked 
contribution of donor T cells to the observed CD52-negative T-cell populations. Notable exceptions 
were recipients 6, 19, 38, and 57, who displayed high percentages of CD52-negative T cells coinciding 
with high levels of patient chimerism, indicating that, in some patients, the observed CD52-negative 
T-cell populations were dominated by T cells of recipient origin. These four patients had received NMA 
conditioning; in addition, recipient 19 had received high doses of ALM shortly before transplantation to 
treat the primary disease, and recipient 38 was transplanted for severe aplastic anemia and might have 
possessed GPI-negative paroxysmal nocturnal hemoglobinuria (PNH)-like cells pretransplantation (not 
tested because of the absence of sample material).
These data show that the majority of CD52-negative T cells reconstituting following ALM-based T cell 
depleted alloSCT are of donor origin.
CD52-negative T cells lack expression of the GPI anchor
To unravel the mechanism underlying the loss of CD52 membrane expression on a portion of the 
circulating T cells in recipients of an ALM-based T-cell depleted alloSCT, we analyzed CD52 mRNA 
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Figure 3. Loss of CD52 membrane expression directly results from loss of GPI-anchor expression
(A) Representative examples of flow cytometric analysis of CD52 and GPI-anchor (FLAER) expression within CD4 
and CD8 T cells from recipients 2, 28, and 37. Numbers represent the percentage of cells within the quartiles. 
(B) Correlation between the percentage of CD52-negative CD4 (left panel) and CD8 (right panel) T cells and the 
percentage of GPI-anchor negative CD4 and CD8 T cells within recipients. Each dot represents one recipient (n = 46). 
Linear regression analysis was performed and depicted as solid lines and the r-value of the curve is presented in the 
upper left corner of each graph.
by FACS from PBMC of recipients 2, 28, and 37. Normal CD52 mRNA expression was observed in CD4 and 
CD8 T cells without CD52 membrane expression and in their CD52-positive counterparts (Figure S1A), 
showing that loss of CD52 membrane expression was not caused by loss of CD52 gene expression.
CD8 T cells



























Because CD52 membrane expression depends on expression of the GPI anchor, we evaluated whether 
loss of CD52 membrane expression resulted from loss of GPI-anchor expression. We examined GPI-
anchor (by direct FLAER staining) and CD52 membrane expression on CD4 and CD8 T cells in PBMC 
from 46 recipients using flow cytometry. Figure 3A shows in three representative examples that loss 
of CD52 membrane expression coincided with the absence of GPI-anchor expression in the majority of 
CD52-negative CD4 T cells and CD8 T cells (lower left quadrant), whereas the remaining CD52-negative 
T cells expressed significantly lower levels of the GPI anchor (lower right quadrant) compared with 
CD52-positive T cells (upper right quadrant). Aggregated results from all 46 recipients showed strong 
correlations between the percentages of CD52-negative and GPI-anchor negative cells (CD4 r = +0.94, 
p < 0.0001; CD8 r = +0.88, p < 0.0001; Figure 3B). These data illustrate that loss of CD52 membrane 
expression is due to defective GPI-anchor expression.
Mutations in PIGA lead to loss of GPI-anchor expression
To study whether loss of GPI-anchor expression in the T cells lacking CD52 membrane expression occurs 
by active genetic downregulation of one of the 28 genes that make up the GPI-anchor biosynthesis 
pathway, we performed mRNA expression analysis for these genes in purified GPI/CD52-negative 
and GPI/CD52-positive CD4 and CD8 T-cell populations from recipients 2, 28, and 37. Normal mRNA 
expression was observed for all 28 GPI-anchor genes within the GPI/CD52-negative CD4 and CD8 T-cell 
populations of all three recipients (Figure S1B, representative example), indicating that loss of GPI-
anchor expression was not caused by loss of expression of one of the GPI-anchor biosynthesis pathway 
genes.
Because loss of GPI-anchor expression in bone marrow disorders, such as PNH and aplastic anemia, was 
reported to result from mutations in the PIGA gene,17,18 one of the 28 GPI-anchor biosynthesis genes and 
unique for its location on the X-chromosome, we analyzed whether the GPI/CD52-negative phenotype 
of T cells found in recipients after ALM-based T-cell depleted alloSCT also resulted from mutations in 
the PIGA gene. Initial analysis of bulk isolated GPI/CD52-negative T-cell populations indicated that they 
were polyclonal and carried multiple mutations in the PIGA gene. To perform detailed analyses, we 
clonally isolated and expanded GPI/CD52-negative CD4 and CD8 T cells from recipients 2, 28, and 37. 
As controls, GPI/CD52-positive CD4 and CD8 T-cell clones were generated from the same individuals. 
For each clone, PIGA mRNA was amplified by PCR and analyzed by Sanger sequencing. In total, 61 
GPI/CD52-negative CD4, 12 GPI/CD52-positive CD4, 12 GPI/CD52-negative CD8, and 6 GPI/CD52-
4
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Table 1. Clonal analysis of PIGA mutations
Del indicates deletion; Ins insertions; aa amino acid
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positive CD8 T-cell clones were screened. PIGA mutations were detected in 52 of 61 GPI/CD52-negative 
CD4 T-cell clones and in 10 of 12 GPI/CD52-negative CD8 T-cell clones (Table 1). Mutations included 
deletions (n = 24), substitution mutations (n = 16), exon skipping (n = 14), and insertions (n = 8). In 
48 T-cell clones (all clones except those that displayed exon skipping), the exact nucleotide sequence 
resulting in the mutation was identified. Most mutations were detected only once, with the exception 
of one mutation (r.427del) that was found three times within CD4 T-cell clones from recipient 37, two 
mutations (r.1102_1103ins; r.679-834del) that were found within the CD4 and CD8 T-cell compartments 
of recipient 28, and one mutation (r.693-697del) that was found in recipients 28 and 37. No mutations 
in PIGA mRNA were found in the GPI/CD52-positive CD4 or CD8 T-cell clones from the same recipients. 
Figure 4. Retroviral transduction with wtPIGA restores CD52 and GPI-anchor expression 
in clonally expanded GPI/CD52-negative T cells
Flow cytometric analysis of CD52 and GPI-anchor (FLAER) expression on clonally expanded GPI/CD52-negative CD4 
T-cell clones retrovirally transduced with a construct encoding wtPIGA coupled to the tNGFR marker gene or with a 
control construct encoding marker gene only (Mock). A representative clone is displayed for each type of mutation 
that was found in the PIGA gene by Sanger sequencing. The upper panels depict the mock transduced clones gated 
on tNGFR marker gene positive cells and the lower panels depict the clones transduced with wtPIGA gated on tNGFR 



















HIGH MUTATION FREQUENCY OF THE PIGA GENE 89
These data show that GPI-anchor deficiency in the CD52-negative T cells reconstituting after ALM-based 
T-cell depleted alloSCT coincided with a highly polyclonal mutational landscape in the PIGA gene.
To confirm that mutations found in PIGA caused the GPI-anchor negative phenotype, we retrovirally 
transduced all GPI/CD52-negative T-cell clones (n = 73) with a construct encoding wtPIGA, or empty 
vector as a control. In 48 T-cell clones, marker gene expression indicated successful transduction (CD4 
clones n = 46; CD8 clones n = 2; median transduction efficiency within these clones = 15%) which 
always coincided with restored GPI-anchor and CD52 membrane expression in the wtPIGA transduced 
cells, independent of the type of mutation found in the individual clones (Figure 4, representative 
examples). No restored expression was observed in the mock transduced controls. These data validate 
that the various mutations found in the PIGA gene in the individual T-cell clones were solely responsible 
for the GPI/CD52-negative phenotype.
Figure 5. GPI/CD52-negative donor T-cell clones re-express CD52 and GPI-anchor expression upon retroviral 
transduction with wtPIGA
Three examples of GPI/CD52-negative CD4 T-cell clones from donor A retrovirally transduced with a construct 
encoding wtPIGA coupled to the tNGFR marker gene or with a control construct encoding the marker gene only 
(Mock). Depicted are flow cytometric analyses of CD52 and GPI-anchor (FLAER) expression. The upper panels depict 
the mock transduced clones gated on tNGFR marker gene positive cells and the lower panels depict the clones 
transduced with wtPIGA gated on tNGFR marker gene positive cells. Numbers represent the percentage of cells 
within the quartiles.
wtPIGA







PIGA mutations found in GPI/CD52-negative donor T cells 
Because it has been reported that low numbers of circulating GPI/CD52-negative T cells can be found in 
healthy individuals,17 we explored whether GPI/CD52-negative T cells carrying PIGA mutations could be 
detected in donors. We screened PBMC from two donors for the presence of GPI/CD52-negative T cells 
by flow cytometry. GPI/CD52-negative T cells were detected at frequencies of 22 per 106 T cells for donor 
A (donor of recipient 2) and 27 per 106 T cells for donor B (donor of recipient 37). To explore whether 
the GPI/CD52-negative phenotype in these cells resulted from mutations in PIGA, we purified, clonally 
expanded, and screened GPI/CD52-negative T cells from donor A for PIGA mutations. A total of 40 GPI/
CD52-negative CD4 and 3 GPI/CD52-negative CD8 T-cell clones was analyzed. The pattern of mutational 
diversity of the PIGA gene within this donor was similar to the one of the recipients (who showed full 
donor chimerism at the time of analysis) and included substitution mutations (n = 25), deletions (n = 
16), and exon skipping (n = 2) (Table 2). One of these mutations (r.499a>g) was found twice; in donor 
A and in corresponding recipient 2. No mutations in PIGA mRNA were found in GPI/CD52-positive T-cell 
clones isolated from this donor (CD4 n = 9, CD8 n = 9; data not shown). Retroviral transduction was 
performed on the GPI/CD52-negative donor T-cell clones (n = 43), with a construct encoding wtPIGA or 
an empty vector as a control. Marker gene expression indicated successful transduction in 28 clones 
(only CD4 clones; median transduction efficiency within these clones = 16%) which always coincided 
with a restored GPI/CD52-positive phenotype in the wtPIGA transduced cells, but not in the control 
condition (Figure 5, 3 representative examples). These results confirmed that the mutations found in 
PIGA caused the GPI/CD52-negative phenotype in donor T cells.
Functional T cells specific against multiple viral targets are present within the 
GPI/CD52-negative T-cell population
Because loss of GPI-anchor expression results in the loss of membrane expression of a large number 
of GPI-anchored proteins, some of which are involved in T-cell activation,19 we explored whether T cells 
that lost GPI-anchor expression remained functional. We screened PBMC from recipients 2, 28, and 37 to 
identify GPI/CD52-negative and/or GPI/CD52-positive CD8 T-cell populations specific against antigens 
from CMV or EBV by flow cytometry using fluorescently labeled HLA/peptide complexes (tetramers). In 
PBMC from recipient 37, an HLA-B*08:01/CMV-IE1-QIK positive CD8 T-cell population was identified that 
contained GPI/CD52-negative and GPI/CD52-positive T cells. These cells were purified and expanded. 
Comparable levels of IFN-γ were produced between GPI/CD52-negative HLA-B*08:01/CMV-IE1-QIK 
CD8 T cells and their GPI/CD52-positive counterparts upon stimulation with EBV-LCLs loaded with 
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the relevant viral peptide (Figure 6A). In addition, similarly high levels of IFN-γ were observed when 
GPI/CD52-negative CD8 T cells positive for tetramers HLA-A*02:01/CMV-IE1-VLE (recipient 2) and 
HLA-B*35:01/CMV-pp65-IPS (recipient 28) were tested and compared with GPI/CD52-positive CD8 T 
cells positive for tetramer HLA-B*08:01/EBV-BZLF1-RAK (recipient 37) (Figure 6B). These data show 
that loss of GPI-anchor expression did not impair the functionality of virus-specific GPI/CD52-negative 
CD8 T cells.
Figure 6. Functional T cells specific against multiple viral targets are present within GPI/CD52-negative T-cell 
populations
(A) Reactivity of GPI/CD52-negative and GPI/CD52-positive virus specific T cells (HLA-B*08:01/CMV-IE1-QIK) isolated 
and expanded from recipient 37 tested against third party EBV-LCLs loaded with a serial dilution of the relevant peptide 
in IFN-γ ELISA. Data are presented as concentration IFN-γ released in the supernatant after 24 h of co-incubation. (B) 
Reactivity of isolated and expanded GPI/CD52-negative virus specific T-cell populations (HLA-A*02:01/CMV-IE1-VLE 
GPI- and HLA-B*35:01/CMV-pp65-IPS GPI-) tested against EBV-LCLs loaded with a serial dilution of relevant viral peptides 
in IFN-γ ELISA. As a reference, reactivity of a GPI/CD52-positive T-cell population (HLA-B*08:01/EBV-BZLF1-RAK GPI+) 
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ALM-based T-cell depleted alloSCT protocols are used to prevent acute GvHD and graft rejection. In this 
study we show in a cohort of 89 ALM-based T-cell depleted alloSCT recipients that early lymphocyte 
reconstitution generally consists of reconstitution of large populations of T cells lacking membrane 
expression of the ALM target antigen CD52. In contrast, CD52-negative cells were found to be 
uncommon within B cells and NK cells, confirming earlier reports.9,10 We and other investigators have 
shown previously that lack of CD52 expression from the membrane of T cells following ALM-based 
alloSCT results from the loss of GPI-anchor expression. However, the mechanism resulting in this loss 
remained unknown. In this article, we illustrate that a highly polyclonal mutational landscape in the PIGA 
gene results in the loss of GPI-anchor expression in CD52-negative T cells reconstituting following ALM-
based T-cell depleted alloSCT. The patterns of PIGA mutations were highly diverse between recipients, 
as well as within T cell populations from single recipients. A similar diverse pattern of PIGA mutations 
was observed within the extremely low frequency of CD52-negative T cells isolated from PB of a healthy 
donor, indicating that the susceptibility for gaining mutations in the highly mutagenic PIGA gene of T 
cells is a general phenomenon and is not solely caused by exposure to ALM. In turn, this provides an 
explanation for the frequent presence of CD52/GPI-anchor negative T cell populations following ALM 
treatment, because this treatment allows the preferential outgrowth of CD52-negative cells. We show 
that, despite loss of GPI-anchor expression, GPI/CD52-negative T-cell populations contain functional T 
cells specific against multiple viral antigens.
CD52 is expressed on all mature lymphocyte subsets, but at different levels: CD4 T cells generally express 
higher levels of CD52 than CD8 T cells.20 Subsets with higher CD52 expression levels are more sensitive 
to ALM-induced cell death resulting in more profound depletion.8,20 We show that, upon lymphocyte 
reconstitution following ALM-based T-cell depleted alloSCT, ALM-resistant CD52-negative cells were 
more abundant in the CD4 T-cell compartment than in the CD8 T-cell compartment (median 81.3 and 
32.0%, respectively).These fractions of CD52-negative T cells are inversely correlated with the normal 
level of CD52 expressed on these subsets in healthy individuals, suggesting that more profound ALM-
induced selective pressure resulted in higher proportions of CD52-negative ALM-resistant cells. Higher 
selective pressure also likely explains why CD52-negative T cells are mainly from donor origin, because 
ALM concentrations present in the bag containing the graft are >5-fold higher compared with ALM 
plasma concentrations reached in the patient (F.C. Loeff, H.M. van Egmond, J.H.F. Falkenburg, C.J.M. 
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Halkes, and I. Jedema, unpublished observations). In concordance, in patients receiving transplantation 
without ALM treatment, CD52-negative T cell populations are detected at the same low frequencies as 
seen in PB of healthy donors.9
Many of the PIGA mutations found in this study have previously been reported to result in a GPI-anchor 
deficient phenotype in patients with PNH, aplastic anemia, or myelodysplastic syndrome.21-24 In these 
patients, this phenotype results from clonal outgrowth of a progenitor cell carrying a single PIGA 
mutation that generally affects multiple hematopoietic cell lineages. In contrast, the GPI/CD52-negative 
cell populations found in ALM-based T-cell depleted alloSCT recipients were mainly restricted to the T-cell 
lineage. Furthermore, the GPI/CD52-negative phenotype in T-cell populations from individual alloSCT 
recipients resulted from a multitude of PIGA mutations. The mechanism resulting in PIGA mutations 
in GPI/CD52-negative T cells was not studied, but they are likely acquired spontaneously during cell 
division. This implies that cell populations that have experienced an (antigen driven) expansion phase 
are especially likely to have acquired these mutations, which is supported by the observation that T cells 
with a memory phenotype preferentially survive ALM-based T-cell depletion.25,26 Although this study has 
focused on the presence of GPI/CD52-negative T cells early after transplantation, when few naive T cells 
are present in the circulation, we indeed observed, in a different cohort, that, at later time points, GPI/
CD52-negative T cells are mainly observed in the effector and memory T cell populations (F.C. Loeff, H.M. 
van Egmond, J.H.F. Falkenburg, C.J.M. Halkes, and I. Jedema, unpublished observations).
We found GPI/CD52-negative T cells in donor PBMC at frequencies similar to those previously reported 
in healthy individuals.17 In contrast to that article, which recorded only one or two PIGA mutations 
per individual as a result of limited testing, we show that the GPI-anchor negative phenotype in the 
donor T-cell population resulted from ≥41 different PIGA mutations within a single individual. Our data, 
in combination with the data published for patients with PNH, aplastic anemia, or myelodysplastic 
syndrome, show that hundreds of distinct mutations in PIGA can result in the GPI-deficient phenotype. 
This may explain why only one of the mutations that we detected in donor material correlated with a 
mutation in the corresponding recipient.
Based on the frequencies of GPI/CD52-negative T cells determined in the donors, the average composition 
of a G-CSF-mobilized PB graft (384x106 T cells/kg of recipients body weight)27,28, and the assumption 
that GPI/CD52-negative T cells survive ALM treatment, an average of 1.0x104 GPI/CD52-negative donor 
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T cells per kg of recipients body weight are infused with the graft during alloSCT. Antigen-dependent and 
homeostatic proliferation of these pre-existing GPI/CD52-negative cell likely explains why GPI/CD52-
negative T cells are abundantly present during the first months following alloSCT.29 However, de novo-
acquired loss-of-function PIGA mutations in rapidly proliferating GPI/CD52-positive T cells that survived 
ALM-based depletion may also contribute to the GPI/CD52-negative T-cell population. The long lifespan 
of T cells30 results in the persistence of GPI/CD52-negative T cells for years before they are completely 
replaced by GPI/CD52-positive T cells derived from engrafted stem cells.9
We show that functionality of GPI/CD52-negative T cells is comparable to their GPI/CD52-positive 
counterparts, confirming previous reports using T cells derived from PIGA deficient mice.31,32 The clinical 
relevance of these GPI/CD52-negative T cells in the setting of alloSCT remains largely unknown. They may 
be beneficial by promoting GvT or by eliciting early antiviral immune protection. Alternatively, they may 
result in toxicity by induction of GvHD. We show that GPI/CD52-negative T-cell populations contained 
functional T cells specific against multiple viral antigens implicating their involvement in early immune 
protection. Because GPI/CD52-negative T cells are likely of memory phenotype, they are less prone to 
induce GvHD33-35 compared with unselected T cells. Together, this may explain the clinical success of the 
ALM-based T-cell depleted alloSCT protocol.
In conclusion, loss of CD52 membrane expression in T cells reconstituting early after ALM-based T-cell 
depleted alloSCT is the result of various mutations in the PIGA gene and consequential loss of GPI-anchor 
expression. These GPI/CD52-negative populations contain functional virus-specific T cells and may be 
essential in immune protection early after transplantation.
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ND indicates not detectable; AML, acute myeloid leukemia; BC, blast crisis; B-ALL, B cell acute lymphoblastic leukemia; B-NHL, B cell non-
Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; MCL, 
mantle cell lymphoma; MDS REAB-2, myelodysplastic syndrome refractory anemia with excess blasts-2; MM, multiple myeloma; NOS, 
not otherwise specified; SAA, severe aplastic anemia; T-ALL, T cell acute lymphoblastic leukemia; T-NHL, T cell non-Hodgkin lymphoma; 
NMA, non-myeloablative; MA, myeloablative; SIB, sibling; UD, unrelated donor; MPB, mobilized peripheral blood; BM, bone marrow.
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Figure S1. No loss of mRNA expression of CD52 or any of the GPI-anchor synthesis pathway genes in GPI/CD52-
negative T cells
(A) Agarose gel electrophoresis results from a representative CD52 mRNA expression analysis of CD4 and 
CD8 T cells derived from recipients 2, 37, and 28 which were positive (+) or negative (-) for CD52 membrane 
expression (ME). CD52-negative and CD52-positive CD4 and CD8 T cells were purified by flow cytometric cell 
sorting, followed by mRNA isolation, cDNA synthesis, and a PCR amplification using specific primers (Table S2). 
Equimolar amounts of cDNA of the CD52-negative and CD52-positive samples were used for PCR amplification. 
As a control GAPDH was amplified. (B) Representative example of mRNA expression analysis for the GPI-anchor 
synthesis pathway genes performed on FACS purified GPI/CD52-negative and GPI/CD52-positive CD4 T cells 
from recipient 37. GPI/CD52-negative and GPI/CD52-positive CD4 T cells were purified by FACS, followed by 
mRNA isolation, and cDNA synthesis. PCR amplification was performed using primer sets specifically designed to 
individually amplify all 28 proteins involved in the GPI-anchor biosynthesis pathway. Equimolar amounts of cDNA 
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CHAPTER 5108
Adult B-lymphoblastic leukemia (B-ALL) is a hematological malignancy 
characterized by genetic heterogeneity. Despite successful remission induction with 
classical chemotherapeutics and novel targeted agents, enduring remission is often 
hampered by disease relapse due to outgrowth of a pre-existing subclone resistant 
against the treatment. In this study, we show that small glycophosphatidylinositol 
(GPI)-anchor deficient CD52-negative B-cell populations are frequently present 
already at diagnosis in B-ALL patients, but not in patients suffering from other B-cell 
malignancies. We demonstrate that the GPI-anchor negative phenotype results from 
loss of mRNA expression of the PIGH gene, which is involved in the first step of GPI-
anchor synthesis. Loss of PIGH mRNA expression within these B-ALL cells follows 
epigenetic silencing rather than gene mutation or deletion. The coinciding loss of 
CD52 membrane expression may contribute to the development of resistance to 
alemtuzumab (ALM) treatment in B-ALL patients resulting in the outgrowth of CD52-
negative escape variants. Additional treatment with 5-aza-2’-deoxycytidine may 
restore expression of CD52 and revert ALM resistance.
ABSTRACT
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Despite introduction of new treatment modalities, such as immunotherapeutics and kinase inhibitors, 
the survival rate for adult patients with B-lymphoblastic leukemia (B-ALL) remains disappointing due to 
a high risk of relapse after initial successful induction of complete remission.1 Relapse often results from 
outgrowth of subclones carrying mutations that confer resistance to therapy.2,3
Incorporation of alemtuzumab (ALM, Campath-1H) in treatment protocols can lead to successful disease 
control in a wide variety of hematological malignancies.4-6 In contrast, introduction of ALM as a single 
drug treatment for B-ALL resulted in only modest clinical efficacy. Despite similarly high membrane 
expression of the glycophosphatidylinositol (GPI)-anchored ALM target antigen CD52 across all the 
B-ALL molecular subtypes (with t(4;11) as the only exception),7 only a minority of the patients achieved 
an enduring complete remission due to early relapses.8,9 This could be the result of outgrowth of CD52-
negative B-ALL escape variants,10,11 as demonstrated in a mouse model engrafted with human B-ALL.10 
These CD52-negative B-ALL cells displayed normal CD52 gene expression, but remarkably loss of CD52 
membrane expression coincided with loss of other GPI-linked proteins like CD55 and CD59, indicating 
that loss of GPI-anchor expression had been the underlying cause. This loss of GPI-anchor expression 
was not the result of mutations in the X-linked PIGA gene,10 one of 28 genes essential for GPI-anchor 
synthesis,12 which causes loss of GPI-anchor expression in paroxysmal nocturnal hemoglobinuria 
(PNH).13,14
The aim of this study was to unravel the mechanisms underlying loss of GPI-anchor expression and 
coinciding loss of CD52 membrane expression in B-ALL. We show that small pre-existing GPI/CD52-
negative B-cell populations are frequently present in peripheral blood (PB) and bone marrow (BM) of 
B-ALL patients already at diagnosis, but not in patients suffering from other B-cell malignancies or in 
healthy donor B cells. We demonstrate that loss of mRNA expression of the PIGH gene, which is involved 
in the first step of GPI-anchor synthesis, was the underlying cause of loss of GPI-anchor expression 
in B-ALL cells. This loss of PIGH mRNA expression was not due to genetic aberrations, but rather due 
to epigenetic silencing. These data describe a new mechanism of loss of GPI-anchor expression. The 
resulting loss of CD52 membrane expression may confer ALM resistance to B-ALL patients due to the 





Residual BM or PB samples from ALM-naive patients with B-ALL, chronic lymphocytic leukemia (CLL), hairy 
cell leukemia (HCL), or mantle cell lymphoma (MCL) which were taken at diagnosis and stored anonymously 
were used for this study. Mononuclear cells (MNC) were isolated by Ficoll-Isopaque separation and 
cryopreserved in Iscove’s Modified Dulbecco’s Media (IMDM, Lonza, Verviers, Belgium) supplemented 
with 25% fetal calf serum (FCS, Lonza) and 10% dimethyl sulfoxide (DMSO, Sigma-Aldrich, Zwijdrecht, 
the Netherlands). MNC isolated from PB of healthy donors were taken as control. The use of these 
materials for research was approved by the Leiden University Medical Center medical ethical committee.
For one patient (ALL-06), a PB sample taken 1 month after relapse that occurred after ALM-treatment 
was available. In this patient, successful ALM-treatment, as indicated by the absence of circulating 
lymphocytes 2 months after treatment initiation, was followed by an early relapse at month 4.
Flow cytometry and cell sorting
GPI-anchor expression was analyzed by flow cytometry on thawed MNC samples stained with the 
GPI-anchor specific inactivated toxin pro-aerolysin coupled to AlexaFluor488 (FLAER-ALX488, Sanbio, 
Uden, the Netherlands), allophycocyanin (APC)-conjugated anti-CD52 (ITK diagnostics, Uithoorn, the 
Netherlands), anti-CD3-phycoerythrin/cyanine7 (ITK) or anti-CD3-PacificBlue (BD, Becton Dickinson, 
Breda, the Netherlands), and phycoerythrin (PE)-conjugated anti-CD19 (BD) and analyzed on an LSRII 
(BD) (gating strategy in Figure S1). Samples containing FLAER-negative cells, were further characterized 
by staining with FLAER, anti-CD45-PE (BD), and  anti-CD19-APC (BD). FACS-sorting was performed using 
the same antibodies on a FACSARIA III (BD). 
Fluorescent in situ hybridization analysis
High–resolution karyotype analysis on primary B-ALL samples was performed by combined binary ratio 
labeling fluorescent in situ hybridization as described before.15  Fluorescent in situ hybridization analysis 
specific for cytogenetic aberrations t(9;22) and del7q on FACS-sorted GPI-anchor negative (FLAER-) 
malignant B cells (CD19+/CD45dim) was performed using Vysis probe combinations LSI BCR/ABL ES 
and D7S486/CEP 7 (both Abbott Molecular, Des Plaines, IL, USA), respectively.
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Expression analysis of GPI-anchor synthesis pathway genes
For each patient sample,  equal numbers of GPI-anchor negative and positive B cells (range 3000 - 
670,000 cells) were isolated from thawed MNC samples by FACS-sorting. mRNA was isolated using 
the RNAqueous-Micro Kit (Thermo Fisher scientific, Bleiswijk, the Netherlands), which included DNAse 
treatment, quantified using a spectrophotometer (ND-1000, Thermo Fisher scientific), and completely 
converted to cDNA using M-MLV transcriptase (Thermo Fisher) and oligo-dT primers. cDNA input was 
equalized for the different samples using the mRNA Nanodrop measurements as reference (minimum of 
6 ng of converted mRNA per sample). PCR amplification was performed using specific primers for the 28 
GPI-anchor synthesis genes (Table S1) and PWO SuperYield DNA polymerase with a touchdown protocol 
which consisted of initial denaturing at 95°C (2 min), 7 cycles at 95°C (15 sec), 65°C-58°C with a 1°C 
decrement per cycle (30 sec), and 72°C (60 sec), 25 cycles at 95°C (15 sec), 58°C (30 sec), and 72°C 
(60 sec + 5 sec/cycle), and a final extension step at 72°C (7 min).
Expression analysis of the full protein coding region of PIGH was performed by amplification using 
specific primers (Table S2) and Phusion Flash High-Fidelity PCR Master Mix (Thermo fisher scientific) 
with a touchdown protocol which consisted of initial denaturing at 98°C (2 min), 7 cycles at 98°C (1 
sec), 65°C-58°C with a 1°C decrement per cycle (5 sec), and 72°C (30 sec), 30 cycles (PIGH) or 20 
cycles (GAPDH) at 98°C (1 sec), 58°C (5 sec), and 72°C (60 sec), and a final extension step at 72°C (7 
min). As cDNA loading control, GAPDH was amplified.
Cell culture conditions and generation of subcultures
Cell lines Leiden-ALL-BV and Leiden-ALL-HP were generated previously in our laboratory from primary 
B-ALL cells.15 B-ALL cell lines were maintained in Iscove’s Modified Dulbecco’s Media (IMDM, Lonza) 
supplemented with 6  mg/mL human serum albumin (HSA, Sanquin, Amsterdam, the Netherlands), 
10  µg/mL cholesterol, 1 µg/mL insulin, 50 µM 2-mercaptoethanol (all three from Sigma-Aldrich), 200 
µg/mL human apo-transferrin (Invitrogen, Carlsbad, Ca, USA), 2 mM glutamine (Lonza), 0.5 µg/mL 
amphotericin (Bristol-Myers Squibb, Utrecht, the Netherlands) and 50 units/mL penicillin/streptomycin 
(Lonza).
GPI-anchor negative and GPI-anchor positive subcultures of Leiden-ALL-BV and Leiden-ALL-HP were 
generated by FACS-sorting using counterstaining with FLAER-ALX488 and APC-conjugated anti-CD52. 
Upon subsequent expansion the four new subcultures were termed Leiden-ALL-BV-GPI-positive (BV 
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GPIpos), Leiden-ALL-BV-GPI-negative (BV GPIneg), Leiden-ALL-HP-GPI-positive (HP GPIpos), and Leiden-ALL-
HP-GPI-negative (HP GPIneg). Purity of the newly formed subcultures was analyzed by flow cytometry 
staining with FLAER-ALX488 and APC-conjugated anti-CD52.
Generation of PIGH, PIGA, and mock expression constructs 
and retroviral transduction
A construct encoding wtPIGH coupled via a GSG linker and a self-cleaving T2A peptide sequence to 
a truncated form of the nerve growth factor receptor (tNGFR), which served as a marker gene, were 
cloned into the LZRS plasmid. As controls, constructs encoding wtPIGA coupled to tNGFR (PIGA) or tNGFR 
only (mock) were used. The constructs were transfected into the ϕ-NX-A retroviral packaging cell line 
using Fugene HD Transfection Reagent (Roche, Woerden, the Netherlands). After 4 days, transfected 
cells were selected by addition of 2 µg/mL puromycin (Clontech, TaKaRa Bio, Mountain View, CA, USA) 
to the culture medium. After 24 h, selected cells were further expanded in absence of puromycin for 
several weeks before supernatant was collected and stored at -80°C.
Retroviral transduction was performed as described before.16 Supernatant containing the retroviral 
particles was added to wells of a flat bottom non-tissue culture treated 24-well plate coated with human 
fibronectin fragments (CH-296, Retronectin, TaKaRa Bio) and centrifuged for 20 min at 3000 x g. After 
removal of the supernatant, 1.5x105 B-ALL cells were added per well and incubated for 24 h at 37°C and 
5% CO2. Transduced cells were transferred to tissue culture treated plates and allowed to expand for 5 
days before analysis by flow cytometry, counterstaining with FLAER-ALX488, APC-conjugated anti-CD52, 
and PE-conjugated anti-NGFR (BD).
PIGH mRNA expression and mutational analysis 
mRNA was isolated from 5.0x105 cells and partial PIGH transcription variants were amplified by PCR 
using specific primers (Table S2) and Phusion Flash High-Fidelity PCR Master Mix using the protocol 
described above.
For mutational analysis, DNA was isolated from 2.0x106 cells using the Gentra Puregene Cell Kit (Qiagen, 
Venlo, the Netherlands). Amplification of the 10 kbp PIGH genomic region was performed using specific 
primers (Table S2) and the Expand Long Template PCR System with the following parameters, initial 
denaturing at 94°C (5 min), 10 cycles at 94°C (30 sec), 59°C (30 sec), and 68°C (8 min), 30 cycles at 
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94°C (30 sec), 59°C (30 sec), and 68°C (8 min + 20 sec/cycle), and a final extension step at 72°C (7 min). 
The resulting product was analyzed by gel electrophoresis using the SmartLadder LF (Eurogentec) as a 
marker. The correctly sized bands were excised and cleaned using the Wizard SV Gel and PCR Clean-Up 
System (Promega, Leiden, the Netherlands). Nested PCR’s were performed using specific primers (Table 
S2) and PWO SuperYield DNA polymerase with the following parameters, initial denaturing at 94°C (5 
min), 10 cycles at 94°C (15 sec), 58°C (30 sec), and 72°C (150 sec), 25 cycles at 94°C (15 sec), 58°C 
(30 sec), and 72°C (150 sec), and a final extension step at 72°C (7 min). Products from the nested 
PCR’s were analyzed for mutation in the promoter region, exon boundaries, and gene body by Sanger 
sequencing using the same primers. All Sanger sequencing was performed by Baseclear (Leiden, the 
Netherlands) and analyzed using Geneious 8 software (Biomatters limited, Auckland, New Zeeland).
Microarray analysis
Total RNA of 2x106 cells of subcultures BV GPIpos, BV GPIneg, HP GPIpos, and HP GPIneg was isolated using 
an RNAqueous Total RNA Kit (Thermo Fisher scientific), cleaned using an RNeasy mini kit (Qiagen), 
and quality checked using Agilent RNA6000 chips and the Agilent Bioanalyser (Santa Clara, CA, USA). 
RNA was amplified using the TotalPrep RNA amplification kit (Ambion). Samples were analyzed using a 
whole-genome gene expression direct hybridization assay with Human HT-12 v4 Expression BeadChips 
on a BeadArray 500GX device (all Illumina, San Diego, CA, USA). Data was analyzed using R 2.15 as 
described before.17
ChIP-qPCR
Chromatin immunoprecipitation (ChIP) was performed as described before.18 For each subculture 
100x106 cells were fixed using 1% formaldehyde for 10 min at 20°C. Formaldehyde was quenched by 
addition of 1/20 volume 2.5 M glycine for 15 min at 20°C. Cells were washed twice using PBS, supernatant 
was discarded, and the cell pellet was snap frozen at -80°C. The cell pellet was thawed and resuspended 
in lysis buffer, sonicated twice for 15 min using a Bioruptor (30 sec ON/OFF interval, output high, 
Diagenode, Seraing, Belgium), and split into four identical samples of which three were incubated with 
200 µL Dynabeads Protein G pre-incubated with 5 µg of either anti-histone H3, anti-histone H3K4me3 and 
anti-histone H3K27me3 overnight at 4°C. The fourth sample was used as untreated reference (refDNA). 
Beads were washed in a Dynamag-2 magnet (Thermo Fisher scientific) followed by elution (50 mM Tris-
HCl, 10 mM EDTA, 1% SDS). All samples were reverse cross-linked by overnight heating at 65°C. DNA was 
purified using phenol-chloroform extraction. DNA was quantified using a ND-1000 spectrophotometer.
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Per condition, 5 ng of DNA was analyzed in duplicate by qPCR using specific primers targeting PIGH 
(Table S2), FastStart Taq DNA polymerase (Roche), and Evagreen (Biotium, Fremont, CA, USA) using the 
following protocol, initial denaturing at 95°C (10 min), followed by 45 cycles at 95°C (10 sec), 65°C (30 
sec), 72°C (20 sec), and a plate read. GAPDH (promoter region) and MYOD1 (gene body) were amplified as 
positive controls for histone marks H3K4me3 or H3K27me3, respectively. qPCR analysis was performed 
on a LightCycler-480 (Roche). An average Ct-value was calculated from the duplicate measurement. For 
the positive control genes an average Ct-value was calculated from the two primer sets. Presence of 
PIGH coding DNA in the histone mark ChIP DNA samples relative to refDNA and normalized for a positive 
control gene (GAPDH for H3K4me3, MYOD1 for H3K27me3) was calculated using the 2-∆∆Ct method,19 
where ∆∆Ct = (CtPIGH – CtGAPDH or MYOD1)refDNA – (CtPIGH – CtGAPDH or MYOD1)ChIPDNA. The difference between the GPI
neg 
and GPIpos subcultures of Leiden-ALL-BV or Leiden-ALL-HP were calculated by dividing the 2-∆∆Ct from 
the GPIneg sample by the 2-∆∆Ct from the GPIpos sample. Results were normalized for the GPIpos subcultures.
Promoter methylation analysis
DNA was extracted using the QIAamp DNA Blood Mini Kit (Qiagen) and 1 µg was bisulfite-converted 
using the EZ DNA Methylation Kit (Zymo Research, Orange, CA, USA). Amplification and methylation 
specific melting curve analysis (MS-MCA) was performed by using specific primers (Table S2) on a 
CFX384 Touch Real-Time PCR Detection System (Bio-Rad, Veenendaal, the Netherlands) using a 
touchdown PCR protocol with the following parameters, initial denaturing at 95°C (30 sec), 7 cycles 
at 95°C (30 sec), 65°C-58°C with a 1°C decrement per cycle (40 sec), and 72°C (40 sec), following 
by 33 cycles at 95°C (30 sec), 60°C (40 sec), and 72°C (40 sec), and a final extension step at 72°C (3 
min). Following amplification, melting curves were acquired in the presence of iQ SYBR Green Supermix 
(Bio-Rad) during a linear temperature transition from 65°C to 90°C with increments of 0.2°C/10 sec. 
Bisulfite converted CpGenome Universal Methylated DNA (Chemicon, Hampshire, United Kingdom) and 
unmethylated male DNA were used as references. Methylation levels of individual CpGs were analyzed 
by Sanger sequencing (ratio between height of cytosine signal relative to thymine signal).
Demethylation assay
For each subculture, 1.0x105 cells were cultured in 200 µL medium with or without 0.5 µM 5-aza-2’-
deoxycytidine (5-aza, Vidaza, Pharmion Corporation, Boulder, CO, USA) for 15 days. Daily, 100 µL culture 
supernatant was replaced with 100 µL fresh medium containing 1.0 µM 5-aza. Presence of GPI-positive 
cells was evaluated by flow cytometry using counterstaining with FLAER-ALX488.
5
LOSS OF THE GPI-ANCHOR IN B-ALL 115
RESULTS
GPI/CD52-deficient cells are commonly present in B-ALL, 
but not in other B-cell malignancies
To examine whether pre-existing populations of GPI/CD52-negative malignant B cells were already 
present at diagnosis in patients with B-ALL who had not previously received ALM-treatment, we 
screened primary PB (n = 13) or BM (n = 12) samples from 25 patients with B-ALL who carried various 
cytogenetic aberrations (Table 1). In 13/22 evaluable samples (both PB and BM) clear (>0.025%) 
GPI-anchor negative populations (median 0.25%) were detected within the B-cell compartment 
(representative examples in Figure 1; aggregated result in Table 1). These GPI-anchor negative B cells 
consistently lacked CD52 membrane expression. Detailed flow cytometric analysis demonstrated that 
the GPI-anchor negative B cells were present in the malignant (CD45dim) but not in normal B-cells 
(CD45bright) within the same sample (representative examples for three cases in Figure S2). The 
malignant nature of the GPI-anchor negative B cells was further confirmed for these three B-ALL cases 
by flow cytometric cell sorting of the GPI-anchor negative populations and subsequent FISH analysis. The 
GPI-anchor negative B cells contained the same cytogenetic aberrations as the bulk of the malignancy 
(del7q for ALL-03, and t(9;22) for ALL-05 and ALL-12) (data not shown). In the samples of three 
patients carrying a mixed-lineage leukemia (MLL) translocation t(4;11) (samples 23-25) an atypical 
pattern of low GPI-anchor expression was observed (Figure S3), hampering proper discrimination of 
potential GPI-anchor negative B cells. The GPI-anchor positive B-cells within the other B-ALL samples 
displayed broad, but clearly positive CD52 expression patterns (Table 1), with the exception of sample 
ALL-08. Whereas the presence of GPI/CD52-negative cells in the malignant B cell populations was a 
frequent event, within the T cells of the same samples no clear GPI/CD52-negative cells were detected 
(representative examples in Figure 1). No overt GPI/CD52-negative B-cells were found in PB samples 
from healthy donors (n = 6, representative examples in Figure S4). To investigate whether GPI/CD52-
negative cells were common in patients carrying B-cell malignancies, we screened samples from 
patients with CLL (PB, n = 5), HCL (PB, n = 5; spleen, n = 1), and MCL (PB, n = 2; BM, n = 2) taken 
at diagnosis. No GPI/CD52-negative cells were detected within these malignant B cells (Figure S5).
For one patient (ALL-06), material taken at diagnosis and material of the relapse that occurred after 
ALM-treatment was available for analysis. An enlarged GPI/CD52-negative B-cell population (32.5%) was 
found in the sample taken 1 month after relapse (Figure S6).
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These data demonstrate that the presence of GPI/CD52-negative B-cells is a frequent event in B-ALL, 
but not in other B-cell malignancies and in healthy donor B cells.
Loss of PIGH mRNA expression in GPI-anchor negative primary B-ALL cells
To unravel the underlying mechanism resulting in GPI-anchor deficiency within GPI/CD52-negative 
B-ALL cells, we performed mRNA expression analysis for all 28 genes that are essential for GPI-anchor 
synthesis in FACS purified GPI-anchor negative B-ALL cells (from ALL-01, ALL-04, and ALL-05), using GPI-
anchor positive B cells from the same samples as controls. In all three cases, no PIGH mRNA expression 
was detected in the GPI-anchor negative cells, whereas normal PIGH mRNA expression was detected in 
the GPI-anchor positive cells (Figure 1B, representative example). Transcriptional activity for all other 27 
GPI-anchor synthesis genes was observed in both the GPI-anchor negative and positive cell populations.
Table 1. GPI-anchor deficiency in B-lymphoblastic leukemia
MFI, median fluoresce intensity; BM, bone marrow; PB, peripheral blood
* A cut-off percentage of 0.025% was used to exclude back-ground events
** Most frequent cytogenetic aberration
















































































































































Sample Number of B-cells 
screened
CD52 expression 
of GPIpos B cells (MFI)
GPIneg/CD52neg 
B-cells (%)*
Sample type Cytogenetic 
abnormalities**
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To explore whether absence of PIGH mRNA expression was a common phenomenon in GPI-anchor 
negative B-ALL cells, mRNA expression analysis for the protein-coding region of PIGH was performed 
in purified GPI-anchor negative B-cells derived from PB (n = 4) or BM (n = 4) samples of eight patients. 
Absence of PIGH mRNA expression was observed within the GPI-anchor negative cells and not within the 
GPI-anchor positive cells for all patients (Figure 1C).
These data show that loss of PIGH mRNA expression is a common phenomenon and associated with the 
GPI-anchor negative phenotype in B-ALL cells.
GPI-anchor expression is restored by enforced PIGH expression
To assess whether absence of PIGH mRNA expression was the sole cause of the GPI-anchor negative 
phenotype in B-ALL cells, we restored PIGH expression by retroviral transduction. We used cell lines 
Leiden-ALL-BV and Leiden-ALL-HP which were generated from primary B-ALL cells of samples ALL-
02 and ALL-06 (after relapse following ALM-treatment), respectively. These cell lines contained 10.4% 
(Leiden-ALL-BV) and 0.4% (Leiden-ALL-HP) GPI-anchor negative cells. GPI-anchor negative and GPI-
anchor positive subpopulations were purified by FACS-sorting (Figure S7). The GPI-anchor phenotype 
of these subcultures was stable during culturing. Absence of PIGH mRNA within GPI-anchor negative, 
but not within GPI-anchor positive subcultures was shown by mRNA expression analysis (Figure S8). In 
contrast, identical transcriptional activity was observed between the GPI-anchor negative and positive 
subcultures for the remaining GPI-anchor synthesis genes (Figure S9). High levels of CD52 mRNA were 
present in both the GPI-anchor negative and positive subcultures (Figure S9). Restored GPI-anchor and 
coinciding CD52 membrane expression was observed in the GPI-anchor negative subcultures upon 
retroviral transduction with a construct encoding PIGH, but not with PIGA or a mock construct (Figure 
2A). In the GPI-anchor positive subcultures no effect on GPI-anchor or CD52 membrane expression was 
observed upon transduction (Figure 2B).
In conclusion, the GPI-anchor negative phenotype in B-ALL cells was solely mediated by absence of PIGH 
mRNA expression.
Loss of PIGH mRNA expression does not result from a genetic aberration
To investigate if genetic aberrations resulted in loss of PIGH mRNA expression in GPI-anchor negative 
B-ALL cells, we first tested whether the inability to detect PIGH mRNA expression in the GPI-anchor 
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Figure 2. Retroviral transduction with PIGH, and genomic 
analysis of the PIGH gene loci in the GPIneg and GPIpos B-ALL 
subcultures 
Flow cytometric analysis of GPI-anchor (FLAER) and CD52 
membrane expression in (A) GPIneg and (B) GPIpos subcultures 
of cell lines Leiden-ALL-BV (BV-GPIneg and BV-GPIpos) 
and Leiden-ALL-HP (HP-GPIneg and HP-GPIpos) retrovirally 
transduced with an empty control construct (mock) or with 
constructs encoding PIGA or PIGH, coupled to tNGFR as 
marker gene. Transduction efficiency ranged between 13.6% 
and 52.9%. Dot plots are gated on tNGFR positive cells. (C) 
Schematic representation of analyses performed on DNA 
and mRNA isolated from GPIneg and GPIpos subcultures of cell 
lines Leiden-ALL-BV (BV-GPIneg and BV-GPIpos) and Leiden-ALL-HP 
(HP-GPIneg and HP-GPIpos). The PIGH genomic locus (chromosome 
14:67601700-67588700, GRCh38.p7) is shown, numbered 
black boxes represent coding exons connected by straight 
black lines representing intronic regions. SNPs rs12893796 
and rs11547225 (dbSNP build 144) are depicted by triangles. 
Figure 1. Loss of GPI/CD52-expression is due to absence of 
PIGH mRNA expression in B-ALL samples at diagnosis
(A) Four representative flow cytometric analyses of GPI-
anchor (FLAER) and CD52 membrane expression on B cells 
(CD19+CD3-, left panels) or T cells (CD3+CD19-, right panels) 
in MNC samples taken at diagnosis from patients with B-ALL. 
The percentages of GPI/CD52-negative cells are indicated.
(B) Representative example of mRNA expression analysis for 
the 28 genes comprising the GPI-anchor synthesis pathway 
on equimolar amounts of cDNA from GPI/CD52-negative 
(GPIneg) and GPI/CD52-positive (GPIpos) B cells purified 
from MNC sample ALL-04. (C) mRNA expression analyses 
of the PIGH protein-coding region (717 bp) performed 
on equimolar amounts of cDNA from purified GPIneg and 
GPIpos B cells from PB (n = 4, left panels) or BM (n = 4, 
right panels) samples of patients with B-ALL, using GAPDH 
(351 bp) as a loading control (M defines the marker lane).
PCR amplicons are numbered and indicated as stripped lines connecting the relevant primers (arrows). mRNA 
transcription variants are depicted by boxes connected with curved lines and identified by their Ensemble transcript 
number. The protein coding transcript is in black, predicted protein coding mRNA transcription variants are in grey. 












































(D, E) Gel electrophoresis results for the indicated PCR amplifications on (D) mRNA or (E) DNA isolated from the GPIneg 
and GPIpos subcultures (GAPDH as loading control). (F) Sanger sequencing results from nested PCR amplifications VII 
(Leiden-ALL-BV) and VI (Leiden-ALL-HP) with assembly GRCh38.p7 as reference sequence. SNPs rs12893796 and 




























































































































































negative subcultures of the Leiden-ALL-BV and -HP cell lines was the result of loss of a primer binding 
site due to alternative splicing of the pre-mRNA. We performed PCR specific for sections of PIGH mRNA 
that include all possible transcription variants (Figure 2C, amplicons I-IV). No amplicons were generated 
for the GPI-anchor negative subcultures, whereas all amplicons were generated for the GPI-anchor 
positive subcultures (Figure 2D). This shows that inability to detect PIGH mRNA in GPI-anchor negative 
subcultures was due to complete absence of PIGH mRNA expression.
To examine if loss of PIGH mRNA expression in the GPI-anchor negative subcultures resulted from 
genomic deletion of PIGH, we performed PCR using primers designed to amplify the complete 10 kbp 
PIGH genomic region (Figure 2C, amplicon V). Amplicons of the correct size were obtained for both 
the GPI-anchor negative and positive subcultures (Figure 2E), indicating that the gene was present 
at the genomic level with no detectable deletions or insertions. Nested PCR (Figure 2C, amplicons VI-
VII) followed by Sanger sequencing identified two single nucleotide polymorphisms (SNP, rs12893796 
in Leiden-ALL-BV, rs11547225 in Leiden-ALL-HP) for which both allelic variants were detected in the 
GPI-anchor positive subcultures. Both allelic variants were also detected in the GPI-anchor negative 
subcultures (Figure 2F), indicating that both alleles of the PIGH gene had been amplified and thus were 
present at the genomic level. Absence of a focal genomic deletion was further implied by comparable 
transcriptional activity of genes proximal to the PIGH genetic locus in the GPI-anchor positive and 
negative subcultures (Figure S10).
To investigate if a mutation, small deletion, or insertion in the promoter region (starting 630 bp before 
the transcription start site), at one of the splice sites, or in the gene body was the cause of loss of 
PIGH mRNA expression, we examined these genetic loci by Sanger sequencing (Figure 2C, amplicons 
VII-X). No differences in DNA sequences were found between the GPI-anchor negative and positive 
subcultures. Within each amplicon, at least one known SNP was identified for which both allelic variants 
were detected (data not shown). These SNPs were always detected in both the GPI-anchor negative 
and positive subcultures, indicating that each analyzed amplicon originated from both alleles of the 
PIGH gene.
In summary, the intact PIGH gene was present in both GPI-anchor negative B-ALL subcultures, illustrating 
that loss of PIGH expression in these cells could not be explained by obvious genetic aberrations in the 
coding gene.
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Loss of PIGH mRNA could be explained by epigenetic control of gene transcription
To explore whether loss of PIGH mRNA expression in GPI-anchor negative B-ALL cells resulted 
from epigenetic down regulation, we analyzed the presence of two predominant types of histone 
modifications at the PIGH gene locus. We considered histone mark H3K4me3, of which presence is 
strongly correlated with actively transcribed genes, and histone mark H3K27me3, of which presence 
correlates with transcriptional gene silencing.20 We performed H3K4me3 and H3K27me3 specific ChIP 
on DNA isolated from the GPI-anchor negative subcultures, using the GPI-anchor positive subcultures 
as references, followed by qPCR to quantify the relative presence of these histone marks at the PIGH 
gene locus. Almost complete loss of histone mark H3K4me3 from the PIGH promoter region was found 
in both GPI-anchor negative subcultures (Figure 3A). In contrast, presence of histone mark H3K27me3 
was increased in both GPI-anchor negative subcultures, with the largest effect between the Leiden-ALL-
BV subcultures (Figure 3A). These data imply that the PIGH gene in the GPI-anchor negative subcultures 
was transcriptionally silenced.
Histone modifications are only one part of the interrelated epigenetic code that directs gene 
transcription. To further investigate whether loss of PIGH mRNA expression resulted from epigenetic 
down regulation of gene transcription, we analyzed the level of DNA methylation at the PIGH promoter 
region, which contains a CpG-island. We performed MS-MCA (Figure 3B) and Sanger sequencing 
(Figure 3C) on bisulfite converted DNA from the GPI-anchor negative and positive subcultures. In the 
GPI-anchor positive subcultures, mono-allelic DNA methylation (Leiden-ALL-BV) and unmethylated DNA 
(Leiden-ALL-HP) were observed by MS-MCA, compatible with transcriptional activity of at least one 
allele and expression of PIGH mRNA. Since Sanger sequencing cannot distinguish between individual 
alleles, average levels from the two alleles were measured resulting in mostly intermediate (Leiden-
ALL-BV) and low (Leiden-ALL-HP) levels of methylation at individual CpGs. In the GPI-anchor negative 
subculture of Leiden-ALL-BV, a shift toward high level of DNA methylation was observed by MS-MCA 
and by Sanger sequencing, consistent with bi-allelic DNA methylation and loss of PIGH transcription. In 
the GPI-anchor negative subculture of Leiden-ALL-HP, a shift away from unmethylated was observed by 
MS-MCA, indicating partial methylation of the analyzed region, and Sanger sequencing analysis showed 
high levels of methylation in the region directly preceding the transcription start site (TSS) (CpG -11 to 
-6), but not in the bordering CpGs. Since high levels of methylation in this region were shared between 
the GPI-anchor negative subcultures of both Leiden-ALL-BV and Leiden-ALL-HP, CpGs at this position are 
likely to be essential for regulation of PIGH transcription and function as a so-called CpG “traffic light”.21 
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No CpG methylation was detected at the PIGH promoter region in bisulfite converted DNA from purified 
healthy donor B cells, further highlighting the abnormal DNA methylation in B-ALL cells.
To test if PIGH promoter methylation is essential in retaining the GPI-anchor negative phenotype in B-ALL 
cells, we tested whether treatment of the GPI-anchor negative subcultures with the demethylating agent 
5-aza would restore GPI-anchor expression. Gradual increase of the percentages of GPI-anchor positive 
cells was observed over time in samples treated with 5-aza in the GPI-anchor negative subcultures, and 
not in samples incubated without 5-aza (Figure 3D).
This illustrates that epigenetic down regulation of PIGH mRNA transcription results in loss of GPI-anchor 
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Figure 3. Epigenetic down regulation of PIGH gene transcription in GPIneg B-ALL subcultures
(A) ChIP–qPCR analysis of the relative presence of histone marks H3K4me3 and H3K27me3 at the PIGH gene location 
in the GPIneg subcultures compared to the GPIpos subcultures of Leiden-ALL-BV and Leiden-ALL-HP. PIGH DNA was 
quantified in H3K4me3 and H3K27me3 ChIP samples by qPCR and compared to a non-immunoprecipitated DNA 
reference sample (refDNA) and normalized for a positive control gene (GAPDH for H3K4me3 and MYOD1 for H3K27me3). 
Bars represent the relative presence of PIGH DNA in the GPIneg compared to the GPIpos subcultures (whiskers represent 
standard deviation; * P < 0.05, ** P < 0.01, *** P < 0.001, NS = not significant; two-sided unpaired T-test). Primer set 
1 (targeting the region 246 bp to 371 bp downstream of the TSS) and primer set 2 (329 bp to 496 bp downstream 
of the TSS) used for qPCR of H3K4me3 targeted the PIGH promoter region. Primer set 1 used for qPCR of H3K4me3 
doubled as primer set 1 for qPCR of H3K27me3. Primer set 2 (4486 bp to 4570 bp downstream of the TSS) and 
primer set 3 (6261 bp to 6373 bp downstream of the TSS) used for qPCR of H3K27me3 targeted the PIGH gene body. 
(B) MS-MCA curves for the PIGH promoter region (-212 bp to +101 bp relative to the TSS, CpGs -19 to +15) on bisulfite 
converted DNA from the GPIpos and GPIneg B-ALL subcultures (solid black line). Bisulfite converted DNA from purified 
healthy donor B cells served as a control. MS-MCA curves for unmethylated reference DNA (striped gray line, peak 
Tm 83.4°C) and methylated reference DNA (dotted grey line, peak Tm 89.0°C) are plotted in each graph. (C) Sanger 
sequencing analysis of the methylation state of 24 individual CpGs in the PIGH promoter region (-161 bp to +51 bp relative 
to the TSS, CpGs -16 to +8) on bisulfite converted DNA from the GPIpos and GPIneg B-ALL subcultures and from purified 
healthy donor B cells. The levels of methylation of individual CpGs were determined by the ratio between the height of 
the cytosine signal and the thymine signal. (D) Percentages of GPI-anchor positive cells in the GPIneg B-ALL subcultures 
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Durable remission in patients with B-ALL is often hampered by early disease relapse due to outgrowth of 
pre-existing subclones resistant to treatment.2,3 In this study, we showed that small GPI/CD52-negative 
B-cell populations were found already at diagnosis in the majority of patients with B-ALL at frequencies 
that are in line with previous reports.10,11 We showed that GPI-anchor negative B-cell populations were 
present in B-ALL patients carrying various cytogenetic abnormalities, implying that this phenotype can 
be acquired independent of the primary cause of malignant transformation. Nevertheless, these cells 
are part of the malignancy as demonstrated by their phenotype and genotype, and their presence 
within the cell lines generated from primary malignant B-ALL cells. No GPI-anchor negative B cells were 
detected in leukemic samples from patients suffering from mature B-cell malignancies such as CLL, HCL, 
and MCL, suggesting that the GPI-anchor negative phenotype in B-ALL develops as result of a cellular 
process that is part of the early stage of B-cell maturation in which B-ALL cells are arrested.
Considering the low frequencies of GPI-anchor negative cells in B-ALL, loss of GPI-anchor expression 
and coinciding loss of the GPI-anchor associated proteins unlikely provides a direct significant clonal 
growth advantage. This notion is supported by knock-out experiments in mice which demonstrated that 
GPI-anchor negative lymphocytes do not have intrinsic survival or growth benefits.22,23 However, loss of 
the GPI-anchored protein CD52 renders the cells resistant to the CD52-targeting therapeutic antibody 
ALM, as demonstrated by outgrowth of GPI/CD52-negative escape variants mice engrafted with human 
B-ALL.10 This may explain why ALM mono-therapy displays only limited efficacy in treatment of B-ALL.8,9
In PNH, lack of GPI-anchor expression is linked to a defect in the PIGA gene. We have previously shown 
that no mutations were present in PIGA in GPI-anchor negative B-ALL cells.10 Here, we demonstrated 
that the GPI-anchor negative phenotype in B-ALL cells resulted from loss of PIGH mRNA expression. The 
PIGH gene is essential in GPI-anchor synthesis as was previously shown in a CRISPR-Cas9 knock-out 
screen.12 Our study is the first to associate an anomaly related to the PIGH gene with a hematological 
disorder. Exploration of cancer genome databases did not yield an association between a genetic 
anomaly in PIGH and B-ALL (or any other malignancy), potentially as a result of the small contribution of 
the GPI-anchor negative cells to the total malignancy.
DISCUSSION
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In contrast to the X-linked PIGA, PIGH is an autosomal gene located on chromosome 14q24.1, implying 
that two affected alleles are required for complete loss of PIGH mRNA expression. Molecular analysis 
revealed that epigenetic silencing rather than gene mutation or deletion resulted in loss of PIGH 
mRNA expression. Epigenetic silencing of tumor suppressor genes is a frequent event in cancer. B-ALL 
cells may be particularly affected by this mechanism as they are arrested in an early stage of B-cell 
development at which major epigenetic changes take place to lock-in the lineage commitment and to 
initiate and maintain allelic exclusion of one of the immunoglobulin genes.24,25 Continued exposure to 
cellular processes triggering these epigenetic changes may lead to silencing of genes that are normally 
unaffected. In concordance, genome-wide de novo promoter DNA methylation was recently shown to 
be common in pediatric patients with B-ALL.26,27
Crosstalk between the various components of the epigenetic code and transcription factors renders 
it difficult to predict whether active gene silencing, via direct targeting by histone-modifying enzymes 
or DNA methyltransferases, or passive gene silencing, following the loss of an activating transcription 
factor or gain of a transcription repressor, had initiated silencing of PIGH gene transcription.26,28-30 
Irrespective of the mechanism, we demonstrated that silenced PIGH gene expression could be reversed 
in B-ALL cells, as illustrated by re-expression of the GPI-anchor following treatment with the epigenetic 
modifying agent 5-aza. Therefore, addition of epigenetic modifying drugs to ALM monotherapy may 
prevent ALM resistance.
In summary, the majority of patients with B-ALL harbor a small GPI/CD52-negative B-cell population 
already at diagnosis. These cells lost PIGH mRNA expression, a key component in GPI-anchor synthesis. 
This was not due to a genomic aberration, but rather to epigenetic silencing of PIGH gene transcription. 
Selective pressure provided by ALM-treatment may result in the outgrowth of GPI/CD52-negative 
escape variants in B-ALL patients and may be canceled by additional 5-aza-2’-deoxycytidine treatment.
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SUPPLEMENTAL DATA
Figure S1. Gating strategy for detection of GPI/CD52 negative B cells in primary samples
Representative example of flow cytometric analysis to detect and quantify the presence of GPI/CD52 negative cells 
in primary samples. Shown is the analysis for sample ALL-07. Lymphocytes were selected based on forward scatter 
(FSC) and side scatter (SSC) (25,000 events shown). Within the lymphocyte gate, B cells were defined as CD19+/
CD3- and T cells as CD3+/CD19- (25,000 events shown). Within these gates GPI/CD52 negative cells were defined as 
FLAER/CD52 negative (lower left quadrant) (all 369,534 events shown).
Figure S2. GPI-anchor negative B cells were present in the malignant and absent in normal B-cells within the same 
sample
Representative examples of flow cytometric analysis of primary B-ALL samples ALL-03, ALL-05, and ALL-12. Horizontally 
distributed panels belong to the same sample. Lymphocytes were selected based on forward scatter (FSC) and side 
scatter (SSC). Within the lymphocyte gate, malignant B cells were defined as CD19+/CD45dim and normal B cells as 
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Figure S3. GPI-anchor and CD52 expression in B-ALL cells carrying t(4;11) MLL translocation and in sample ALL-08
Flow cytometric analysis of GPI-anchor expression (FLAER) and expression of CD52 on samples from patients carrying 
the t(4;11) MLL translocation (Sample ALL-23, ALL-24, and ALL-25) and from non-MLL sample ALL-08. Shown are 
cells within the lymphocyte gate that were CD19+CD3- (B cells, upper panels) or CD3+CD19- (T cells, lower panels). 
Numbers indicate the percentage of cells within the quadrants.
Figure S4. GPI-anchor and CD52 expression in PB samples from healthy donors
Flow cytometric analysis of GPI-anchor expression (FLAER) and expression of CD52 on PB samples from healthy 
donors. Shown are all cells within the lymphocyte gate (left panels) and cells within the lymphocyte gate that were 




















Figure S5. GPI-anchor and CD52 expression in samples from patients with CLL, HCL, or MCL
Flow cytometric analysis for GPI-anchor expression (FLAER) and expression of CD52 on PB, BM, or spleen samples 
from patients with CLL, HCL, or MCL. Shown are cells within the lymphocyte gate that were positive for CD19 and 
negative for CD3 (B cells). Numbers indicate the percentage of cells within the respective quadrant.
Figure S6. GPI-anchor and CD52 expression before and after ALM-treatment in patient ALL-06
Flow cytometric analysis of GPI-anchor expression (FLAER) and expression of CD52 on samples taken 3 months 
before start of ALM-treatment (left) and 1 month after secession of treatment due to relapse (right). Shown are 
cells within the lymphocyte gate that were positive for CD19 and negative for CD3 (B cells). Numbers indicate the 
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Figure S7. GPI-anchor and CD52 expression on the subcultures of cell lines Leiden-ALL-BV and Leiden-ALL-HP
Flow cytometric analysis of GPI-anchor (FLAER) and CD52 membrane expression in the GPIneg and GPIpos subcultures 
of B-ALL cell lines Leiden-ALL-HP (HP GPIneg and HP GPIpos, respectively) and Leiden-ALL-BV (BV GPIneg and BV GPIpos, 
respectively). Numbers indicate the percentage of cells within the quadrants.
Figure S8. Loss of PIGH mRNA expression in GPI-anchor negative B-ALL subcultures
Gel electrophoresis results for PIGH mRNA expression analysis in the GPIneg and GPIpos subcultures of cell lines Leiden-
ALL-HP (HP GPIneg and HP GPIpos, respectively) and Leiden-ALL-BV (BV GPIneg and BV GPIpos, respectively). Equimolar 






































Figure S9. Global mRNA expression analysis of the GPI-anchor synthesis genes in the GPI/CD52-negative and GPI/
CD52-positve cell cultures
Global mRNA expression analysis of the GPI-anchor synthesis genes, CD19, and CD52 in cell cultures BV GPIneg, HP 
GPIneg, BV GPIpos, and HP GPIpos as determined by microarray analysis. Probe background fluorescence is generally 
between 40-60.17
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Figure S10. No difference in expression of genes proximal to PIGH in GPI/CD52-negative cell cultures compared to 
GPI/CD52-positve cell cultures
Global mRNA expression analysis of genes proximal (1.1 Mbp upstream to 1.2 Mbp downstream) to the PIGH 
chromosomal location in cell cultures BV GPIneg, HP GPIneg, BV GPIpos, and HP GPIpos as determined by microarray 
analysis. Nearest 10 genes for which probes were present on the Human HT-12 v4 chip are depicted.









































































































































































Primers set Gene name Reverse primerForward primer Amplicon size
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Table S2. Primer sequences for construct generation, mutational screening, and bisulfite sequencing






PIGH mRNA expression Analysis
Reverse primerForward primer
Exon 1-4, amplicon I
Exon 2-4, amplicon II
Exon 1-2, amplicon III










Full PIGH gene 10 kbp, amplicon V
Exon 1, amplicon VI
Exon 2, amplicon VII
Exon 3, amplicon VIII
Exon 4, amplicon IX














H3K4me3 PIGH primer set 1
H3K4me3 PIGH primer set 2
H3K27me3 PIGH primer set 2
H3K27me3 PIGH primer set 3
H3K4me3 GAPDH primer set 1
H3K4me3 GAPDH primer set 2
H3K27me3 MYOD1 primer set 1






















Summary and general discussion
CHAPTER 6138
SUMMMARY
Alemtuzumab (ALM) is a cytotoxic monoclonal antibody that is used as a therapeutic agent in a variety 
of clinical settings. The target antigen for ALM is CD52, which is highly expressed on the membrane 
of mature lymphocytes, but not or only marginally on hematopoietic stem cells, red blood cells, and 
non-hematopoietic tissues. As such, ALM can be administered for the purpose of lymphocyte depletion 
with no or only minimal toxicity to other tissues. In this thesis, the mechanism of action of ALM was 
investigated in the context of two clinical settings, i.e. T-cell depletion before allogeneic stem cell 
transplantation (alloSCT) and depletion of malignant cells in B lymphoblastic leukemia (B-ALL).
 
ALM-based T-cell depletion before allogeneic stem cell transplantation is applied to prevent the highly 
destructive side effect of graft versus host disease (GvHD). To obtain insight into ALM pharmacokinetics 
and its effect on the circulating T cells in patients who received alloSCT with a T-cell depleted graft by 
addition of ALM “to the bag” with or without prior ALM as part of the conditioning regimen, we analyzed 
in a prospective study ALM plasma levels and the number of circulating T cells in a cohort of 36 patients. 
Results from this analysis are described in chapter 2. We observed considerable variation in inter-
patient peak ALM plasma levels after graft infusion. This variation was demonstrated to depend on plasma 
volume rather than the number of circulating lymphocytes present before the start of ALM treatment. 
Effective T-cell depletion was observed in all patients. Patients with peak ALM plasma levels above 6.5 
µg/ml did not develop severe GvHD. Continued presence of ALM prevented reconstitution of CD52-
positive T cells when post-transplantation ALM plasma levels were above 0.7 µg/mL. Despite this, none 
of the patients had major complications related to Epstein-Barr virus (EBV) or cytomegalovirus (CMV). 
This outcome likely relates to the immunoprotective effect of early reconstitution of CD52-negative T 
cells which we demonstrated was not affected by enduring ALM exposure after transplantation.
In chapter 3 we examined the relative contribution of various factors that influence the efficiency 
of antibody-induced complement dependent cytotoxicity (CDC), one of the mechanisms employed by 
antibodies to induce target-cell lysis, using ALM together with exemplar therapeutic antibodies rituximab 
(RTX) and ofatumumab (OFA) (both targeting CD20) against a panel of B-ALL cell lines and primary 
B-ALL samples. We demonstrated that the sensitivity of target cells for antibody-induced CDC was 
predominantly determined by the level of target antigen expression and by antibody concentration. 
Purified glycosylphosphatidylinositol (GPI)-anchor negative subcultures from two B-ALL cell lines 
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were found to be especially sensitive to CDC induced by RTX and OFA, due to the lack of expression of 
membrane-bound complement inhibitors CD55 and CD59. Forced expression of CD55 and CD59 allowed 
us to demonstrate that both inhibitors were able to individually constrain CDC. This inhibiting effect 
was only observed within a specific range for target antigen expression and antibody concentration, 
indicating that the effect of CD55 and CD59 acts secondary to these parameters. Using primary B-ALL 
samples, we demonstrated that the natural variation of CD55 and CD59 could not be used as a single 
factor to predict sensitivity to CDC.
Early reconstitution of T cells that lack CD52 membrane expression may convey an immunoprotective 
effect after ALM-based T-cell depleted alloSCT. In chapter 4 we performed a comprehensive analysis to 
investigate the extent to which these CD52-negative T cells contribute to early T-cell reconstitution. Also, 
we elucidated the mechanism resulting in loss of CD52 membrane expression. In a consecutive cohort 
of 89 patient who had received an alloSCT for a variety of malignant and non-malignant hematological 
diseases, we showed that in the majority of patients the bulk of CD4 T cells and a substantial fraction of 
the CD8 T cells were negative for CD52 membrane expression at week 6 after graft infusion. In contrast, 
no obvious CD52-negative cell population was found within the NK or B cells from the same individuals. 
Direct staining of the GPI-anchor confirmed that loss of CD52 membrane expression was due to loss of 
GPI-anchor expression, as suggested by previous reports. Targeted sequence analysis on mRNA from 
clonally expanded GPI/CD52-negative and positive T cells from three alloSCT recipients demonstrated 
that a highly polyclonal mutational landscape in the PIGA gene had resulted in the loss of GPI-anchor and 
coinciding absence of CD52 membrane expression. Forced re-expression of wildtype PIGA in the GPI/
CD52-negative T-cell clones restored the GPI/CD52-positive phenotype. The GPI/CD52-negative cells 
after alloSCT were mainly of donor origin as demonstrated by chimerism analysis. In cells collected 
from two donors, GPI/CD52-negative T cells were already present at low frequencies. PIGA-specific 
sequence analysis on mRNA from clonally expanded donor T cells indicated the presence of a similar 
highly mutational landscape in the PIGA gene as found in the recipient. Only a minority of mutations 
were found in both the donor and the matched recipient, probable due to the limited depth of our 
analysis. Functional analysis of the GPI/CD52-negative T-cell population showed that this population 
contained multiple functional virus-specific T cells, supporting the hypothesis that these cells have a 
beneficial role in early immune protection after ALM-based T-cell depleted alloSCT. 
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When ALM was applied as a monotherapy for the treatment of B-ALL, initial clinical responses were 
frequently followed by early relapse due to the outgrowth of a CD52-negative subclone resistant to 
the therapy. In chapter 5 we aimed to elucidate the mechanism resulting in loss of CD52 expression 
in B-ALL. We demonstrated that the lack of CD52 membrane expression was the result of loss of GPI-
anchor expression. Analysis of a cohort of patients with B-ALL showed that malignant cells with this 
GPI/CD52-negative phenotype were already present at low frequencies before the initiation of ALM-
treatment. An unbiased mRNA expression analysis of the genes involved in GPI-anchor synthesis 
indicated that synthesis of the GPI-anchor within these cells was defective due to lack of PIGH mRNA 
expression. To further investigate what caused the loss of PIGH expression, we exploited the two 
purified GPI/CD52-negative B-ALL subcultures used in chapter 3 that were generated from primary 
B-ALL samples. Forced expression of PIGH mRNA restored GPI-anchor expression and coinciding CD52 
membrane expression in these subcultures confirming that absence of PIGH mRNA expression was 
the primary underlying reason for the GPI/CD52-negative phenotype. Epigenetic silencing rather than 
gene mutation or deletion had resulted in loss of PIGH mRNA expression within these B-ALL cells, as 
demonstrated by in-depth mutational and epigenetic analysis. Treatment with the epigenetic modifying 
drug 5-aza-2’-deoxycytidine was able to revert the GPI/CD52-negative phenotype in these malignant 





Proper CD52 antigen expression and a sufficient ALM level were demonstrated in this thesis to be 
the major determinants for successful ALM-induced target cell depletion. In contrast, membrane-
bound complement inhibitors CD55 and CD59 were shown to convey protection against CDC-mediated 
depletion. Manipulation of these factors in the clinical setting may improve treatment outcome of ALM-
therapy.
Regulating the peak ALM level after alloSCT
In chapter 3 we demonstrated that antibody concentration was one of the primary factors that 
determines the efficiency of CDC-induced target cell lysis. The same applies for antibody-dependent 
cellular cytotoxicity (ADCC).1,2 Control of the in-vivo antibody concentration could be a potent tool to 
ensure successful depletion of donor T cells during alloSCT. The current paradigm for ALM dosing in both 
in-vivo and in-vitro T-cell depletion in alloSCT is flat dosing for adults patients and dosing per kg body 
weight in the pediatric setting. At the Leiden University Medical Center, all adult patients within a specific 
conditioning regimen receive the same ALM schedule and dosing regardless of patient characteristics. 
This dosing schedule consist of 30 mg ALM intravenously as part of in-vivo conditioning and 20 mg ALM 
added “to the bag” containing the graft, except for MA-conditioned patients with a sibling donor who 
only receive 20 mg of ALM added to the bag. In chapter 2 we showed that peak ALM plasma levels 
varied widely between recipients. Importantly, an ALM peak level below 6.5 µg/mL was associated 
with the development of mild GvHD, whereas higher levels were shown to prevent GvHD. Together this 
argues for the introduction of individualized dosing. A user friendly ALM level predication tool in the form 
of a dashboard system loaded with a relevant pharmacokinetics (PK)-model,3 such as generated in 
chapter 2, could be employed to adjust the final ALM dose at the moment of graft infusion. Patient 
specific covariates such as length, weight, and hematocrit (to estimate the patients’ plasma volume) 
together with an accurate ALM plasma measurement taken before graft infusion, likely suffice as input 
to estimate the peak ALM plasma level after graft infusion. One goal of dose adjustment guided based 
on the PK-model would be to achieve a peak ALM plasma level of at least 6.5 µg/mL to prevent GvHD. 
On the other hand, since in most patients the current dose of 20 mg ALM added “to the bag” resulted 
in a peak level higher than 6.5 µg/mL, downward dose adjustment may also be envisioned. Hereby 
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the goal would be to limit unnecessary ALM exposure after transplantation which results in delayed 
reconstitution, while maintaining a peak ALM level higher than 6.5 µg/mL to prevent GvHD. Before 
clinical implementation, the assay used for the ALM plasma measurement and the predictive power 
of the PK-model presented in this thesis need to be validated. The latter may be done initially as an 
observational study in a patient cohort with standard conditioning protocols, followed by a prospective 
interventional study. Whether this dose adjustment approach will also be applicable in MA-conditioned 
patients with a sibling donor who do not receive ALM as part of the conditioning regimen, restricting PK 
prediction solely to covariates without a pre-graft infusion ALM measurement, needs to be evaluated.
Optimizing the ALM level for the treatment of malignancies
No formal dose optimization studies were performed when ALM was introduced for the treatment of 
hematological malignancies. The first two patients that were treated with ALM (Campath-H1) for non-
Hodgkin lymphoma (NHL) were dosed based on tolerability of the infusion reaction and on the amount 
of ALM available.4 Based on the results from that study, various phase II studies were conducted in 
patients with chronic lymphocytic leukemia (CLL), NHL, and T-cell prolymphocytic leukemia (T-PLL) 
using similar approaches; a starting dose of 3 mg daily, increased to 10 mg daily as soon as infusion 
reactions were tolerated, followed by 30 mg infusions trice weekly for up to 12 weeks.5-8 This strategy 
was subsequently selected for the accelerated U.S. Food and Drug Administration approval of ALM for 
the treatment of CLL and has not been challenged in large trials. Although pharmacokinetic studies have 
since demonstrated that responders have higher circulating ALM levels compared to non-responders,9,10 
this may simply be a reflection of the initial tumor burden. As demonstrated in chapter 3 for CDC, 
higher antibody concentrations are required to induce lysis of cells with low antigen expression. 
Considering the heterogeneity of antigen expression within most tumors, this would suggest an aim to 
achieve high circulating ALM levels to also deplete malignant cells with the lowest antigen expression. 
However, since CD52 is also expressed at low levels on NK-cells and macrophages that induce ADCC 
and antibody-dependent cellular phagocytosis, respectively, high ALM levels may result in abrogation 
of these effector mechanisms thereby decreasing the efficacy of the treatment. Thus, the optimal ALM 
dose for eradication of the malignant cells may not be found until the relative contributions of its in-
vivo mechanisms of action become clear. In addition, depletion of CD52 expressing immune cells may 
put patients at risk of developing life threatening infections which should be considered for the overall 
effectiveness of the treatment.
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Increasing sensitivity to ALM-treatment by blocking complement inhibitors
A potential option to increase the efficiency of ALM-induced target cell lysis mediated via CDC would be 
elimination of the protective effect provided by complement inhibitors. In chapter 3 we demonstrated 
that overexpression of GPI-linked membrane-bound complement regulatory proteins (mCRP) CD55 and 
CD59 individually increased protection of B-ALL cells from CDC, whereas loss of GPI-anchor synthesis 
and coinciding loss of membrane expression of CD55 and CD59 expression sensitized B-ALL cells for 
CDC. Although our study was limited to analyzing the protective effect of CD55 and CD59, various 
other membrane-bound and soluble complement inhibiters also convey protection against antibody 
induced-CDC.11 Blocking the function of membrane-bound complement inhibitors is likely preferred 
over blocking soluble inhibitors. First, because the generally high serum concentrations of soluble 
complement inhibitors such as factor I (35 µg/mL) and factor H (300 µg/mL) would probably hamper 
effective blocking.12-14 Second, therapies targeting soluble complement inhibitors would induce systemic 
dysregulation of the complement system which may result in extensive side effects that are normally 
associated with diseases of the complement system, such as angioedema. In contrast, mCRP, such as 
CD55, CD59, complement receptor 1 (CD35), and membrane cofactor protein (CD46), could be blocked 
specifically on the targeted cells by using a bi- or multispecific antibody construct designed to block 
the mCRP with one domain, while engaging an antigen expressed only on the targeted cell with another 
domain.15 It could also be envisioned to design an mCRP-blocking treatment targeted to an antigen with 
broader tissue expression to increase its clinical applicability. For example, an mCRP blocking treatment 
targeting CD52 expressing cells might be beneficial in conjunction with CD20, CD19, and CD38 targeting 
CDC-inducing antibody therapeutics thereby being applicable for treatment against multiple B-cell 
malignancies. Some bystander lysis of healthy cells targeted by the mCRP-blocking treatment, but not 
the antibody therapeutic, may be expected and should be monitored to assess the overall safety of such 
combination treatment.
Reverting loss of CD52 membrane expression in B-ALL
Patients with B-ALL are particularly prone to develop treatment resistant relapse, due to the genetic 
intra-tumor heterogeneity. In chapter 5 we showed that in the majority of patients with B-ALL, 
small CD52/GPI-negative malignant cell populations are present already at diagnosis. In one patient 
from whom pre- and post-ALM treatment blood samples were available, outgrowth of the pre-existing 
CD52/GPI-negative clone was demonstrated. To mitigate the chance of developing treatment resistant 
relapse in B-ALL, therapies combining multiple treatment modalities, such as chemotherapeutic agents, 
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targeted agents like tyrosine kinase inhibitors, and monoclonal antibodies, could be employed. Our 
group and others have previously shown that a combination of ALM and the CD20-targetting antibody 
RTX may result in reciprocal treatment synergy in B-ALL due to (1) loss of mCRP expression on the 
CD52/GPI-negative cells, increasing their sensitivity for RTX-induced lysis and (2) upregulation of 
CD52 expression on the RTX-resistant cells making them more prone to ALM-induced lysis.16,17 The 
combination of ALM and RTX has already shown clinical success in patients with previously untreated 
or refractory CLL.18-20 Unfortunately, CD20-positive malignant cells are only present in half of B-ALL 
patients and often constitute only a subfraction of the malignant cells.16,21,22 As such, design of other 
combination treatments remains desired. Since loss of CD52 membrane expression in B-ALL cells results 
from epigenetic downregulation of PIGH expression and subsequent loss of the GPI-anchor, epigenetic 
modifying drugs may restore the expression of CD52 and revert ALM resistance. In chapter 5 we 
demonstrated that the DNA demethylating agent 5-aza-2’-cytidine can revert the CD52/GPI-anchor-
negative phenotype in B-ALL cells. A similar effect may be induced by other epigenetic modifying 
drugs that promote gene expression, such as the DNA demethylating agent decitabine, the histone 
deacetylase inhibitors valproic acid and vorinostat, and the DNA and histone demethylating agent 
cladribine. Interestingly, the addition of cladribine with or without vorinostat or valproic acid to ALM-
treatment of patients with T-PLL overcame ALM-resistance.23 This effect was observed in the absence of 
apoptosis of T-PLL cells, suggesting absence of a direct toxic effect induced by the epigenetic modifying 
drug. The mechanism of loss of CD52 expression and subsequent ALM-resistance in T-PLL is currently 
unknown,24-26 but ALM treatment had no effect on CD52 mRNA levels suggesting involvement of the GPI-
anchor.23 The observation that ALM-resistance in these cells could be prevented by epigenetic modifying 
drug suggest that a mechanism similar to what we found in the B-ALL cells was at play, as opposed to 
for example a crippling mutation of the PIGA gene. Importantly, this study in T-PLL shows that combining 
ALM with epigenetic modifying drugs is safe and may have a synergistic effect.
The effect of ALM-treatment on the immunobiology of alloSCT
Following alloSCT there are three major complications that may cause unfavorable treatment outcome, 
including development of GvHD, relapse resulting from inadequate graft versus tumor (GvT) effect, 
and infections. ALM-based T-cell depletion may affect all three processes. The activation and effector 
function of T cells is mediated via the interaction between T-cell receptors (TCR) expressed on the 
cell surface of T cells and small protein sequences (peptides) presented in human leukocyte antigen 
(HLA) molecules expressed on the surface of stimulator/target cells. Normally, during maturation in the 
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thymus, T cells are negatively selected when their TCR interacts with high affinity with self-peptide-HLA 
complexes.27 Because of genetic differences between patient and donor within either the HLA (major 
histocompatibility antigen) or in the presented peptides (minor histocompatibility antigens, MiHA), mature 
donor T cells infused with the graft may recognize peptide-HLA complexes presented on patient cells 
as non-self and eliminate these cells resulting in the detrimental GvHD or the beneficial GvT reactivity. 
Recognition of pathogen-derived peptides presented in self-HLA may result in immunoprotection.
The effect of CD52/GPI-negative T cells on GvHD and GvT
As shown in chapter 4, CD52/GPI-negative T cells found in recipients of ALM-based T-cell depleted 
alloSCT are predominantly donor-derived T cells with a memory phenotype. Unless the donor has been 
exposed to alloantigens through blood transfusion, organ transplantation, or pregnancy, this memory 
phenotype must have been the result of an antigenic challenge by past infections in the donor. In an HLA-
matched transplantation, these pathogen-specific CD52/GPI-negative memory T cells are not expected 
to contribute to either GvHD or GvT. This is in contrast to CD52/GPI-negative naive T cells that, being 
trained in the thymus of the donor not to recognize self-peptide in self-HLA, would be able to recognize 
MiHA and contribute to GvHD and GvT. In the (partially) HLA-mismatched setting, besides the CD52/GPI-
negative naive T cells, the pathogen-specific CD52/GPI-negative memory T cells may still induce GvHD 
and GvT.28 This may result from cross-reactivity of these memory cells towards any peptide in nonself-
HLA, a combination that was obviously not present during thymic selection in the donor, that by chance 
may be present in the pathogen-specific CD52/GPI-negative memory T-cell repertoire. Whether this 
mechanism is a potent driver of GvHD and GvT remains to be established. Although we did establish the 
dynamics of CD52/GPI-negative T cells following alloSCT with a T-cell depleted graft by addition of ALM 
“to the bag” with or without prior ALM as part of the conditioning regimen in chapter 2, this study was 
limited in the number of patients and only three developed mild GvHD. Of these patients that developed 
GvHD, one had received myeloablative condition and a graft from a sibling donor, one had received 
myeloablative conditioning and a graft from an unrelated donor (10/10 match), and one had received 
non-myeloablative conditioning and a graft from a sibling donor. The contribution of CD52/GPI-negative 
cells to GvHD in these patients was not studied. However, since they all had low ALM plasma peak levels, 
it is likely that naive donor T cells that had escaped ALM conditioning contributed to the development of 
GvHD. Conclusively demonstrating that CD52/GPI-negative donor T cells do not (dominantly) take part 
in the processes of GvHD or GvT is difficult since only the opposite can be proven. However, utilizing the 
large numbers of MiHA that have currently been identified, screens could be developed using peptide-
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MHC-multimers to assess the relative frequency of alloreactive T cells in the CD52/GPI-negative and 
CD52/GPI-positive T-cell populations.29 The ongoing effort to identify novel MHC-II restricted MiHA and 
the improvement of MHC-II multimer technology will likely be essential to the success of such screen,30-32 
since CD52/GPI-negative cells were more abundantly present in the CD4 T-cell than in the CD8 T-cell 
compartment (chapter 4).
The effect of CD52/GPI-negative T cells on infectious complications
Infectious complications are one of the major causes of morbidity associated with alloSCT. Since 
immune protection is prominently mediated via T cells, depletion of donor T cells may increase the 
risk of infection. Following T-cell depleted alloSCT, this risk is in part mitigated by the lack for need of 
post-transplantation application of immunosuppressive drugs, which is typically given to prevent the 
occurrence of GvHD after infusion of an unmanipulated graft, allowing for an unrestrained immune 
response. Following ALM-based T-cell depletion, enduring exposure to ALM may prevent reconstitution 
of adaptive immune cells that express high levels of CD52. In contrast, reconstitution of innate immune 
cells, such as neutrophils, NK-cells, and monocytes, which typically have low CD52 expression levels is 
relatively unaffected. In chapter 2 we showed that reconstitution of T cells with a CD52/GPI-negative 
phenotype was unaffected by residual ALM. In chapter 4 we showed that these polyclonal CD52/
GPI-negative T-cell populations contained virus-specific T cells with a functional potential comparable to 
that of CD52/GPI-positive T cells, suggesting that they may contribute to early immune protection. Since 
they are of memory phenotype they do not require stimulation by professional antigen presenting cells 
(APC) for their activation, which renders them ideal effectors in the cell deprived environment shortly 
after alloSCT. To conclusively demonstrate that CD52/GPI-negative T cells contribute to early immune 
protection, the relative fraction of pathogen-specific CD52/GPI-negative and -positive T cells could be 
followed during an infection by flow cytometry using labeled MHC-multimers loaded with pathogen-
derived peptides. 
An interesting and relatively recently defined population of T cells that may be of specific importance 
in the early immune protection of tissue are the tissue resident memory T cells. Despite their high 
levels of CD52 expression, they were not cleared from skin following high-dose ALM treatment (180 
mg cumulative dose) in patients with mycosis fungoides.33,34 Analogously, addition of ALM (20-50 mg 
cumulative dose) to the conditioning regimen of alloSCT recipients is unlikely to extensively deplete 
these cells. This is supported by our own observation of the slow replacement of patient T cells with 
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donor T cells in dermal tissue following ALM-based T-cell depleted alloSCT.35 Upon infusion of an 
unmanipulated graft, tissue resident memory T cells may be depleted as a result of the donor T-cell 
mediated alloimmune response. Thus, depletion of donor T cells from the graft may counterintuitively 
contribute to early immune protection, by sparing of the tissue resident memory T cells.
Effect of ALM-based depletion on APC
One cell type that is of high importance in all these processes are the APC, such as dendritic cells (DC). 
Whereas memory T cells can become activated solely by recognition of their target antigen, DC are 
essential in priming naive T cells during the initial phase of the immune response. Unlike circulating DC 
that express CD52 at varying levels, tissue “resident” DC such as epidermal Langerhans cells and small 
intestine DC do not express CD52 and are thus likely to survive ALM-induced cytotoxicity.36,37 Typically 
GvHD sensitive tissues, such as gut, skin, liver, and lung contain especially large populations of tissue 
“resident” DC. Mouse models have demonstrated that recipient DC that survive conditioning are essential 
to initiate GvHD.38-40 However, recipient DC have also been demonstrated to be powerful mediators of 
GvT resulting from the presentation of hematopoiesis-associated MiHa.41,42 In transplantation protocols 
without ALM-based T-cell depletion, tissue resident DC will initially be mainly of recipient origin before 
being replaced by DC from donor hematopoietic origin over the course of several months.43 Whether 
these dynamics are similar after ALM-based T-cell depleted alloSCT is currently not known. Specific 
targeting of tissue DC during conditioning may prevent GvHD, however, may also diminish GvT and 
immunoprotection.
Concluding remarks
The expression pattern of CD52 has made ALM a unique therapeutic antibody with broad clinical 
applicability. The combined results presented in this thesis add to the continuing expansion of our 
understanding of factors that regulate the sensitivity of target cells for depletion by ALM. This knowledge 
is relevant for the ongoing use of ALM as a treatment against hematological malignancies, for its use 
as a T-cell depleting agent to prevent GvHD after alloSCT, for new applications of ALM such as the 
treatment of multiple sclerosis, and more broadly for other and future cytolytic antibody therapeutics. 
Antigen escape resulting in treatment resistance is a continuing challenge for antibody therapeutics 
and has recently been demonstrated to also affect chimeric antigen receptor T cell therapy.44-46 Our 
demonstration of non-traditional pathways of escape, by epigenetic dysregulation and by a polyclonal 
mutational landscape, may allow others to identify new pathways more rapidly. Finally, the insights 
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gained into the pharmacokinetics of ALM following alloSCT and the recognition of the abundance and 
function of CD52/GPI-negative T cells may aid timing of cellular interventions and may help to fine tune 
future T-cell depleting strategies. 
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Alemtuzumab; de mechanismen van differentiële gevoeligheid en resistentie
Het afweersysteem, ook wel het immuunsysteem genoemd, heeft zich geëvolueerd tot een zeer 
efficiënt systeem dat als doel heeft ziektes te voorkomen. Dit doet het door herkenning en vernietiging 
van gevaarlijke lichaamsvreemde entiteiten en van ontregelde lichaamseigen cellen. In uitzonderlijke 
gevallen faalt het afweersysteem. Therapieën die erop gericht zijn direct invloed uit te oefenen op het 
afweersysteem, door stimulatie of juist onderdrukking, zijn in de laatste decennia zeer effectief gebleken 
in de genezing van een breed scala aan ziekten waarbij het natuurlijke afweer onvoldoende was.
Alemtuzumab is een medicijn dat gebaseerd is op een molecuul, een antilichaam, dat van nature deel 
uitmaakt van het afweersysteem. Antilichamen zijn eiwitten die met hoge specificiteit hun doelwit binden. 
Dit doen zij met hun variabele domeinen. Antilichamen worden geproduceerd door B cellen, waarbij elke 
B-cel kloon een antilichaam produceert met een uniek variabel domein. Door de grote diversiteit aan 
B-cel klonen is het afweersysteem in staat om een breed scala aan doelwitten te herkennen. Naast de 
variabele domeinen bevatten antilichamen ook een constant domein, dat gelijk is tussen verschillende 
antilichamen. Via dit constante domein zijn antilichamen in staat tot het rekruteren en het activeren 
van andere componenten van het afweersysteem, die vervolgens in staat kunnen zijn tot vernietiging 
van het doelwit. Voor het antilichaam-geïnduceerde vernietigen van lichaamscellen is van de volgende 
mechanismen bekend dat zij hieraan bijdragen; complement gemedieerde lysis (CDC), antilichaam-
afhankelijke celgemedieerde cytotoxiciteit, en antilichaam-afhankelijke celgemedieerde fagocytose. De 
efficiëntie van deze mechanismen wordt beïnvloed door diverse factoren zoals de concentratie van het 
antilichaam, de mate van aanwezigheid van het doelwit(eiwit), en in het geval van CDC, de aanwezigheid 
van complement en complement-inhibitoren.
Alemtuzumab is een monoklonaal antilichaam, wat betekent dat alle antilichamen in dit medicijn van 
een enkele B-cel kloon afkomstig zijn en identieke domeinen hebben. Het doelwit voor alemtuzumab 
is CD52, een eiwit dat indirect geankerd is aan het buitenmembraan van cellen door een covalente 
binding te vormen met het glycolipide glycosylfosfatidylinositol (GPI). CD52 wordt tot expressie gebracht 
op het celmembraan van rijpe lymfocyten, maar niet op bloedvormende stamcellen, rode bloedcellen, 
of op niet-bloedvormende cellen. Door deze unieke distributie zal het toedienen van alemtuzumab 
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leiden tot de vernietiging van rijpe lymfocyten zonder dat het schade toebrengt aan overige weefsels. 
Rijpe lymfocyten is de verzamelnaam van een brede set aan gedifferentieerde witte bloedcellen die een 
zeer potent onderdeel van het afweersysteem vormen. Belangrijke voorbeelden van rijpe lymfocyten 
zijn T cellen en B cellen. En zijn verscheidene klinische toepassingen waarbij het doel is om rijpe 
lymfocyten te vernietigen doormiddel van de toediening van alemtuzumab. Twee toepassingen die 
worden beschreven in dit proefschrift zijn T-cel depletie voor allogene stamceltransplantatie (alloSCT) 
en depletie van maligne B cellen.
AlloSCT is een in opzet curatieve therapie voor patiënten met ziekten die hun oorsprong hebben in het 
bloedvormend systeem. Het doel van alloSCT is om de bloedvormende stamcellen van de patiënt te 
vervangen door stamcellen van een gezonde donor om daarmee een normale, van de donor stamcellen 
afkomstige, bloedcelontwikkeling te introduceren. In het stamcel transplantaat (graft) dat afgenomen is 
bij de donor zitten naast stamcellen ook rijpe lymfocyten. Zowel het positieve therapeutische effect van 
alloSCT alsmede de ongewenste bijwerkingen worden met name veroorzaakt door donor T cellen die in 
het transplantaat aanwezig zijn op het moment van infusie bij de patiënt. Deze donor T cellen zijn in staat 
om cellen van de patiënt te herkennen en te vernietigingen. In het geval van vernietiging van maligne 
cellen die de voorbehandeling van de patiënt hebben overleefd zal dit leiden tot het therapeutische 
’graft-versus-tumor‘ (GvT)-effect. In het geval van herkenning van gezond patiëntweefsel (bijvoorbeeld 
huid, lever, of darm) zal dit leiden tot orgaanschade, een toxisch en potentieel dodelijk proces dat ‘graft-
versus-host’-ziekte (GvHD) wordt genoemd. Depletie van donor T cellen door directe toevoeging van 
alemtuzumab aan het transplantaat voor infusie in de patiënt kan er voor zorgen dat zowel het GvT-
effect als de GvHD een halt wordt toegeroepen. Deze vorm van voorbehandeling van het transplantaat 
heeft bewezen de incidentie van GvHD sterk te reduceren. Desalniettemin ontwikkelt een klein deel 
van patiënten nog steeds GvHD. Alemtuzumab dat aanwezig is in de zak van het transplantaat, al 
dan niet gebonden aan cellen, wordt samen met de stamcellen per infuus aan de patiënt gegeven. 
Het is waarschijnlijk dat deze infusie van alemtuzumab in de patiënt de vroege ontwikkeling van rijpe 
lymfocyten negatief beïnvloedt, wat vervolgens een negatieve impact kan hebben op de kracht van het 
afweersysteem. Details van dit proces waren echter onduidelijk.
Een tweede klinische toepassing van alemtuzumab is de behandeling van maligniteiten in bloedvormende 
cellen die CD52 tot expressie brengen. Een voorbeeld hiervan is B-cel acute lymfatische leukemie 
(B-ALL), een ziekte waarbij ongeremde groei van voorloper B cellen de normale vorming van bloedcellen 
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in het beenmerg verdrukt. B-ALL cellen van vrijwel alle sub-classificeringen brengen CD52 tot expressie 
op het membraan. Toediening van alemtuzumab kan daardoor celdood van de maligne B-ALL cellen tot 
gevolg hebben. Helaas is echter gebleken dat bij veel patiënten kort na een succesvolle behandeling met 
alemtuzumab de ziekte terugkomt. Deze teruggekomen vorm van de ziekte bleek in veel gevallen niet 
langer gevoelig voor behandeling met alemtuzumab doordat de B-ALL cellen CD52 expressie hadden 
verloren. De oorzaak van afwezigheid van CD52 op deze cellen was onbekend.
Dit proefschrift 
Om de klinische toepassingen van alemtuzumab te optimaliseren is het van belang om te weten welke 
factoren invloed uitoefenen op de efficiëntie waarmee alemtuzumab vernietiging van doelwitcellen kan 
induceren. Ook is het van belang om te achterhalen via welk(e) mechanisme(n) doelwitcellen kunnen 
ontsnappen aan alemtuzumab. 
Om de potentieel ernstige gevolgen van GvHD na alloSCT te voorkomen worden T cellen uit het 
stamceltransplantaat verwijderd doormiddel van alemtuzumab-geïnduceerde T-cel depletie. Om inzicht 
te krijgen in de kinetiek van alemtuzumab en zijn effect op circulerende T cellen in patiënten die een 
alloSCT hebben ondergaan met een stamceltransplantaat waarvan de T cellen waren gedepleteerd 
doormiddel van toevoeging van alemtuzumab, waarbij in de voorbehandeling van de patiënt ook of juist 
geen alemtuzumab was gebruikt, hebben we in een prospectieve studie de concentratie alemtuzumab 
in plasma en het aantal circulerende T cellen na alloSCT gemeten in een cohort van 36 patiënten. 
De resultaten van deze analyse staan beschreven in hoofdstuk 2. We laten zien dat de hoogste 
concentratie alemtuzumab gemeten na transplantatie substantieel verschilt tussen de patiënten. Dit 
verschil was met name toe te schrijven aan verschillen in plasma volume en niet aan de hoeveelheid T 
cellen die aanwezig waren voor de start van alemtuzumab behandeling. De depletie van T cellen was 
efficiënt in alle patiënten. Patiënten die een alemtuzumab concentratie boven de 6,5 µg/mL bereikten 
ontwikkelden geen ernstige GvHD. De aanwezigheid van alemtuzumab na alloSCT in een plasma 
concentratie boven de 0,7 µg/mL belemmerde CD52-positieve T cellen om in aantal te herstellen. 
Desondanks had geen van de patiënten zware complicaties als gevolg van het Epstein-Barr-virus of 
het cytomegalovirus, wat aangeeft dat ze nog voldoende anti-virale T-cel immuniteit hadden. Dit heeft 
waarschijnlijk te maken met het beschermende effect van het uitgroeien van CD52-negatieve T cellen, 
hetgeen niet beïnvloed werd door de aanwezigheid van alemtuzumab na transplantatie.
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CDC is een van de mechanismen waarvan wordt gedacht dat zij belangrijk is voor het vernietigen van 
door therapeutisch antilichaam gebonden doelwitcellen. In hoofdstuk 3 hebben we de relatieve 
bijdrage bestudeerd van verschillende factoren op de efficiëntie van antilichaam-geïnduceerde CDC. 
We hebben gebruik gemaakt van alemtuzumab en de representatieve therapeutische antilichamen 
rituximab en ofatumumab (beide anti-CD20) om CDC te induceren van een selectie van B-ALL cellijnen 
en primaire B-ALL samples. We laten zien dat de gevoeligheid van doelwitcellen voor antilichaam-
geïnduceerde CDC voornamelijk afhankelijk is van de antilichaam concentratie en van de dichtheid 
van het doelwiteiwit van het antilichaam op de cel. Gezuiverde GPI-anker negatieve celculturen van 
twee B-ALL cellijnen bleken extra gevoelig te zijn voor CDC geïnduceerd door rituximab en ofatumumab, 
omdat zij geen expressie hadden van de membraangebonden complement inhibitoren CD55 en CD59. 
Door CD55 en CD59 geforceerd tot expressie te brengen hebben we laten zien dat beide inhibitoren 
onafhankelijk van elkaar in staat zijn om CDC te beperken. Dit beperkende effect was alleen aanwezig 
binnen een begrensde spreiding van expressie van het doelwiteiwit van de antilichamen en binnen een 
begrensde antilichaam concentratie, wat impliceert dat het effect van CD55 en CD59 ondergeschikt is 
aan deze factoren. Door gebruik te maken van primaire B-ALL samples hebben we laten zien dat de 
natuurlijke variatie van CD55 of CD59 expressie niet kan worden gebruikt als een individuele factor voor 
het voorspellen van de gevoeligheid van doelwitcellen voor CDC.
Een relatief vroeg herstel van het aantal circulerende T cellen is te zien na een alloSCT met een 
transplantaat gedepleteerd van T cellen doormiddel van toevoeging van alemtuzumab. Dit komt omdat 
er, in tegenstelling tot een niet-gedepleteerde alloSCT, minder gebruik wordt gemaakt van medicatie 
die de uitgroei van afweercellen remt. Een deel van deze circulerende T cellen is negatief voor CD52 
membraanexpressie, zoals beschreven en uitgelegd in hoofdstuk 2. Deze CD52-negatieve T cellen 
leveren mogelijk een positieve bijdrage aan het afweersysteem vroeg na een alloSCT. In hoofdstuk 
4 laten we een uitgebreide analyse zien van de mate waarin CD52-negatieve T cellen een bijdrage 
leveren aan het vroege herstel in het aantal T cellen. Daarnaast helderen we op wat het mechanisme is 
dat resulteert in het verlies van CD52 expressie van het membraan van deze cellen. In een cohort van 89 
patiënten die een alloSCT hadden ondergaan voor verschillende maligne en niet-maligne aandoeningen 
aan het bloedvormend systeem, hebben we laten zien dat 6 weken na infusie van het transplantaat in 
de meerderheid van patiënten het grootste deel van de CD4-positieve T cellen en een substantieel deel 
van de CD8-positieve T cellen negatief waren voor CD52 membraanexpressie. Binnen de NK en B cellen 
van dezelfde patiënten waren daarentegen geen duidelijk CD52-negatieve cel populaties detecteerbaar. 
160
Directe kleuring van het GPI-anker bevestigde dat verlies van CD52 membraanexpressie het resultaat 
was geweest van verlies van GPI-anker expressie, wat in voorgaande publicaties al gesuggereerd werd. 
Doelgerichte sequentieanalyse op mRNA van klonaal geëxpandeerde GPI/CD52-negatieve en -positieve 
T cellen van drie patiënten die een alloSCT hadden ondergaan liet zien dat een zeer polyklonale diversiteit 
aan mutaties in het PIGA gen de oorzaak was van het verlies van het GPI-anker en de samenvallende 
afwezigheid van CD52 membraanexpressie. Geforceerde expressie van wildtype PIGA in de GPI/CD52-
negatieve T-cel klonen herstelde het GPI/CD52-positieve fenotype. De GPI/CD52-negatieve cellen die 
aanwezig waren na alloSCT hadden hun oorsprong voornamelijk vanuit de donor, wat aangetoond werd 
door chimerisme analyse. In cellen afkomstig van twee donoren waren GPI/CD52-negatieve T cellen reeds 
aanwezig in lage frequenties. Sequentie analyse van het PIGA gen op mRNA van klonaal geëxpandeerde 
T cellen van de donor liet zien dat een zeer polyklonale diversiteit aan mutaties in het PIGA gen aanwezig 
was, die gelijkenis vertoonde met die van de patiënten die een alloSCT hadden ondergaan. Niettemin 
waren slechts enkele identieke mutaties aanwezig in zowel de donor als de gematchte patiënt, wat 
waarschijnlijk het gevolg is van de beperkte diepte van onze analyse. Functionele analyse van de GPI/
CD52-negatieve T-cel populaties toonde aan dat deze meerdere functionele virus-specifieke T cellen 
bevatten, wat een ondersteuning biedt voor de hypothese dat deze cellen een heilzame rol kunnen 
vervullen vroeg na alloSCT met een transplantaat gedepleteerd van T cellen doormiddel van toevoeging 
van alemtuzumab.
Behandeling van B-ALL met enkel alemtuzumab resulteert in eerste instantie in goede klinische 
responsen, echter deze worden frequent gevolgd door een snelle terugkeer van de ziekte door uitgroei 
van een deel van de maligne cellen die negatief zijn voor CD52 en daardoor resistent zijn tegen de 
behandeling. In hoofdstuk 5 tonen we het mechanisme waardoor deze B-ALL cellen negatief 
worden voor CD52 expressie. We hebben laten zien dat de afwezigheid van CD52 membraanexpressie 
het resultaat was van verlies van GPI-anker expressie. Analyse van een cohort patiënten met B-ALL toont 
aan dat maligne cellen met een GPI/CD52-negatief fenotype al in een lage frequentie aanwezig waren 
voor de start van de behandeling met alemtuzumab. Een onvooringenomen analyse van mRNA expressie 
van genen die betrokken zijn bij de vorming van het GPI-anker bracht aan het licht dat afwezigheid van 
PIGH expressie de oorzaak was van de afwezigheid van het GPI-anker. Om de diepere oorzaak van het 
verlies van PIGH expressie te onderzoeken hebben we gebruik gemaakt van twee gezuiverde GPI/CD52-
negatieve celculturen die afkomstig waren van primaire B-ALL samples en die reeds gebruikt werden 
in de experimenten beschreven in hoofdstuk 3. Geforceerde expressie van PIGH mRNA in deze 
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celculturen herstelde expressie van het GPI-anker en de samenvallende membraanexpressie van CD52, 
wat bevestigde dat afwezigheid van PIGH mRNA expressie de primaire onderliggende oorzaak was van 
het GPI/CD52-negatieve fenotype. Epigenetische onderdrukking van gen expressie en niet een mutatie 
in of deletie van het PIGH gen was de oorzaak van verlies van PIGH mRNA expressie in deze B-ALL cellen, 
bleek na een diepte analyse. Behandeling met 5-aza-2’-deoxycytidine, een medicijn dat effect heeft op 
de epigenetica van cellen, herstelde het GPI/CD52-positieve fenotype in de maligne B-ALL cellen, wat 
erop duidt dat dit medicijn potentieel synergie kan opleveren wanneer het wordt gegeven in combinatie 
met alemtuzumab behandeling.
Samenvattend
Het patroon van CD52 expressie maakt alemtuzumab een uniek therapeutisch antilichaam met een brede 
klinische inzetbaarheid. De resultaten beschreven in dit proefschrift dragen bij aan het vergroten van 
onze kennis over de factoren die de gevoeligheid van doelwitcellen voor vernietiging door alemtuzumab 
beïnvloeden. Deze kennis is relevant voor huidige behandelingen van maligniteiten met alemtuzumab, 
voor het gebruik van alemtuzumab voor depletie van T cellen voor alloSCT om GvHD te voorkomen, 
voor nieuwe toepassingen van alemtuzumab zoals de behandeling van multiple sclerosis, en breder 
bekeken voor andere en toekomstige therapeutische antilichamen die celdood induceren. Ontsnapping 
aan therapie door verlies van expressie van het doelwiteiwit van het membraan van doelwitcellen is een 
voortdurende uitdaging voor therapeutische antilichamen en is recent ook beschreven voor chimere 
antigeenreceptor T-cel therapie. De in dit proefschrift beschreven niet-traditionele mechanismen van 
ontsnapping van doelwitcellen, doormiddel van epigenetische onderdrukking of door een zeer polyklonale 
diversiteit aan mutaties, stelt andere onderzoekers in staat om nieuwe ontsnappingsmechanismen 
sneller te identificeren. Tot slot, het inzicht dat we hebben gekregen in de kinetiek van alemtuzumab na 
alloSCT en de erkenning van de overvloed en functie van CD52/GPI-negatieve T cellen zou het correct 
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